

ASSOCIATE EDITOR: CHARLES FRANCE

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, Uwe Grether, Allyn C. Howlett, Tian Hua, Alexandros Makriyannis, Daniele Piomelli, Natsuo Ueda, and Mario van der Stelt

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy (M.M.); European Center for Brain Research, Santa Lucia Foundation, Rome, Italy (M.M.); Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, University of Laval, Quebec, Canada (V.D.); Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bern, Switzerland (J.G.); Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (U.G.); Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (A.C.H.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H.); Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (A.M.); Departments of Pharmaceutical Sciences and Biological Chemistry, University of California, Irvine, California (D.P.); Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa, Japan (N.U.); Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands (M.S.)

Abstract	886
Significance Statement	886
I. Introduction	886
A. Phytocannabinoids	887
B. Cannabinoid Receptors, Endocannabinoids, and Their Congeners	888
C. Diverse Phytocannabinoids and Endocannabinoid Targets and Signaling Pathways	889
D. Metabolic Routes	890
1. Metabolism of N-Arachidonyl Ethanolamine	890
2. Metabolism of 2-Arachidonoylglycerol	891
E. Trafficking of Endocannabinoids	892
II. Cannabinoid Receptor Physiology and Pharmacology	895
A. Therapeutic Potential of Cannabinoid Receptor 1	898
1. CB ₁ R Agonists and Positive Allosteric Modulators	899
2. Cannabinoid Receptor 1 Antagonists	906
B. Therapeutic Potential of Cannabinoid Receptor 2	907
1. Cannabinoid Receptor 2 Agonists	908
a. Endocannabinoids and related fatty acid derivatives	908
b. Plant-derived cannabinoids	909
2. Cannabinoid Receptor 2 Antagonists and Allosteric Ligands	912
3. Cannabinoid Receptor 2 Chemical Probes for Research and Diagnostics	914
C. Summary of Clinical Status of Cannabinoid Receptor 1 and Cannabinoid Receptor 2 Agonists	915
III. Therapeutic Potential of Metabolic Enzymes of AEA	917
A. Enzymes of AEA Production	917
1. NAT and iNAT	917
2. N-Acyl Phosphatidylethanolamine-Specific Phospholipase D	917
3. Alternative Pathways	918
B. Enzymes of N-Arachidonyl Ethanolamine Degradation	918
1. Fatty Acid Amide Hydrolase	918

Address correspondence to: Mauro Maccarrone, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio snc, I-67100 L'Aquila (Italy). E-mail: mauro.maccarrone@univaq.it.

All authors have contributed equally to this study.

For this investigation M.M. was partly supported by the Italian Ministry of Health through the competitive Ricerca Finalizzata 2018 [Grant RF-2018-12365391]. A.C.H. was supported by National Institutes of Health National Institute on Drug Abuse [Grant R01-DA042157]. A.M. was supported by the National Institute on Drug Abuse [Grant P01-DA009158] and by the National Institute on Alcohol Abuse and Alcoholism [Grant U01-AA028963].

No author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/pharmrev.122.000600.

2. N-Acylethanolamine Acid Amide Hydrolase	919
C. Fatty Acid Amide Hydrolase Inhibitors	919
D. N-Acylethanolamine Acid Amide Hydrolase	920
IV. Therapeutic Potential of Metabolic Enzymes of 2-AG	922
A. Metabolism of 2-Arachidonoylglycerol	922
B. Therapeutic Potential of Diacylglycerol Lipase- α	923
C. Therapeutic Potential of Diacylglycerol Lipase- β	924
D. Therapeutic Potential of Monoacylglycerol Lipase	925
V. Therapeutic Potential of Transmembrane, Intracellular, and Extracellular Transporters	926
A. Endocannabinoid Trafficking and Transport	927
B. Evolution of Pharmacological Inhibitors of N-Arachidonyl Ethanolamine Transport	929
C. Preclinical Development of Selective Endocannabinoid Reuptake Inhibitors	933
D. Preclinical Development of Fatty Acid Binding Protein Inhibitors	934
E. Translational Implications of Endocannabinoid Transport Inhibitors	936
VI. Therapeutic Potential of Additional Targets Within the “Endocannabinoidome”	936
A. Definition of the Endocannabinoidome	936
B. Interaction with the Gut Microbiome	940
VII. Conclusion	943
Acknowledgments	944
References	944

Abstract—The cannabis derivative marijuana is the most widely used recreational drug in the Western world and is consumed by an estimated 83 million individuals (~3% of the world population). In recent years, there has been a marked transformation in society regarding the risk perception of cannabis, driven by its legalization and medical use in many states in the United States and worldwide. Compelling research evidence and the Food and Drug Administration cannabis-derived cannabidiol approval for severe childhood epilepsy have confirmed the large therapeutic potential of cannabidiol itself, Δ^9 -tetrahydrocannabinol and other plant-derived cannabinoids (phytocannabinoids). Of note, our body has a complex endocannabinoid system (ECS)—made of receptors, metabolic enzymes, and transporters—that is also regulated by phytocannabinoids. The first endocannabinoid to be discovered 30 years ago was anandamide (N-arachidonoyl-ethanolamine); since then, distinct elements of the ECS have been the target of drug design programs aimed at curing (or at least slowing down) a

number of human diseases, both in the central nervous system and at the periphery. Here a critical review of our knowledge of the goods and bads of the ECS as a therapeutic target is presented to define the benefits of ECS-active phytocannabinoids and ECS-oriented synthetic drugs for human health.

Significance Statement—The endocannabinoid system plays important roles virtually everywhere in our body and is either involved in mediating key processes of central and peripheral diseases or represents a therapeutic target for treatment. Therefore, understanding the structure, function, and pharmacology of the components of this complex system, and in particular of key receptors (like cannabinoid receptors 1 and 2) and metabolic enzymes (like fatty acid amide hydrolase and monoacylglycerol lipase), will advance our understanding of endocannabinoid signaling and activity at molecular, cellular, and system levels, providing new opportunities to treat patients.

I. Introduction

Paleobotanical records date the beginning of human cannabis cultivation in Eurasia to > 8000 years ago, while archaeological evidence anchors its use as a psychotropic substance to approximately 2500 years ago

(Russo et al., 2008; Long et al., 2017). Today, cannabis is one of the world's most widely used recreational drugs, after alcohol and tobacco, and is consumed by an estimated 83 million individuals (~3% of the world population) (<https://www.unodc.org/wdr2017/field/>

ABBREVIATIONS: AA, arachidonic acid; 2-AG, 2-arachidonoylglycerol; AEA, N-arachidonyl ethanolamine (anandamide); CADD, computer-aided drug discovery; CBD, cannabidiol; CB₁R, cannabinoid receptor 1; CB₂R, cannabinoid receptor 2; CNS, central nervous system; COVID-19, coronavirus disease of 2019; COX, cyclooxygenase; cPLA, cytosolic phospholipase A; CYP450, cytochrome P450; DAGL, diacylglycerol lipase; DSE, depolarization-induced suppression of excitation; eCB, endocannabinoid; eCBome, endocannabinoidome; ECS, endocannabinoid system; EMA, European Medicines Agency; FAAH, fatty acid amide hydrolase; FABP, fatty acid binding protein; FDA, Food and Drug Administration; GPCR, G protein-coupled receptor; LOX, lipoxygenase; MAGL, monoacylglycerol lipase; MS, multiple sclerosis; NAAA, N-acylethanolamine acid amide hydrolase; NAPE-PLD, N-acyl phosphatidylethanolamine-specific phospholipase D; NAT, N-acyl-transferase; NOS, nitric oxide synthase; PAM, peptidyl-glycine alpha-amidating monooxygenase; PGE₂-G, prostaglandin E₂ glyceryl ester; PGH₂-EA, prostaglandin H₂ ethanolamide; PLC, phospholipase C; PPAR, peroxisome proliferator-activated receptor; SAR, structure-activity relationship; SERI, selective eCB reuptake inhibitor; (S)-OOPP, N-[(3S)-2-oxo-3-oxetanyl]-3-phenylpropanamide; THC, Δ^9 -tetrahydrocannabinol; TRP(V), transient receptor potential (vanilloid).

Booklet_1_EXSUM.pdf). Cannabis' increasingly expanding legal status heightens the need for research into its therapeutic potential for a wide range of pathologic conditions (National Academies of Sciences, Engineering, and Medicine, 2017; Cohen et al., 2019; Friedman et al., 2019; Cristino et al., 2020) but also raises concerns about its possible hazards to health. Indeed, medical and nonmedical cannabis use has been associated with short-term and long-term adverse effects, including schizophrenia, alterations in cognition, and mood disorders (Cohen et al., 2019), as well as an impact on adult neurogenesis (Oddi et al., 2020) and female (Cecconi et al., 2020) and male reproductive health (Maccarrone et al., 2021).

A. *Phytocannabinoids*

The trichomes, specialized structures in the inflorescences of the female cannabis plant, produce a family of terpenophenolic substances, called phytocannabinoids (pCBs), which contain tricyclic, bicyclic, and monocyclic structures. In most cannabis varieties, the most abundant pCBs are the acidic (i.e., carboxylic) precursors of Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), which are converted to THC and CBD by drying or heating, but many others have been identified whose pharmacological properties are still awaiting clarification (Gomez-Cañas et al., 2023). Indeed, cannabis contains more than 110 pCBs as well as hundreds of terpenoids, flavonoids, sterols, and other non-pCB substances (El Sohly and Gul, 2014; El Sohly et al., 2017; Solymosi and Köfalvi, 2017). THC and its analogs (including Δ^8 -tetrahydrocannabinol and the propyl derivative Δ^9 -tetrahydrocannabivarin), CBD and its analogs (including cannabidivarin), cannabinol and its analogs (including the propyl derivative cannabivarin), and cannabigerol and its analogs are highly abundant. In addition, trace amounts of cannabidiol, cannabichromene, cannabicyclol, cannabielsoin, and cannabitriol are also detectable (Mechoulam, 2005; El Sohly and Gul, 2014; El Sohly et al., 2017; Morales et al., 2017; Li et al., 2022). The structures of the main pCBs identified so far are shown in Table 1.

To date, the therapeutic potential of THC and CBD, alone or in combination, seems apparent and has been critically discussed in recent reviews (Maccarrone et al., 2017; Friedman et al., 2019; Pacher et al., 2020; Rock et al., 2021; Stella, 2023). Here, the main applications of THC and CBD for human health are summarized in Table 2.

By contrast, our understanding of the pharmacological properties of less prevalent pCBs has only scratched the surface, and very little information is available on their effect in the human body (Russo, 2018; Franco et al., 2020; Maccarrone, 2020; Rock et al., 2021; Mechoulam, 2023; Li et al., 2022). For instance, cannabidiolic acid and cannabichromene are used in creams, foods, and beverages (Straiker et al., 2021), and the methyl ester of cannabidiolic acid has been shown to suppress nausea and anxiety (Pertwee et al., 2018), to reduce depression-

like effects (Hen-Shoval et al., 2018), and to have a potent antihyperalgesic effect (Zhu et al., 2020). Further research has shown that cannabidiol exhibits neuroprotective effects in an experimental model of glaucoma (Somvanshi et al., 2022); cannabigerol reduces inflammation, pain, and obesity (Kogan et al., 2021); and both pCBs hold anticancer potential (Li et al., 2022). Humans and other mammals do not produce pCBs but can effectively remove them via the cytochrome P450 and glucuronidation pathways in the liver and other organs (Huestis, 2007; Watanabe et al., 2007; Schafroth and Carreira, 2017; Solymosi and Köfalvi, 2017).

Overall, it is apparent that the term “phytocannabinoid” serves to cluster different plant-derived lipophilic compounds (Pertwee, 2014; Ligresti et al., 2016). It is also worth noting that different cannabis varieties can have distinct chemical profiles (referred to as “chemovars”) and can thus display both qualitative and quantitative differences in their constituents. Because differences in genetics, cultivation technique, harvest, and extraction can affect the ultimate product consumed by humans, it is reasonable to conclude that there is no “one cannabis” and that caution must be taken in generalizing its effects (Hanuš et al., 2016; Procaccia et al., 2022). This variability may also confound our understanding of cannabis' pharmacological properties, and, indeed, remaining uncertainties represent a serious obstacle to its clinical applications (Friedman et al., 2019). Unsurprisingly, despite its use for millennia, cannabis remains surrounded by controversies, debates, and misconceptions related to its medical potential, legalization, and long-term health consequences.

Taken together, the complexity of cannabis extracts seems apparent. However, such a complexity is mirrored, and possibly even exceeded, by that of the ensemble of receptors, enzymes, and transporters of endocannabinoid (eCB) substances that together form the “eCB system” (ECS), recently discussed in comprehensive reviews (Iannotti et al., 2016; Maccarrone, 2017; Baggelaar et al., 2018; Cristino et al., 2020; Kilaru and Chapman, 2020; Simard et al., 2022; Piomelli and Mabou Tagne, 2022). Notably, the main components of the ECS support and control the manifold actions of the eCBs both in the central nervous system (CNS) (Maccarrone et al., 2014; Iannotti et al., 2016; Cristino et al., 2020) and the periphery (Maccarrone et al., 2015). Here it should be stressed that little is still known about the effects that pCBs have on the ECS. Emerging evidence indicates that, even at low concentrations, THC can alter eCB signaling, especially when administered during critical periods such as adolescence (Lee et al., 2022). Additionally, 24-hour treatment with cannabigerol, cannabichromene, Δ^9 -tetrahydrocannabivarin, and cannabigerolic acid has been shown to modulate the function of distinct ECS elements in human HaCaT keratinocytes, where they all increase binding of [3 H]CP55940 to cannabinoid receptors 1 and 2 (CB₁R and CB₂R), stimulation of transient receptor

TABLE 1
Major phytocannabinoids (pCBs)

Name (abbreviation)	Chemical Structure
More Abundant pCBs	
Δ^9 -Tetrahydrocannabinol (THC)	
Cannabidiol (CBD)	
Cannabinol (CBN)	
Cannabigerol (CBG)	
Cannabivarin (CBV)	
Cannabidivarin (CBDV)	
Δ^9 -Tetrahydrocannabivarin (THCV)	
Less Abundant pCBs	
Cannabichromene (CBC)	

(continued)

TABLE 1—Continued

Name (abbreviation)	Chemical Structure
Cannabinodiol (CBND)	
Cannabicyclol (CBL)	
Cannabielsoin (CBE)	
Cannabitriol (CBT)	

potential vanilloid 1 (TRPV1) channels, as well as catalytic activity of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) catabolic enzymes (Di Meo et al., 2022). These data extend previous studies on the effects of cannabinoid-enriched cannabis extracts on transient receptor potential (TRP) channels (De Petrocellis et al., 2011) and of cannabidiol- and cannabigerol-type pCBs on CB₁R and CB₂R (Navarro et al., 2020), suggesting that these minor pCBs could have an impact when present in various cannabis formulations (Di Marzo and Piscitelli, 2015; Turner et al., 2017).

B. Cannabinoid Receptors, Endocannabinoids, and Their Congeners

The discovery of THC in the 1940s (Adams et al., 1948) and its complete structural elucidation 20 years later (Gaoni and Mechoulam, 1964) allowed researchers to synthesize radiolabeled synthetic analogs that were instrumental to the identification and localization of specific cannabinoid binding sites in the brain (Devane et al., 1988; Herkenham, et al., 1990). In particular, a radiolabeled THC congener, the nonclassical bicyclic cannabinoid CP55940, allowed researchers to perform initial binding assays and structure-activity relationship studies of the receptor (Devane et al., 1988; Howlett et al., 1988). This was followed by development of radiolabeled 5'-(1,1-dimethylheptyl)-7-hydroxyhexahydrocannabinol (Devane

TABLE 2
Approved and potential indications for THC and CBD

Cannabinoid	Approved (A) and Potential (B) Indications
THC	(A) Chemotherapy-induced nausea and vomiting; appetite stimulant (HIV/AIDS). (B) Spasticity in MS; neuropathic pain in MS; cancer pain unresponsive to opioids; other pain conditions (i.e., postherpetic neuralgia, postoperative pain); intraocular pressure in glaucoma; depression; anxiety/sleep disorder; psychosis; tics of Tourette syndrome; tremor/bladder dysfunction in MS; dyskinesias in HD; levodopa-induced dyskinesias in PD; cervical dystonia; epilepsy; and AD.
CBD	(B) Childhood epilepsy; tuberous sclerosis complex seizure; Lennox-Gastaut syndrome; Dravet syndrome and infantile spasms.
THC/CBD	(A) Spasticity in MS. (B) Paraplegia and spasticity in amyotrophic lateral sclerosis; cancer pain unresponsive to opioids; other pain conditions (i.e., postherpetic neuralgia, postoperative pain); intraocular pressure in glaucoma; depression; anxiety/sleep disorder; psychosis; tics of Tourette syndrome; tremor/bladder dysfunction due to MS; dyskinesias in HD; levodopa-induced dyskinesias in PD; cervical dystonia; epilepsy; and AD.

AD, Alzheimer's disease; CBD, cannabidiol; HD, Huntington's disease; MS, multiple sclerosis; PD, Parkinson's disease; THC, Δ^9 -tetrahydrocannabinol.

et al., 1992a). The pharmacological characterization eventually led to the molecular cloning of the CB₁R from rat (Matsuda et al., 1990) and human (Gerard et al., 1990, 1991) orphan G protein-coupled receptor (GPCR) clones. CB₁R activation in mice led to a standard set of cannabinomimetic responses, the so-called “tetrad test,” which sequentially assesses antinociception, catalepsy, hypomotility, and hypothermia (Smith et al., 1994). Shortly afterward a second molecular target of THC was found and named CB₂R (Munro et al., 1993), predominantly localized to the immune system (Lynn and Herkenham, 1994), where it leads to immune suppressive responses (Howlett et al., 2002; Klein and Cabral, 2006; Cabral and Griffin-Thomas, 2008; Cabral et al., 2008). For a comprehensive review of both cannabinoid receptors see the report of the International Union of Pharmacology Cannabinoid Receptor Nomenclature Committee (Howlett et al., 2002).

The identification of CB₁R, the most abundant GPCR in the mammalian brain, and of CB₂R prompted intense research into the endogenous ligands for these receptors (Di Marzo and Fontana, 1995). Such ligands were identified as anandamide [*N*-arachidonylethanolamine (AEA)] (Devane et al., 1992b) and 2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995). The first endogenous ligand of CB₁R and CB₂R was named anandamide after the Sanskrit word “Ananda,” which means bliss, and on its chemical nature as an amide. Indeed, AEA and 2-AG are an amide and an ester of the ω -6 arachidonic acid (AA), respectively (Table 3), and remain the best-studied eCBs.

Other potential members of the eCB family have been discovered, including: (1) ω -6 fatty acid-derived eCBs like AEA, 2-AG, 2-arachidonoylglycerol (noladin) ether, and the “inverted anandamide” virodhamine, reported to have various biologic activities (Maccarrone, 2017; Bagelaar et al., 2018; Cristino et al., 2020), and (2) ω -3 fatty acid-derived eCBs like *N*-eicosapentaenylethanolamine and *N*-docosahexaenylethanolamine, endowed with promising anticancer activity (Brown et al., 2010, 2020). In addition, various eCB-like fatty acid ethanolamides, including *N*-palmitoylethanolamine and *N*-oleoylethanolamine, have been described, which

serve important functions in the control of energy metabolism (Rodríguez de Fonseca et al., 2001; Schwartz et al., 2008; Misto et al., 2019), pain (Calignano et al., 1998; Fotio et al., 2021b), and inflammation (Solorzano et al., 2009) by engaging the nuclear receptor peroxisome proliferator-activated receptor (PPAR) α (Fu et al., 2003; Lo Verme et al., 2005). *N*-stearoylethanolamine also has anti-inflammatory activity but via activation of PPAR γ (Kosiakova et al., 2022). Finally, eCB-like amino acids (also known as lipoamino acids) have been isolated, such as *N*-arachidonoylglycine, *N*-arachidonoyldopamine, *N*-arachidonoylserine, *N*-oleoylethanolamine, and *N*-oleoylethanolamine (Ayoub et al., 2020), which may have a number of distinct biologic activities and hold therapeutic potential against vasodilation and osteoporosis (Table 3).

Although THC and AEA have completely different structures, with THC being a terpene-resorcinol derivative (Table 1) and AEA being an AA amide linkage with ethanolamine (Table 3), their biologic activities were found to be closely related (Fride and Mechoulam, 1993; Vogel et al., 1993). Also of note is the observation based on phylogenetic analyses that eCBs appear to be much older than pCBs. Cannabis (aged ca. 76–107 million years) is much younger than organisms like black truffles (*Tuber melanosporum*, aged ca. 156 million years) (Pacioni et al., 2015), hydra (De Petrocellis et al., 1999), and tetraymena (Anagnostopoulos et al., 2010) where eCBs can be detected.

C. Diverse Phytocannabinoids and Endocannabinoid Targets and Signaling Pathways

The number of receptors activated by pCBs and eCBs in the same cell, both on the plasma membrane and in the nucleus, appears striking and is schematically depicted in Fig. 1.

Indeed, pCB- and eCB-binding receptors include (1) seven-transmembrane GPCRs CB₁ and CB₂ (Howlett et al., 2002), as well the recently deorphanized GPCRs GPR55, GPR119, and GPR18 that can also bind cannabinoid-like ligands (Godlewski et al., 2009; Pertwee et al., 2010; Zhao and Abood, 2013; Shore and Reggio, 2015; Morales and Reggio, 2017; Alhouayek et al., 2018; Morales et al.,

TABLE 3
Major endocannabinoids and congeners

Name (abbreviation)	Chemical Structure
Major ω -6 eCBs	
<i>N</i> -Arachidonylethanolamine (Anandamide, AEA)	
2-Arachidonoylglycerol (2-AG)	
2-Arachidonoylglycerol (Noladin) Ether (2-AGE)	
Virodhamine (<i>O</i> -Arachidonylethanolamine, <i>O</i> -AEA)	
Major ω -3 eCBs	
<i>N</i> -Eicosapentaenylethanolamine (EPEA)	
<i>N</i> -Docosahexaenylethanolamine (DHEA)	
Major eCB-like Compounds	
<i>N</i> -Palmitoylethanolamine (PEA)	
<i>N</i> -Oleylethanolamine (OEA)	
<i>N</i> -Stearoylethanolamine (SEA)	
<i>N</i> -Linoleylethanolamine (LEA)	
2-Oleoylglycerol (2-OG)	
Major eCB-Amino Acids	
<i>N</i> -Arachidonoyl dopamine (NADA)	
<i>N</i> -Arachidonoyl glycine (NAGly)	
<i>N</i> -Arachidonoyl serine (ARA-S)	
<i>N</i> -Oleoyl glycine (OIGly)	
<i>N</i> -Oleoyl alanine (OIAla)	

2020; Im, 2021); (2) receptors that are located on the plasma membrane and have intracellular binding sites, such as ionotropic TRP vanilloid 1, 2, 3, 4 channels, TRP cation channel A1, and melastatin 8, which are all six-transmembrane spanning receptors; and (3) nuclear PPARs

α , γ , and δ , which are transcription factors able to regulate gene expression (Maccarrone, 2020; Gomez-Cañas et al., 2023). Of note, CB₁R has been shown to move in and out of distinct microdomains of the plasma membrane known as lipid rafts, which might contribute to the control of their G protein-dependent signaling (Oddi et al., 2017; Saumell-Esnaola et al., 2021). In addition, CB₁R appears to localize also in the outer membrane of mitochondria, where it modulates energy metabolism of neuronal and nonneuronal cells (Pagano Zottola et al., 2022). GPCRs, TRPs, and PPARs trigger different transduction pathways, summarized in Fig. 2.

Therapeutic benefits have been documented by targeting the pCB/eCB-binding receptors and signal transduction thereof, both in CNS and peripheral pathologies as detailed in the following sections. It is now widely appreciated that GPCRs instigate intracellular signaling by two transducer families, heterotrimeric G proteins and GPCR kinases/arrestin. These transducers interact with agonist-bound GPCRs to trigger alternative signaling cascades, so that biased agonists that favor either heterotrimeric G protein or GPCR kinases/arrestin signaling are of profound pharmacological interest (Chen and Tesmer, 2022). In this context, recent advances in understanding biased signaling and off-target activity of CB₂R (Soethoudt et al., 2017), also in living cells (Sarott et al., 2020), and molecular mechanism of allosteric modulation of CB₁R (Yang et al., 2022) suggest that biased signaling driven by eCBs might be better appreciated in the near future and usher in a new generation of drugs with greatly reduced side effects.

D. Metabolic Routes

Metabolism of AEA and 2-AG has been intensely investigated since their discovery in the mid-1990s, whereas little information is as yet available on the metabolic routes of the additional eCBs and congeners. AEA and 2-AG are metabolized by a complex array of distinct biosynthetic and catalytic enzymes and are transported through the plasma membrane, intracellularly and extracellularly, by distinct and poorly understood mechanisms that engage putative protein carriers.

In general, it is of paramount importance that all biologic activities of eCBs, either receptor dependent or independent, are subjected to a stringent “metabolic control,” which means that they depend on the cellular concentration of eCBs, which in turn depends on a balance between synthesis and degradation by multiple regulated enzymes (Friedman et al., 2019; Cristino et al., 2020; Maccarrone, 2020).

1. Metabolism of *N*-Arachidonoyl Ethanolamine.

AEA can be produced by membrane phospholipid precursors via multiple pathways, as schematically depicted in Fig. 3. Among these, *N*-acyltransferase (NAT), either Ca²⁺-dependent or independent (iNAT), and *N*-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) catalyze the most classic route for the release of AEA from phosphatidylethanolamine and phosphatidylcholine precursors. In addition,




Fig. 1. Endocannabinoid binding receptors. The two major endocannabinoids anandamide and 2-arachidonoylglycerol bind to and activate metabotropic and ionotropic membrane receptors (with either an intracellular or an extracellular binding site) and nuclear receptors.

soluble phospholipase A₂, α/β hydrolase domain protein 4, phospholipase C, lyso-phospholipase D, protein tyrosine phosphatase non-receptor type 22, SH2 domain-containing polyinositol-5-phosphatase 1, and various glycerophosphodiesterase family members catalyze parallel routes for the biosynthesis of AEA.


Multiple pathways also exist for the degradation of AEA, which can be cleaved into ethanolamine and AA, thus terminating its biologic activity. This hydrolysis is primarily catalyzed by fatty acid amide hydrolase-1 (FAAH-1) but also by the less widespread FAAH-2 or by the lysosomal enzyme *N*-acylethanolamine acid amidase (NAAA) (Piomelli et al., 2020), as shown in Fig. 4.

As an alternative to degradation, AEA can be biotransformed by oxygenation (i.e., addition of molecular O₂) of the AA moiety catalyzed by lipoxygenase 5, 12, 15 isozymes (5-, 12-, 15-LOX), cyclooxygenase-2 (COX-2) or cytochrome P450 (CYP450), as summarized in Fig. 4 and recently reviewed (Rouzer and Marnett, 2011; Fezza et al., 2014; Simard et al., 2022). Remarkably, COX-2-generated prostamides and the other oxidative derivatives of AEA are endowed with biologic activities on their own (Van der Stelt et al., 2002; Simard et al., 2022). To date, their

pathophysiological roles remain rather elusive, but apparently they include neuroprotection of the brain (Veldhuis et al., 2003).

2. Metabolism of 2-Arachidonoylglycerol. Much like AEA, membrane phospholipid precursors like phosphatidylinositol and phosphatidic acid are cleaved via phospholipase A₁ or phosphohydrolase, respectively, to release 2-arachidonoylglycerol-3-phosphate or diacylglycerol, respectively (Fig. 5). Then, a Ca²⁺-dependent phospholipase C (PLC) or Ca²⁺- and glutathione-dependent DAG lipases (DAGL) α and β release 2-AG. The latter DAGL α/β -dependent pathway is the classic biosynthetic route for 2-AG (Bisogno et al., 2003), and glutathione seems to be a key regulator in the brain (Maccarrone et al., 2008).

Alternative pathways have been discovered for the degradation of 2-AG, which is primarily cleaved to glycerol and AA by MAGL, as shown in Fig. 6. In addition, α/β hydrolase domain proteins 2, 6, and 12, carboxylesterases 1 and 2, and palmitoyl-protein thioesterase 1 can degrade 2-AG to AA and glycerol (Baggelaar et al., 2018; Maccarrone, 2020), as shown in Fig. 6. Much like AEA, 2-AG can be oxygenated by COX-2, 12- and 15-LOX (Rouzer and Marnett, 2011; Fezza et al., 2014; Simard



AKT: α -Serine/threonine-protein kinase

AMP: Adenosine monophosphate

cAMP: Cyclic adenosine monophosphate

CREB: cAMP response element-binding protein

ERK: Extracellular signal-regulated kinase

GSK3 β : Glycogen synthase kinase-3 β

IL: Interleukin

JNK: c-Jun N-terminal kinase

MAPK: Mitogen-activated protein kinase

MMP: Matrix metalloproteinase

mTOR: Mammalian target of rapamycin

NF κ B: Nuclear factor kappa-light-chain-enhancer of activated B cells

NOS: Nitric oxide synthase

PKA: Protein kinase A

STAT: Signal transducer and activator of transcription


Fig. 2. Endocannabinoid signaling pathways. Receptor binding by anandamide and 2-arachidonoylglycerol triggers various signal transduction pathways, which activate G proteins, ion channels, as well as gene transcription.

et al., 2022), leading to oxidative derivatives like prostaglandin- or thromboxane-glycerol esters with their own biologic activities (Baggelaar et al., 2018; Simard et al., 2022).

E. Trafficking of Endocannabinoids

The stringent metabolic control of eCB tone is further modulated by distinct transporters that facilitate the movement of eCBs across the plasma membrane (possibly via a purported and as yet elusive eCB membrane

transporter), as well as intracellularly and extracellularly. Moreover, not only can eCBs be released from membrane precursors when the cell receives a stimulus “on demand,” but they can be stored in cytosolic organelles like adiposomes (Maccarrone, 2020). The mechanisms underlying the membrane transport of eCBs have been extensively investigated, leading to two prevailing models whereby eCBs are transported either by passive diffusion (Fasia




- AEA: *N*-Arachidonoyl ethanolamine
 ABHD₄: α/β -Hydrolase domain protein 4
 GDE_{1,4,7}: Glycerophosphodiesterase isoforms 1, 4 and 7
 GDPD_{1,3}: Lysophospholipase D isoforms 1 and 3
 NAPE-PLD: *N*-acyl phosphatidylethanolamines-specific phospholipase D
 NArPE: *N*-arachidonoyl phosphatidylethanolamine
 (i)NAT: (Calcium independent) *N*-acyltransferase
 p-AEA: Phospho-AEA
 sPLA₂: Soluble phospholipase A₂
 PLC: Phospholipase C
 PLD: Phospholipase D
 PTPN22: Protein tyrosine phosphatase non-receptor type 22
 SHIP1: SH2 domain-containing polyinositol-5-phosphatase 1

Fig. 3. Biosynthetic pathways of anandamide. AEA can be synthesized from membrane phospholipid precursors via different routes. The Ca^{2+} -dependent hydrolysis of NArPE by NAPE-PLD is considered the most relevant among these biosynthetic pathways.

et al., 2003) or by facilitated diffusion through a membrane carrier (Di Marzo et al., 1994; Beltramo et al., 1997). The mechanism(s) of transmembrane transport of eCBs remain(s) a highly debated issue in the field and has/have been the subject of comprehensive critical reviews (Fowler, 2013; Nicolussi and Gertsch, 2015; Kaczocha and Haj-Dahmane, 2022). In addition to passive or facilitated diffusion, eCBs can leave a cell as part of

microvesicles that undergo exocytosis, and indeed such a mode of extracellular transport has been demonstrated in the synaptic cleft for both AEA (Gabrielli et al., 2015) and 2-AG (Nakamura et al., 2019). The different modalities of transmembrane transport of eCBs are schematically depicted in Fig. 7A.

The eCBs are lipids, and as such they cannot travel the aqueous cytosol without a suitable carrier (Maccarrone




AA: Arachidonic acid; AEA: Arachidonoyl ethanolamide;
 CYP450: Cytochrome P450;
 EET-EA: Eicosatetraenoyl ethanolamine;
 EtNH₂: Ethanolamine;
 FAAH: Fatty acid amide hydrolase;
 HAEA: 12-hydroxy-N-arachidoylethanolamide;
 LOX: Lipoxygenase;
 NAAA: N-Acylethanolamine acid amide hydrolase;

Fig. 4. Catabolic pathways of anandamide. AEA can be cleaved to arachidonic acid and ethanolamine by different hydrolytic routes. FAAH-1 is considered the most relevant among these catabolic pathways. Alternatively to hydrolytic routes, AEA can be oxidized by LOXs, COX-2, or cytochrome P450 to generate various eicosanoid-like PG-ethanolamides or hydroxy-AEAs.

et al., 2010). Unsurprisingly, cytosolic AEA-binding proteins have been demonstrated over the last few years and include structurally unrelated proteins like heat shock protein 70 and albumin (Oddi et al., 2009), fatty acid binding proteins (FABPs) 1, 5, and 7 (Kaczocha et al., 2009; Elmes et al., 2019), FAAH-like anandamide transporter (Fu et al., 2011), sterol carrier protein 2 (Hillard et al., 2017), and retinol-binding protein 2 (Plau et al., 2022). These eCB transporters are schematically depicted in Fig. 7B.

While the pathophysiological relevance of intracellular and extracellular trafficking of eCBs remains

elusive (Jacobson et al., 2019; Fauzan et al., 2022), it appears that carriers of these lipids should be actively investigated, because they might be major players in driving eCB signaling. Indeed, these carriers can ferry the right eCB to the right target, at the right time and in the right concentration, thus holding potential as primary action points for the development of effective eCB-oriented therapeutics. Of note, these novel therapeutics should be devoid of unwanted side effects often associated with drugs that target receptors or metabolic enzymes of eCBs (Ciaramellano et al., 2023).



2-AG-3P: 2-Arachidonoylglycerol-3-phosphate
 2-AG: 2-Arachidonoylglycerol
 DAG: Diacylglycerol
 DAGL: Diacylglycerol lipase
 PH: Phosphohydrolase
 PLA₁: Phospholipase A₁
 PLC: Phospholipase C

Fig. 5. Biosynthetic pathways of 2-arachidonoylglycerol. 2-AG can be synthesized from membrane phospholipid precursors via different routes. The Ca²⁺- and glutathione-dependent hydrolysis of DAG by DAGLα/β is considered the most relevant among these biosynthetic pathways.

On a final note, to date, 3D structures of only 23 major components of the ECS have been resolved, whereas many other elements still await clarification of their structural features (Maccarrone, 2020). Among the latter, key receptors (e.g., GPR55, GPR119, and TRPV4), enzymes (e.g., NAT, DAGLα/β, GDE1,4,7, ABHD2, 4, 6, 12), and the putative eCB membrane transporter can be listed. It is apparent that such an information gap is particularly troubling for drug discovery programs and must be urgently filled.

In the following sections, the main properties and therapeutic potential of some of the main ECS components are detailed, whereas the other elements suffer from a lack of information.

II. Cannabinoid Receptor Physiology and Pharmacology

The eCBs and THC are dual effectors at both CB₁R and CB₂R, which share a ligand binding domain sequence identity of 44% (Matsuda et al., 1990; Munro et al., 1993; Howlett et al., 2002; Mackie, 2005). The absolute stereochemistry of THC was deciphered in 1967 (Fig. 1) (Mechoulam and Gaoni, 1967), and this was followed by the development of many analogs by academic chemists (Razdan, 1986). THC is a dual CB₁R and CB₂R partial agonist exhibiting multiple therapeutically interesting physiologic properties involving both receptor types, which include anti-inflammatory,




Fig. 6. Catabolic pathways of 2-arachidonoylglycerol. 2-AG can be cleaved into arachidonic acid and glycerol by different hydrolytic routes. MAGL is considered the most relevant among these catabolic pathways. Alternatively to hydrolytic routes, 2-AG can be oxidized by LOXs or COX-2 to generate various eicosanoid-like PG-glycerol esters or hydroxy-2-AGs.

immunosuppressive, and analgesic effects. THC was the first cannabinoid agonist approved as a medication by the FDA under the generic name dronabinol (Marinol), although its use was restricted due to CNS-mediated psychotropic side effects.

Many additional nonselective cannabinoid agonists have provided insights into pharmacotherapeutic potential (reviewed by Robson, 2001; Pertwee 2008b, 2012). With a goal to develop cannabinoid, nonopioid analgesics, Pfizer produced a series of A-C-bicyclic and A-C-D-tricyclic analogs of THC's CNS-active metabolite 11-OH-THC, and these are referred to as "non-classical cannabinoids" because of their origin and similarity to the A-B-C-tricyclic structure of THC (Johnson et al., 1981; Howlett et al., 1990; Melvin et al., 1993, 1995). Of these, levonantradol was taken to clinical trials for postoperative pain, but the project was discontinued due to prominent sedative and euphoric/dysphoric properties (Jain et al., 1981). The primary outcome of the Pfizer effort was the development of the CB₁R/CB₂R nonselective full agonist CP55940, outperforming THC with regard to CB₁R/CB₂R binding affinity and analgesic activity (Devane et al., 1988; Howlett et al., 1988; Showalter et al., 1996) (Fig. 8). CP55940 is a research tool that has been invaluable in identifying cannabinoid receptor cellular and systems physiology (Devane et al., 1988). Tritiated CP55940 was critically involved in the deorphanization of both CB₁R (Matsuda et al., 1990) and CB₂R (Munro et al., 1993) and has been broadly applied to quantitate the structure-activity relationships of most novel ligands developed for the investigation of cannabinoid receptors.

Sterling-Winthrop discovered that structural modifications of the nonsteroidal anti-inflammatory agent

pravadoline resulted in greater antinociceptive activity with diminished potential to block prostaglandin production (Bell et al., 1991). Although the Sterling-Winthrop project was terminated in the preclinical stages, the introduction of the CB₁R/CB₂R nonselective full agonist WIN55212-2 has contributed greatly to investigations of cannabinoid receptor physiology and pharmacology (Fig. 9). WIN55212-2 in its tritiated form is a standard CB₁R/CB₂R radioligand (D'Ambra et al., 1992; Eissenstat et al., 1995) and with its derivatives is referred to as "aminoalkylindoles" because their structure is built on indole or indene platforms.

Selective activation of either CB₁R or CB₂R by THC or the other nonselective agonists seems to be controlled by differential expression (induction or desensitization/downregulation) of the receptors on a wide variety of cells that control differentiated functions (reviewed by Howlett and Abood, 2017).

Research work using ligand-assisted protein structure methodology has characterized the sites of action at CB₁R and CB₂R (Janero et al., 2017). However, a more detailed CB₁R structure was reported in 2016 in its inactive conformation by using the long-acting CB₁R antagonist AM6538 (Hua et al., 2016), shown in Fig. 10, and the antagonist/inverse agonist taranabant (Shao et al., 2016). This allowed the docking of several CB₁R antagonist analogs and the study of their interactions with the receptor. This work was followed by studies on the structures of the agonist-bound CB₁R (Hua et al., 2017; Krishna Kumar et al., 2019; Hua et al., 2020), which demonstrated that activation of CB₁R induces dramatic conformational changes of both extracellular and intracellular domains of the receptor,




Fig. 7. Transport of endocannabinoids. (A) Anandamide and 2-arachidonoylglycerol can cross the plasma membrane via different mechanisms, which include passive diffusion, exocytosis of microvesicles and a putative membrane transporter. (B) Intracellular trafficking of anandamide and 2-arachidonoylglycerol is driven by various carriers that include structurally unrelated proteins like albumin, RBP2, HSP70, FABPs, SCP2, and FLAT.

accompanied by a serious contraction of the binding pocket. This more expansive conformation of CB₁R in its inactive state explains how several antagonists can be accommodated in the receptor structure.

The high-resolution crystal structure of antagonist-bound CB₂R was determined in 2019, which first discloses the binding mode of antagonist AM10257 (Li et al., 2019). The latter locates at the orthosteric ligand-binding pocket and mainly forms hydrophobic and aromatic interactions with residues from extracellular loop 2, as well as the cytoplasmic parts of transmembrane helices 2, 3, 5, and 6 of CB₂R (Fig. 11A). However, the antagonist AM10257 adopts a constrained binding pose in CB₂R, which is quite different from the extended binding conformation of antagonists in CB₁R (Hua et al., 2016). Of note, the adamantyl moiety of AM10257, adopting a vertical conformation, would clash with the residue Phe102N-term of CB₁R when two structures are superimposed (Fig. 11, B–D). That is the reason why the N-terminus of CB₂R forms a short helix

over the orthosteric pocket, instead of the V-shaped loop that directly interacts with the antagonist in CB₁R (Hua et al., 2016; Shao et al., 2016). In addition, the extracellular part of transmembrane helices 1 and 2 in CB₂R is more compact compared with the conformations of the same helices in CB₁R, resulting in a much smaller antagonist-binding pocket than that of CB₁R (Hua et al., 2016; Shao et al., 2016). The structural analysis provides the basis for the high degree of antagonist selectivity between CB₁R and CB₂R.

In spite of the high selectivity of antagonists or inverse agonists, most agonists can bind both CB receptors with comparable affinity (Pertwee et al., 2010). The recently determined structures of agonist-bound CB₂R provide valuable information at the molecular level for subtype-selective agonist design (Hua et al., 2020; Xing et al., 2020) and subtype-selective receptor activation (Li et al., 2023). Both the synthetic THC-like agonist AM12033 and aminoalkylindole agonist WIN55212-2 form mainly hydrophobic and aromatic




Fig. 8. Chemical structure, CB_2R binding affinity and selectivity of relevant nonclassical cannabinoids. ^aConsensus human CB_2R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017). ^b CB_2R selectivity ($10^{(pK_i CB_2R - pK_i CB_1R)}$).

interactions with CB_2R , including residues from trans-membrane helices 2–3 and 5–7 and the extracellular loop 2 with similar binding mode in the orthosteric ligand-binding pocket (Fig. 11, E–F). Although the core of WIN55212-2 forms π - π interactions with F1173.36 and W2586.48 of CB_2R , the rotamers of F1173.36 and W2586.48 are very similar in these two structures (Fig. 11G). The superposition of agonist-bound CB_1R and CB_2R structures shows that the agonist binding pocket volume, as well as the key residues that form interactions with ligands, are almost identical (Fig. 11, H–M).




Fig. 9. Chemical structure, CB_2R binding affinity and selectivity of representative aminoalkylindole CB_2R ligands. ^aConsensus human CB_2R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017). ^b CB_2R selectivity ($10^{(pK_i CB_2R - pK_i CB_1R)}$).

This accurate molecular information of the CB receptors' orthosteric binding pockets obtained so far should aid the design of selective agonists for safer therapeutics.

The CB_2R activation mechanism was revealed by the comparison of active and inactive structures. Though the antagonists and agonists of CB_2R share similar binding pockets, including the key interaction residues with the receptors, the interaction of CB_2R ligands with the “toggle residue” W2586.48 is related to their efficacies. Compared with antagonist AM10257, agonist AM12033 lacks the moiety that extends deeper into the binding cavity to constrain W2586.48 rotation, which can trigger receptor activation (Fig. 12A). Subsequently, the classic rearrangements of N7.49 P7.50 \times Y7.53 and D3.49 R3.50 Y3.51 motifs were observed that contribute to the conformational change of the intracellular part of CB_2R , eventually forming the G-protein binding cavity (Fig. 12, B–C). However, in contrast to agonist-bound CB_1R , only the intracellular part of CB_2R exhibits obvious conformational changes while the extracellular part including the N-terminus of CB_2R undergoes minor changes during its activation (Fig. 12, D–F). The balloon-like plasticity of CB_1R during its activation indicates its higher ability to respond to a diverse array of ligands than CB_2R , which may explain the low selectivity compared with CB_1R for most classic THC-like agonists of CB_2R .

A. Therapeutic Potential of Cannabinoid Receptor 1

The epigenetic regulation of CB_1R expression and signal transduction pathways following G_i/o or β -arrestin




Fig. 10. (A) X-ray structure of CB₁R (blue) bound to the antagonist AM6538. (B) Cryo-EM structure of CB₁R (green) in complex with G proteins (α subunit in yellow, β subunit in blue, γ subunit in purple) and the classic cannabinoid agonist AM841. (C) Chemical structures of AM6538 and AM841.

activation is related to differentiated cell functions, as reviewed recently (Kendall and Yudowski, 2016; Ligresti et al., 2016; Howlett and Abood, 2017; Lutz, 2020; Schurman et al., 2020). The CB₁R is highly abundant in the CNS and many peripheral tissues and organs (Howlett et al., 2002; Pacher et al., 2006). For instance, it is critically involved in the regulation of mood and appetite, pain perception, learning, and memory, as well as motor control (Marsicano and Lutz, 2006; Kano et al., 2009; De Laurentiis et al., 2014). The CB₁R has been recognized as a target for pharmacotherapeutic development based on a wealth of preclinical data (for reviews, see Mackie, 2008; Pertwee, 2008b, 2012; Tsang and Giudice, 2016; Lu and Anderson, 2017; Amin and Ali, 2019; Schurman et al., 2020; Wilkerson et al., 2021). However, bringing CB₁R agonists and antagonists to market has been fraught with the challenges of selectivity resulting from the abundance of CB₁R throughout all areas of the brain, including expression by neuronal

and nonneuronal cells. This broad distribution increases the probability of unwanted side effects accompanying the therapeutic benefits.

1. CB₁R Agonists and Positive Allosteric Modulators.

The only FDA-approved CB₁R agonists are THC itself (synthesized as dronabinol) and its dimethylheptyl analog nabilone (LY-109514), specifically to treat cancer chemotherapy-induced nausea and vomiting, and these medicines remain within the US Pharmacopeia (Clarivate, 2022d; <https://adisinsight.springer.com/drugs/800025856>). The European Medicines Agency (EMA) approved the mixture of THC and CBD extracted and purified from cannabis (nabiximols) for the treatment of spasticity and pain in multiple sclerosis (MS). Dronabinol, nabilone, and nabiximols exhibit agonist activity at both CB₁R and CB₂R, though therapeutic responses and untoward side effects can be attributed to one or both CB receptors, as determined by pharmacological characterization in in vivo or in vitro models. Nevertheless, targeting CB₁R for unmet




Fig. 11. Comparison of ligand binding modes in CB₁R and CB₂R. (A) The binding pocket of AM10257 in CB₂R crystal structure (PDB code 5ZTY). AM10257 and the key residues are shown in sticks as the following color code: CB₂R, brown; AM10257, light coral. (B–D) Binding pose comparison of AM6538 in CB₁R (PDB code 5TGZ), and AM10257 in CB₂R, using color code as follows: CB₁R, slate blue; AM6538, dodger blue; CB₂R, brown; AM10257, light coral. (E–F) The binding pocket of AM12033 in CB₂R (PDB code 6KPF) and WIN55,212-2 in CB₂R (PDB code 6TP0). Ligands and the key residues are shown in sticks as the following color code: AM12033, brown; CB₂R (6KPF), dark green; WIN55,212-2, royal blue; CB₂R (6TP0), dark salmon. (G) The conformational comparison of “toggle switch” residues Trp258^{6.48} between AM12033- and WIN55,212-2-bound CB₂R. (H–J) Binding pose comparison of THC-like agonist in CB₁R (PDB code 6KPG) and CB₂R (PDB code 6KPF). THC-like agonists are shown as sticks (H) and surface (I–J), the key residues are shown in sticks as the following color code: CB₂R, dark green; AM12033, brown; CB₁R, maroon; AM841, dark khaki. (K–M) Binding pose comparison of agonist FUB in CB₁R (PDB code 6N4B) and agonist WIN55,212-2 in CB₂R (PDB code 6TP0). FUB and WIN55,212-2 are shown as sticks (K) and surface (L–M), the key residues are shown in sticks as the following color code: CB₂R, dark salmon; WIN55,212-2, royal blue; CB₁R, dark cyan; FUB, orange.

therapeutic needs has evolved based on preclinical investigations, and these opportunities will be considered in this section.

Dronabinol was developed to counteract nausea and vomiting in cancer chemotherapy and was later approved to promote appetite stimulation and metabolic maintenance to counteract cachexia in AIDS patients (Plasse et al., 1991). Dronabinol is synthetically produced THC formulated in a sesame oil capsule and marketed as Marinol (<https://adisinsight.springer.com/drugs/800007811>). Dronabinol is also available in a liquid formulation solubilized in ethanol and propylene glycol and marketed as SYN-DROS. The pharmacokinetics, dosage recommendations,

and drug interactions are available at Prescribers Digital Reference (<https://www.pdr.net/drug-summary/Marinol-dronabinol-2726>). The warnings reported include bradycardia and seizures in vulnerable populations. Mild to moderate adverse reactions include emotional lability in 8% to 24% of users; impaired cognition, dysphoria or euphoria, depression, hypotension, drowsiness, paranoia, dizziness, or nausea in 3% to 10% of users; and conjunctivitis, hallucinations, confusion, amnesia, ataxia, tinnitus, nightmares, or diarrhea in 0.3% to 1% of users (<https://www.pdr.net/drug-summary/Marinol-dronabinol-2726>).

Nabilone is synthesized as a 9-ketocannabinoid with a dimethylheptyl side chain (Fig. 13) and is enzymatically




Fig. 12. Conformational changes during CB₂R activation. (A–C) The conformational change of key residues between inactive- and active-CB₂R. “Toggle switch residue” (A), D^{3.49}R^{3.50}Y^{3.51} motif (B), and N^{7.49}P^{7.50}xxY^{7.53} motif (C). (D–F) The overall structure (D), the extracellular region (E), and intracellular region (F) comparison of inactive- (brown) and active-state (dark green) CB₂R structures.

reduced in the liver to the hydroxylated *S*(axial) isomer believed to be the active form (Archer et al., 1977; Rubin et al., 1977; Billings et al., 1980). Nabilone was approved as an antiemetic for cancer chemotherapy but also exhibits anxiolytic properties (Lemberger and Rowe, 1975; Ward and Holmes, 1985). Nabilone is used off-label for treatment of the symptoms of Huntington’s chorea (<https://www.pdr.net/drug-summary/Cesamet-nabilone-692>). The warnings and adverse reactions are similar to those reported for dronabinol: seizures in vulnerable populations, early euphoria or dysphoria, delayed depression, ataxia, hypotension, drowsiness, vertigo, dizziness, asthenia, or headache.

Nabiximols is a mixture of THC and CBD (1:1) in ethanol and propylene glycol solvent as an oromucosal spray formulation marketed as Sativex (see the EMA compendium for information: <https://www.medicines.org.uk/emc/product/602/smpc#gref>). The spray is intended to be applied at the onset of muscle contractions to reduce spasticity and pain in MS patients. Each application provides some fraction of the dosage to be absorbed via the mucosal membranes, and the remainder is swallowed and absorbed from the gastrointestinal tract. Sativex was granted orphan designation by the EMA for the treatment of glioma patients while clinical trials were being conducted; however, this status was later withdrawn

(see EMA notices: EMA, 2022). The EMA reports pharmacokinetic data and recommends dosing schedules for use in MS patients (<https://www.medicines.org.uk/emc/product/602/smpc#gref>). The report includes warnings/precautions for use in patients with histories of seizures or cardiovascular disease. Adverse reactions found in clinical trials include appetite changes, dizziness, disorientation, mood swings, depression, amnesia/memory impairment, somnolence or blurred vision in 1% to 10% of users, and pharyngitis, syncope, anxiety, illusions, paranoia, hallucinations, or delusional beliefs in 0.1% to 1% of users. Adverse effects at the site of application include oral discomfort/pain, altered taste, mouth ulceration, and accompanying pain.

Prior to the recognition of CB receptors, clinical trials provided positive indications for CBD for seizure control and movement disorders (Cunha et al., 1980; Carlini and Cunha, 1981; Consroe et al., 1986, 1991). CBD entered the market for the treatment of Dravet syndrome, infantile severe myoclonic epilepsy, Lennox-Gastaut syndrome, and tuberous sclerosis (Clarivate, 2022b). In addition, CBD and THC combinations have been approved for MS-associated spasticity and pain management (Clarivate, 2022g; <https://citeline.informa.com/drugs/details/175074>). CBD in the nabiximols formulation may or may not exert its




Fig. 13. Structures of the clinically tested cannabinoid agonists (A) and the selective CB₁R antagonists (B).

cellular actions via processes involving CB₁R. CBD exerts both negative and positive interactions with THC over a range of biologic and behavioral responses in animal models and humans (Pertwee, 2008a; McPartland et al., 2015). In a cloned neuronal cell model, CBD competed with the CB₁R agonist [³H]CP55940 in binding to the receptor at concentrations nearly three orders of magnitude greater than did THC (Devane et al., 1988); however, CBD failed to inhibit cAMP production via the CB₁R-coupled G_i protein as does THC (Howlett, 1984; Mukhopadhyay et al., 2002). Similar findings of low potency binding to CB₁R and inability to stimulate CB₁R cellular signaling were reported in multiple studies using other models as compiled in a meta-analysis from a pool of > 200 research publications (McPartland et al., 2015). Two influences of CBD on CB₁R pharmacology are most compelling: (1) CBD could exert a noncompetitive antagonism at CB₁ receptor (Petitet et al., 1998; Thomas et al., 2007; Laprairie et al., 2015) and (2) CBD could indirectly modulate CB₁R activity by FABP competition (Elmes et al., 2015) and FAAH inhibition (Bisogno et al., 2001; De Petrocellis et al., 2011) or activation (Massi et al., 2008), thereby changing eCB tone. Non-CB₁R mechanisms proposed for CBD's neurologic actions minimally include the facilitation of serotonin signaling, activation of TRPV1 or PPAR_γ receptors, neuroprotection via antioxidant activity, and attenuation of proinflammatory processes (Campos et al., 2012; Ibeas Bih et al., 2015; Campos et al., 2017). Other molecular targets for CBD include additional GPCRs (e.g., GPR55, GPR18,

μ and δ opioid receptors) and TRP channels A1, V2, M8 (McPartland et al., 2015; Ligresti et al., 2016).

Because dronabinol, nabilone, and nabiximols are currently approved medicines by regulatory agencies, it is acceptable to repurpose these preparations for treatment or amelioration of other disease symptoms based upon preclinical evidence that justifies their use. Table 4 lists the double-blind clinical trials that have been registered with ClinicalTrials.gov and are completed or ongoing at the date of publication of this review.

Appropriate preclinical data justify these putative uses and warrant evaluation of both efficacy of these cannabinoid agonists for these purposes and relative safety given the risk:benefits assessment and the circumstances of patient treatment. Review articles are cited that summarize research evidence in animal models, address implications and challenges, and provide original references.

Nausea and vomiting that accompany surgical procedures, retroviral therapy, and neoplasms are unmet needs that build upon the original usage approved by regulatory agencies for patients undergoing cancer chemotherapy (Abrams and Guzman, 2015). Preclinical studies using animal models of nausea and vomiting (“retching” or “gaping”) have demonstrated effective attenuation with CB₁R agonists, although the exact neurologic mechanism has not been established (Parker et al., 2011; Sticht et al., 2015). In contrast, in the current population of recreational cannabis users, a novel cannabis-induced hyperemesis syndrome has been attributed to ingestion of very high doses of THC. The mechanism is poorly understood, but it has been

suggested that prolonged exposure to high doses of THC might downregulate CB₁R or otherwise perturb the endogenous regulation of vomiting centers in the brain stem and/or elicit stress mechanisms at the hypothalamic-pituitary axis (Galli et al., 2011; DeVuono et al., 2020). Thus, there may be a “bell-shaped” dose-response curve suggesting multiple mechanisms for the anti- versus pro-nausea/vomiting endpoints.

The appetite stimulation response was the impetus for regulatory approval of CB₁R agonists as “orphan” drugs for the treatment of cachexia in cancer (Plasse et al., 1991). However, it is the appetite suppression by CB₁R antagonism that prompted clinical trials for weight loss in morbidly obese individuals and resulted in an explosion of basic science research linking the CB₁R to metabolic processes associated with energy storage (Piazza et al., 2017; DiPatrizio, 2021; Miralpeix et al., 2021). Studies of CB₁R-mediated inhibition of gut mobility (Pertwee et al., 1992; Pertwee, 2001) led to the consideration of agonist treatments for irritable bowel syndrome and other gastrointestinal pathologies (Lee et al., 2016; Sharkey and Wiley, 2016). Conversely, detrimental influences of CB₁R stimulation on pancreatic β -cell function, diabetic insulin resistance, and hepatic steatosis (Gruden et al., 2016; Nagappan et al., 2019), as well as on female (Cecconi et al., 2020) and male (Maccarrone et al., 2021) reproductive functions, must be considered in the safety profile for CB₁R agonist medicines.

Control of chronic and episodic pain continues to be an unmet therapeutic need. The development of CB₁R agonists as antinociceptive agents by Pfizer Central Research (Johnson et al., 1981; Howlett et al., 1990; Melvin et al., 1993, 1995) was meant to fulfill this need, but the effort was discontinued due to untoward side effects in patients during clinical trials (Jain et al., 1981). A resurgence of interest in cannabinoid analgesics as adjunctive or second/third-line treatments has reassessed the benefits versus risks ratio for pain conditions associated with cancer, neuropathy, fibromyalgia, and spasticity (Tsang and Giudice, 2016; Woodhams et al., 2017). Recent clinical trials suggest that cannabinoid-mediated analgesia in humans could be attributed to a moderate reduction in affective response but not a reduced perception of the experimental pain (Lötsch et al., 2018).

CB₁R agonist efficacy in symptomatic relief in MS and amyotrophic lateral sclerosis is related to the reduced spasticity and tremors, as investigated in an animal model of chronic relapsing experimental allergic encephalomyelitis, as well as reports from patients (Pryce and Baker, 2015; Pertwee, 2002). In addition to relieving the spastic pain, cannabinoid agonists at CB₁R and CB₂R slow the progression of the disease as a result of neuroprotective mechanisms and oligodendrocyte development to promote myelination (Pryce and

Baker, 2015; Ilyasov et al., 2018; Khan et al., 2022). Similarly, agonist stimulation of both CB receptors reduces symptomology and disease progression in other neurodegenerative diseases such as Parkinson's disease, Huntington's chorea, Alzheimer's disease, and stroke (Fernández-Ruiz et al., 2015a,b).

Numerous “cannabinoid products” that are not approved by regulatory agencies are being tested for their potential therapeutic value. It is difficult to discern the composition and concentration of active agents in these herbal preparations, which are variously described as cannabis, cannabis oil, smoked cannabis (cigarettes), inhaled cannabis, vaporized cannabis, cannabis extract, or “CBD-rich”/“THC-rich” marijuana or extracts. These preparations are not further discussed here, because of the lack of quantitative analyses of the materials being used by the patients. Of note, these herbal studies are registered in ClinicalTrials.gov as assessments (blinded or unblinded) for symptomatic improvements in neuropsychiatric and neurologic disorders, including attention deficit and hyperactivity disorder, dementia, anxiety, depression, post-traumatic stress disorder, autism spectrum disorder, obsessive-compulsive disorder, refractory epilepsy, MS, amyotrophic lateral sclerosis, Tourettes' syndrome, pain (migraine, neuropathic, fibromyalgia, pre- and post-surgical, back, and cancer), agitation associated with aging dementia, irritable bowel disease, chronic obstructive pulmonary disease, and retinitis pigmentosa with degeneration. The rationale for using plant products is that the effects of multiple chemical entities (including “cannabinoids,” terpenes, and flavonoids) may synergize, a concept referred to as an “entourage effect.” The idea of combining medicines—referred to as polypharmacology—that provide different but complementary pharmacological responses, such as anti-inflammatory plus analgesic agents, is not new and is often a preferred treatment strategy (Brodie et al., 2015; Ligresti et al., 2016). However, the challenges of determining the active synergistic agents, appropriate dosing schedule, specificity of therapeutic use, and safety profile remain to be overcome when herbals are used as medicinal products.

In an effort to address selectivity for the CB₁R, modifications have been made to pCB, aminoalkylindole, and eCB ligands. For example, AEA analogs arachidonylcyclopropylamide (ACPA) and arachidonyl-2-chloroethylamide (ACEA) exhibit 1-2 nM affinity for the CB₁R but 1-3 μ M affinity for the CB₂R, and both inhibit cAMP CB₁R selectivity of the ACPA (Hillard et al., 1999). This selectivity led to the CB₁R selective (CB₁R/CB₂R Ki ratio = 0.1) dual CB₁R/CB₂R agonist CMX-020, which is currently being explored in phase 2 clinical trials for the treatment of osteoarthritis (<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371547&isReview=true>), pain including sciatica, and diabetic neuropathy (Clarivate, 2022c).

TABLE 4
Diseases/symptoms for treatment with CB₁R agonists and antagonists registered with ClinicalTrials.gov

Generic Name Brand Name Class/Efficacy	Completed Clinical Trials	Ongoing Clinical Trials
Dronabinol Marinol Phytocannabinoid Synthetically produced Δ ⁹ -tetrahydrocannabinol (THC) CB ₁ R/CB ₂ R partial agonist	Chronic pain (with opioid treatment) Fibromyalgia, back pain Migraine pain Neuropathic, low back pain Cervical dystonia Chest pain Neuropathic pain in MS Cramps in ALS Irritable bowel syndrome Complex regional pain syndromes Cannabis dependence Cannabis use disorder Marijuana withdrawal Trichotillomania related behaviors Post-traumatic stress disorder Obstructive sleep apnea PostSurgical N/V Anti-retroviral therapy N/V Brain neoplasms N/V Schizophrenia	Osteoarthritis pain Diabetic neuropathy Knee arthroplasty Arthroscopic surgery Sleep and pain in MS Postsurgical pain-lumbar fusion Postsurgical pain-knee replacement Pain in opioid-maintained pts Alzheimer's agitation Bipolar disorder Sleep Post-traumatic stress disorder Trauma intrusive memories Glaucoma hemodynamics
Dronabinol derivatives BX-1 oral solution Syndros (dronabinol) Namisol THC Namisol THC Namisol THC Namisol THC THC olive oil THC olive oil SCI-110 THC + PEA THX-110 THC + PEA dronabinol + naltrexone	Spasticity Bone pain metastatic breast CA Postsurgical abdominal pain Pancreatitis abdominal pain Dementia–Alzheimer's Dementia w/ neuropsych symptoms Post-traumatic stress disorder Fibromyalgia–pain Tourette syndrome Tourette syndrome Opioid dependence	Chemo N/V, pain in pancreatic CA Tourette syndrome
Nabilone Cesamet Synthetic THC analog CB ₁ R/CB ₂ R agonist	Phantom limb pain Fibromyalgia Failed back surgery pain Inflammatory bowel pain Diabetic neuropathies Spinal injury muscle Spinal cord injury Postsurgical N/V Cancer anorexia/cachexia Parkinson's disease Parkinson's nonmotor symptoms Alzheimer's disease	Spinal neuropathic pain Pain and insomnia End-stage renal disease Obesity Developmental cognitive disability Obsessive-compulsive disorder Alzheimer's disease agitation
PP-01 Nabilone+Gabapentin		Cannabis withdrawal
Nabiximols Sativex Phytocannabinoid Purified Plant Extract THC:CBD (1:1) THC: CB ₁ R/CB ₂ R agonist CBD: CB ₁ NAM	Chemotherapy neuropathic pain Advanced malignancy pain Pain Tourette syndrome Attention deficit hyperactivity disorder Cannabis dependence	Diabetic neuropathy MS spasticity and pain
(Negative Allosteric Modulator) Mixed THC:CBD		
THC:CBD 1:1 THC:CBD 1:1, 1:2 THC:CBD1:10 THC:CBD 1: 50 NanaBis Oro-MucSpray NanaBis Oro-MucSpray THC or THC:CBD 1:10 LGP1-20 THC:CBD (1:20) FibroCann Solution Pure Green SL Tablets MPL-001 THC:CBD 1:25 TN-TC11G THC:CBD1:1 TIL-T150 THC:CBD 1:5;1:25	Endometriosis pain Chronic pain Crohn's disease Childhood epilepsy	Cancer pain Chronic widespread pain Chronic spine back and neck pain Adolescent migraines Fibromyalgia Osteoarthritis pain Postsurgical osteoarthritis pain Glioblastoma (w/standard of care) Depression, insomnia

(continued)

TABLE 4—Continued

Generic Name Brand Name Class/Efficacy	Completed Clinical Trials	Ongoing Clinical Trials
Pure Femme SLTab 1:30 + PEA + terpenes THC or CBD THC + CBD + CBG	Menstrual symptoms	HIV cognition Chronic migraine
Pro-drug paracetamol (or acetaminophen) Biometabolite is AM404 CB ₁ R/CB ₂ R agonist	Pruritis Presurgical analgesia Pain in tonsillectomies	
SR141716 Rimonabant Acomplia, Zimulti CB ₁ R antagonist/inverse agonist	• Carotid atherosclerosis Cannabis dependence Diabetes w/ metformin Obesity, weight loss • Metabolic syndrome Reduce alcohol consumption Fatty liver-NASH in T2D Smoking cessation	Recovery spinal cord injury
MK-0364 Taranabant CB ₁ R antagonist/inverse agonist	Obesity Smoking cessation Fatty liver-NASH in T2D	
CP-945598 Otenabant CB _{1R} antagonist/inverse agonist	Nonalcoholic steato-hepatitis Obesity	
SLV319 Ibipinabant CB ₁ R antagonist/inverse agonist	Obesity	
SR147778 Surinabant CB ₁ R antagonist/inverse agonist	Obesity Smoking cessation	
ANEB-001 CB ₁ R antagonist/inverse agonist		Acute cannabis intoxication
GFB-024 Peripherally acting CB ₁ R inverse agonist monoclonal Ab	Diabetic nephropathies	
Nimacimab Peripherally acting CB ₁ R antagonist/inverse agonist monoclonal Ab	Diabetic gastroparesis	

Another mechanism for achieving selectivity is found in the recent development of allosteric modulators to modify the CB₁R response. Exploiting allosteric modulation is a broadly used approach for targeting GPCRs (Wold et al., 2019). It allows addressing target selectivity issues and associated off-target side effects of orthosteric ligands by binding to a topographically distinct site. Allosteric ligands modify the conformation of the receptor protein, which allows for modulating the affinity of orthosteric ligands. Allosteric ligands can either augment (positive allosteric modulation) or diminish (negative allosteric modulation) the effect of endogenous ligands. Importantly, this provides the opportunity for tissue-specific modulation of ECS signaling, for example, via a local eCB increase as a consequence of an inflammatory stimulus. In contrast to the high evolutionary conservation of orthosteric binding domains, allosteric sites exhibit a greater sequence difference, allowing for the generation of ligands with high subtype selectivity (Kenakin and Miller, 2010). In addition, an interaction with cholesterol was also observed with CB₁R,

suggesting its endogenous allosteric modulating role (Hua et al., 2020). This observation extended previous in vitro (Bari et al., 2005) and ex vivo (Maccarrone et al., 2009) functional data showing that membrane cholesterol controls CB₁R dimerization and binding activity.

Positive allosteric modulation of CB₁R is likely to play an increasingly important role for drug discovery (Saleh et al., 2018; Garai et al., 2021). For instance, ZCZ011 increased the potency and reduced tolerance development in the anti-nociceptive activity of CB₁ agonists (Ignatowska-Jankowska et al., 2015); GAT211 synergized with FAAH- or MAGL-inhibitor-mediated eCB accumulation to attenuate inflammatory and neuropathic pain (Slivicki et al., 2018, 2020). Preclinical studies of CB₁R allosteric modulators have been reviewed recently (Khurana et al., 2017; Hryhorowicz et al., 2019; Manning et al., 2021).

Another promising approach to selectivity is the development of “biased agonists.” The binding mechanism for a biased agonist would be expected to alter the

conformation of the CB₁R to prefer either an interaction with the Gi/o family or alternatively allow phosphorylation of the receptor via G-protein receptor kinases to facilitate interaction with β -arrestins 1 or 2 (Priestley et al., 2017; Al-Zoubi et al., 2019). The selectivity would be for the signal transduction pathway involved in the beneficial effects while diminishing the signal for unwanted side effects. Preclinical studies that explore possible CB₁R-biased agonists have been reviewed recently (Laprairie et al., 2016; Ibsen et al., 2017; Leo and Abood, 2021; Manning et al., 2021).

2. Cannabinoid Receptor 1 Antagonists. Sanofi discovered the first CB₁R selective antagonist in the early 2000s (SR141716), and the compound was initially earmarked for use as a medication for loss of weight (rimonabant, marketed as Acomplia or Zimulti). It was reasoned that since the activation of CB₁R increased food intake with weight gain, the use of its antagonist as a drug would result in weight loss. The potential success of such a medication prompted other drug companies to produce their own compounds that were structurally different but pharmacologically identical. The first CB₁R antagonist to enter clinical trials for several of these indications was rimonabant (Sanofi), followed by taranabant (Merck), otenabant (Pfizer), ibipinabant (Solvay), and surinabant (Sanofi) as shown in Fig. 13. Additional indications that have been explored clinically include hepatic fibrosis and nonalcoholic fatty liver disease, renal diseases, as well as alcohol dependence and smoking cessation (Cinar et al., 2020). Recently, a CB₁R antagonist, ANEB-001 (Anebullo), has been under clinical development as an antidote for acute cannabis intoxication.

Based on results showing weight loss and improved cardiometabolic markers in overweight and obese patients (Despres et al., 2005), rimonabant was accepted by the EMA in 2006 as an adjunct to diet and exercise for the treatment of obesity and related metabolic risks. However, approval by the FDA failed because of its unexpected neuropsychiatric side effects, namely depression and suicidal ideation (Christensen et al., 2007). Some additional side effects of CB₁R antagonists are related to the gastrointestinal tract and include nausea, vomiting, and frequent bowel movements (Addy et al., 2008; Limebeer et al., 2010). When the use of rimonabant was withdrawn by Sanofi in 2008, the development of CB₁R antagonists was discontinued by other pharmaceutical companies. Notwithstanding the failure of rimonabant, its availability allowed research toward understanding the mechanism of action of CB₁R antagonists and the potential use of such compounds for other indications. Ligands like SR141716 and AM251 (Rinaldi-Carmona et al., 1995; Lan et al., 1999) were used to establish the role of CB₁R in physiology (Varga et al., 1995; Petit et al., 1996; Gatley et al., 1997; Liu et al., 2000; Di Marzo et al., 2001; Wang et al., 2003).

The apparent therapeutic value of CB₁R blockade led to much of the research in developing selective CB₁R antagonists and their preclinical and clinical testing for a variety of disorders related to metabolism, the cardiovascular system, and addiction (Pacher et al., 2008; Cinar et al., 2020). Given the clinical efficacy shown by CB₁R blockade for several conditions with unmet medical needs, additional approaches have been explored to retain efficacy and circumvent the unwanted neuropsychiatric side effects. Among these, CB₁R antagonist/inverse agonists that cannot enter the CNS and CB₁R neutral antagonists have shown promising results in preclinical models.

The discovery of functional CB₁R in the periphery and the realization that they mediate many processes of the cardiovascular system, metabolism, and fibrotic conditions (Liu et al., 2000; Di Marzo et al., 2001; Jourdan et al., 2014; Bowles et al., 2015) have led to the hypothesis that peripherally selective CB₁R antagonist/inverse agonists may retain the therapeutic effects of CB₁R blockade without the unwanted CNS effects. Small-molecule CB₁R antagonist/inverse agonists with minimal brain exposure have shown efficacy in animal models of obesity and metabolic syndrome, alcoholic and nonalcoholic liver steatosis, liver fibrosis, and renal diseases, as recently reviewed by Kunos' group (Cinar et al., 2020). The primary methods used to determine brain permeability are pharmacokinetic studies (Zhang et al., 2018; Iyer et al., 2022), while for the specific engagement of brain CB₁R positron emission tomography tracers are used (Tam et al., 2012; Chang et al., 2019), as well as antagonism of the tetrad effects induced by CB₁R agonists (Fulp et al., 2013; Amato et al., 2018). Although many peripherally restricted ligands have minimal brain permeability after acute administration, it remains to be ascertained whether chronic administration would lead to an increase in brain permeability that can affect the profile of unwanted CNS side effects. Furthermore, only a few peripheral CB₁R antagonists/inverse agonists have been evaluated in detail for their unwanted effects, with the most extensively studied being JD5037 (Kale et al., 2019). This compound exhibited only minor side effects such as repetitive grooming at doses much higher than the therapeutic doses, which is translated into a safer therapeutic window compared with the brain-permeant CB₁R antagonist/inverse agonists (Kale et al., 2019).

In a different approach to achieving peripheral restriction, monoclonal antibodies that act as CB₁R antagonists/inverse agonists have been developed and entered clinical evaluation. The two candidates that have been in clinical development for renal diseases and diabetic complications are Nimacimab (Bird Rock Bio) and GFB-024 (Goldfinch Bio), both listed in Table 4. However, there are no publicly available data regarding the efficacy and safety of this innovative approach.

CB₁R is a constitutively active receptor that even in the absence of ligands exists in equilibrium between active and inactive states; this condition is translated into increased basal activity (Pertwee, 2005; Fong, 2014) and may be important for cellular homeostasis. While inverse agonists reduce the basal activity of receptors, neutral antagonists do not significantly affect it (Bond and Ijzerman, 2006; Sink et al., 2008). Additionally, the ECS as a whole exhibits an endogenously active tone controlled by the cellular production of eCBs (Howlett et al., 2011). Therefore, CB₁R neutral antagonists can compete with the endogenous cannabinoid ligands without affecting the basal activity of the receptor. For this reason, it was hypothesized that CB₁R neutral antagonists could produce the therapeutic phenotypes of CB₁R antagonism without the unwanted CNS and gastrointestinal side effects. In this regard, the most extensively studied CB₁R neutral antagonist, AM4113, exhibited therapeutic efficacy with a better tolerability profile. In animal models of obesity, AM4113 was shown to reduce food intake and weight gain, as well as to suppress food-reinforced operant responding and feeding (Chambers et al., 2007; Sink et al., 2008; Gueye et al., 2016). In addiction-related models, AM4113 was effective in suppressing alcohol consumption, reducing drug-seeking behavior of nicotine and THC, as well as inhibiting the self-administration of heroin (Gueye et al., 2016; Schindler et al., 2016b; Balla et al., 2018; He et al., 2019). Moreover, AM4113 did not induce anxiety-like behaviors in elevated plus maze and electrical brain-stimulation reward paradigm, unlike the CB₁R antagonist/inverse agonist AM251 (Sink et al., 2010; Gueye et al., 2016; He et al., 2019). Additionally, in contrast to CB₁R inverse agonists AM4113 did not produce gastrointestinal side effects such as nausea, potentiation of vomiting, and increase in whole gut transit (Chambers et al., 2007; Sink et al., 2008; Storr et al., 2010). Other CB₁R neutral antagonists, such as the peripherally restricted AM6545 and NESS06SM, have been shown to suppress food intake and improve cardiometabolic risk factors (Cluny et al., 2010; Randall et al., 2010; Tam et al., 2010; Mastinu et al., 2013). AM6545 also exhibited efficacy in animal models of experimental diabetic nephropathy, alone and in combination with the CB₂R agonist AM1241 (Barutta et al., 2017; 2018).

On a final note, a novel and attractive dual-targeting approach is represented by the combination of CB₁R antagonists and CB₂R agonists, as evidenced by the synergy shown by coadministration of AM6545 and AM1241 for treating diabetic nephropathy (Barutta et al., 2017). Indeed, there is early evidence that CB₁R and CB₂R promote opposing functions in fibrotic and inflammatory conditions of peripheral organs (Gruden et al., 2016), as well as in some preclinical models of addiction (Delis et al., 2017; Gobira et al., 2019) that could be

leveraged for a therapeutic benefit by dual-acting CB₁R antagonists/CB₂R agonists.

B. Therapeutic Potential of Cannabinoid Receptor 2

The CB₂R is a class A (rhodopsin-like) GPCR (Fig. 14). It is an essential element of the ECS, and indeed CB₂R-mediated signaling plays an important role in many human health and disease conditions (Pacher and Mechoulam, 2011; Gasperi et al., 2023). Therefore, CB₂R holds tremendous therapeutic potential for treating major pathologies affecting humans.

A plethora of preclinical evidence demonstrating the anti-inflammatory and tissue-protective effects of CB₂R activation has been generated, triggering the design, synthesis, and evaluation of multiple CB₂R ligands. Based on their chemical structure, they can be characterized as pCBs, eCBs, and congeners or synthetic ligands (Han et al., 2013; Guba et al., 2020; Brennecke et al., 2021). While the majority of these molecules are CB₂R activators, multiple antagonists/inverse agonists and a few allosteric ligands have also been discovered. Of these, more than 20 CB₂R-selective agonists have been advanced to clinical trials. Recently, several 3D structures of CB₂R in complex with ligands have been reported (Li et al., 2019; Hua et al., 2020; Xing et al., 2020). Furthermore, a wide variety of labeled chemical probes was generated and applied in mechanistic studies (Basagni et al., 2020; Haider et al., 2020; Sarott et al., 2020; Gazzi et al., 2022; Guberman et al., 2022) and has contributed the understanding of the structural basis of selective CB₂R activation (Li et al., 2023). Together this knowledge will facilitate the design of novel, further improved ligands. Here efforts were made to recognize the full range of studies that have contributed to progress CB₂R research since the discovery of the receptor. Due to space limitations, the content of this section highlights only foundational studies and key aspects.

The CB₂R is primarily expressed in immune cells, including macrophages, T and B cells, monocytes and polymorphonuclear neutrophils, as well as tissues like spleen (Bouaboula et al., 1993; Galiègue et al., 1995; Atwood and Mackie, 2010; <http://www.immgen.org/>), bone (Ofek et al., 2006), and the gastrointestinal tract (Atwood et al., 2012). CB₂R is expressed both on the cell surface and intracellularly (Kleyer et al., 2012; Brailoiu et al., 2014; Castaneda et al., 2017) and is highly inducible, for instance, in microglia upon neuroinflammation (Cabral et al., 2008). The CB₂R is a G_{i/o} coupled GPCR, and its activation leads to an inhibition of cAMP production. In addition, the CB₂R recruits β -arrestins, controls the activation and phosphorylation of different mitogen-activated protein kinase family members (ERK1/2, p38 MAPK, JNK), and interacts with PLC as well as G-protein-coupled inwardly rectifying K⁺-channels (Bouaboula et al., 1993; Felder et al., 1995; Howlett et al., 2002; Cabral




Fig. 14. Structures of the CB₂R in different states. (A) Crystal structure of antagonist AM10257-bound CB₂R (PDB code 5ZTY). (B) Crystal structure of agonist AM12033-bound CB₂R (PDB code 6KPC). (C) Cryo-EM structure of AM12033-bound CB₂R-G_i complex (PDB code 6KPF). (D) Cryo-EM structure of WIN55,212-2-bound CB₂R-G_i complex (PDB code 6TP0), using color code as follows: CB₂R-AM10257, brown; CB₂R-AM12033 (PDB code 6KPC), sky blue; CB₂R-AM12033 (PDB code 6KPF), green; CB₂R-WIN55,212-2, dark salmon; G_{αi} in CB₂R-AM12033, purple; G_β in CB₂R-AM12033, teal; G_γ in CB₂R-AM12033, orchid; scFv16 in CB₂R-AM12033, cornflower blue; G_{αi} in CB₂R-WIN55,212-2, medium purple; G_β in CB₂R-WIN55,212-2, turquoise; G_γ in CB₂R-WIN55,212-2, plum; scFv16 in CB₂R-WIN55,212-2, light blue.

et al., 2008; Atwood and Mackie, 2010). Surface and intracellular CB₂R might be able to activate distinct signaling responses (Brailoiu et al., 2014). In addition, agonists binding to the orthosteric site exhibit different transduction profiles that might translate into distinct pharmacodynamics read-outs (Oyagawa et al., 2018; Yuan et al., 2021). Downstream effects of CB₂R activation encompass the differentiation of B and T lymphocytes (Ziring et al., 2006), the suppression of T cell receptor signaling (Börner et al., 2009), the induction of natural killer cell migration (Kishimoto et al., 2005), and the modulation of cytokine release (Cencioni et al., 2010; Correa et al., 2011). CB₂R interactions at the molecular level and its resulting downstream effects translate toward modulation of disease pathogenesis. CB₂R ligands have demonstrated a huge therapeutic potential in a large variety of disease models (e.g., in liver; Mallat and Lotersztajn, 2008; Pacher and Gao, 2008), kidney (Mukhopadhyay et al., 2010a,b, 2016; Zoja et al., 2016), lung (Pacher et al., 2006), and heart disorders (Pacher et al., 2008); skin pathologies

(Bíró et al., 2009; Maccarrone et al., 2015), neurodegenerative diseases (Centonze et al., 2007; Fernández-Ruiz et al., 2007); and pain (Guindon and Hohmann, 2008; Anand et al., 2009). Generally, the reported effects are a consequence of CB₂R-mediated immunosuppressive and anti-inflammatory effects leading to a dampening of tissue injury. In hypoactivated immune states, CB₂R activation might, however, enhance tissue damage (Pacher and Mechoulam, 2011). Under these pathologic conditions, CB₂R inverse agonists/antagonists might provide therapeutic options.

1. Cannabinoid Receptor 2 Agonists. Due to the huge therapeutic potential of CB₂R, multiple ligands have been developed. In 1996, a first patent for a CB₂R-selective antagonist was filed (Rinaldi et al., 1996). Since then, more than 1150 CB₂R patent applications have been registered. CB₂R targeting molecules covered by these papers and patents encompass agonists, modulators, neutral antagonists, inverse agonists, and allosteric ligands. While the majority of these ligands are classic small molecules, including many labeled chemical probes, some are of a peptidic nature. Multiple comprehensive and excellent reviews on this subject have been published (Thakur et al., 2009; Riether, 2012, Han et al., 2013, 2014; Morales et al., 2016; Aghazadeh Tabrizi et al., 2016; Cooper et al., 2017; Guba et al., 2020; Brennecke et al., 2021). Focus within this section has been placed on representative molecules that describe the development of a “CB₂R ligand space” with a strong emphasis on those that made it into clinical development, all of them being activators of CB₂R. CB₂R agonists that are launched or under active development and registered with ClinicalTrials.gov are listed in Table 5.

a. Endocannabinoids and related fatty acid derivatives. Polyunsaturated C20 fatty acids such as AA are the basic building blocks of eCBs and related fatty acid derivatives, which include amides such as AEA, esters like 2-AG, and ethers like noladin ether (Hanus et al., 2001) (Figs. 1 and 2). 2-AG was first isolated from canine gut and rat brain (Mechoulam et al., 1995; Sugiyama et al., 1995) and is considered as the most relevant signaling component of the ECS. Like AEA, it can be generated by several pathways and enzymes (Fezza et al., 2014; Baggelaar et al., 2018; Tsuboi et al., 2018). These key eCBs are synthesized and released on demand following CB_{1/2}R activation (De Petrocellis et al., 2004; Lambert and Fowler, 2005; Di Marzo, 2018; Cristino et al., 2020). Besides CB_{1/2}R (Fig. 15), they interact also with further molecular targets, e.g., the vanilloid TRPV1 ligand-gated ion channel (De Petrocellis et al., 2000).

In the meantime, further eCBs and a multitude of eCB-like mediators have been isolated. Generally, the eCBs are relatively short-acting ligands, especially due to their hydrolysis through FAAH and MAGL.

Therefore, synthetic efforts were undertaken to improve the hydrolytic stability of eCBs, e.g., by modifying the amide residue of AEA, which provided ligands such as ACPA (Fig. 16) (Hillard et al., 1999).

b. Plant-derived cannabinoids. THC and its thermodynamically more stable and similarly potent regioisomer Δ^8 -THC served as a starting point for generating further classic cannabinoids (Razdan, 1986; Mechoulam et al., 1998). Dual CB₁R/CB₂R agonist Lenabasum, also known as Anabasum, Resunab, ajulemic acid, JBT-101, or CT-3 (Tepper et al., 2014), demonstrated efficacy in reducing chronic neuropathic pain in a phase 2 clinical trial (Karst et al., 2003) (Fig. 17). Currently the ligand is being evaluated in phase 3 for the treatment of dermatomyositis and scleroderma (<https://adisinsight.springer.com/drugs/800007180>). Although Lenabasum activates CB₁R in addition to CB₂R, it is not psychoactive (Zurier et al., 1998). Presumably, this is the consequence of its low brain penetrance.

Preferential CB₂R activation can be achieved by omitting the phenolic C-1 hydroxyl of THC (Reggio et al., 1990; Gareau et al., 1996; Huffman et al., 1996), a strategy that was successfully applied for the generation of JWH133. The ligand is one of the first CB₂R-selective agonists ($10^{(pK_i \text{ CB}_2\text{R} - pK_i \text{ CB}_1\text{R})} > 153$), and thus it has been exploited to interrogate CB₂R pharmacology (Pertwee, 1999; Soethoudt et al., 2017). The reference compound CP55940 is a potent dual CB₁R/CB₂R agonist outperforming THC with regard to CB_{1/2}R binding affinity and analgesic activity (Showalter et al., 1996). Its tritiated congener has been broadly applied for the discovery and profiling of many CB_{1/2}R ligands (Devane et al., 1988).

In contrast, nonpsychotropic (-)CBD exhibits moderate affinity for CB₂R (Showalter et al., 1996). CBD has been suggested to function as an inverse agonist of CB₂R (Thomas et al., 2007) but interacts with multiple other targets as well (Ibeas Bih et al., 2015). Second-generation CBD derivative EHP-101 (VCI-004.8) is a dual CB₂R and PPAR γ agonist and activator of protein phosphatase 2A, which is currently investigated in phase 2a clinical trials (Del Río et al., 2016; EMA, 2022). Indications in focus are systemic and multiple sclerosis, for which preclinical proof of concept, e.g., in fibrosis models (García-Martín et al., 2018) and in neuroinflammation (Navarrete et al., 2018), has been demonstrated.

Cannabinoid fumaric acid ester PRS-211375 (Cannabinor) is a selective CB₂R agonist (CB₂R EC₅₀ cAMP = 17.4 nM; 98% efficacy) (Gratzke et al., 2010). It showed efficacy in various rodent in vivo disease models including pain readouts in a chronic constriction injury model (Clarivate, 2022j). Analgesic effects were translated into the clinic. In patients undergoing third molar dental extraction, nociceptive pain was reduced at 12 mg (i.v.) in a phase 2a study (Clarivate, 2022j). Interestingly, no

effect was observed at higher doses. This bell-shaped curve behavior is characteristic of the pharmacodynamics studies with other cannabinoid-derived CB_{1/2}R ligands (Martellotta et al., 1998; Linares et al., 2019). Converting the phenolic C-1 hydroxyl group of CBD-dimethylheptyl into a methoxy moiety can enhance selectivity for CB₂R as exemplified for HU-308. This potent, selective, and bioavailable CB₂R agonist (Soethoudt et al., 2017) has demonstrated anti-inflammatory and tissue-protective effects in multiple rodent disease models such as formalin-induced inflammation (Hanus et al., 1999) and hepatic ischemia/reperfusion injury studies (Rajesh et al., 2007). Attenuated leukostasis, chemotaxis, and oxidative stress associated with reperfusion damage suppressed the acute inflammatory response (Pacher and Haskó, 2008). Structurally close analog HU-910 exhibited high binding and functional selectivity for CB₂R over CB₁R (Soethoudt et al., 2017). In addition, it is highly selective against a representative set of further off-targets and displays favorable pharmacokinetic properties. Therefore, HU-910 was recommended as a preferred CB₂R agonist for studying the role of the receptor in biologic and disease processes (Soethoudt et al., 2017). HU-910 in vivo efficacy studies opened the door for exploring the potential of CB₂R activation for the treatment of type 2 diabetic nephropathy (Zoja et al., 2016) and eye diseases such as uveitis (Porter et al., 2019). Importantly, HU-910 exhibits a different signaling preference in the five CB₂R signal transduction pathways in human and mouse. In contrast to being an unbiased agonist for the human CB₂R, HU-910 exhibited a preference toward G-protein activation as compared with cAMP signaling and β -arrestin recruitment in mice (Soethoudt et al., 2017). Such interspecies differences in signaling preference might influence the translation of preclinical models to the clinic.

The vast majority of synthetic cannabinoids exhibit high lipophilicity, low aqueous solubility, and tight plasma protein binding, which translates into poor pharmacokinetic properties, such as high in vivo clearance and low oral bioavailability (McGilveray, 2005; Huestis, 2007). To overcome these issues, molecules were developed to exhibit favorable physicochemical properties and improved oral bioavailability. In the following paragraphs, key representatives from the most important scaffolds were selected to illustrate the progress made on synthetic CB₂R ligands.

Aminoalkylindoles were among the earliest discovered CB₂R scaffolds. In particular, dual CB₁R and CB₂R agonist WIN55212-2 (Eissenstat et al., 1990; Bell et al., 1991) was very important for identifying and deciphering the role of cannabinoid receptors (Fig. 9). It displays antihyperalgesic activity in multiple rodent pain models (D'Ambra et al., 1992; Fox et al., 2001; Johaneck and Simone, 2004).

TABLE 5
Diseases/symptoms for treatment with CB₂R agonists and antagonists registered with ClinicalTrials.gov^a

Generic Name Brand Name Class/Efficacy	Completed Clinical Trials	Ongoing Clinical Trials
Dronabinol ^b Dronabinol derivatives ^b Nabilone ^b Nabiximols ^b Mixed THC:CBD ^b Cannabidiol Epidiolex CB ₁ R/CB ₂ R ligand others	Sturge-Weber syndrome Opioid-use disorder Prostate cancer Cannabis use disorder Opioid withdrawal Musculoskeletal pain Alcohol use disorder • Post-traumatic stress disorder • Inflammatory bowel disease • Knee osteoarthritis Parkinson's disease Opiate addiction Epilepsy Seizures COVID-19 Burn-out Chronic periodontitis Urinary stone Schizophrenia Blepharospasm Cocaine craving/dependence Generalized anxiety disorder Lennox-Gastaut syndrome Dravet syndrome Psychotic disorders Infantile spasms Fragile X syndrome Tuberous sclerosis complex Psoriatic arthritis Hand osteoarthritis Cancer Diabetic neuropathies Ulcerative colitis Fatty liver	Obsessive-compulsive disorder Tuberous sclerosis complex Typical absence seizures Autism Fibromyalgia Aromatase inhibitor-associated arthralgias Back pain Depressive symptoms Electrical status epilepticus of slow-wave sleep Dental pain Behavioral problems in children and adolescents with intellectual disability Knee arthritis Chemotherapy-induced peripheral neuropathy Bipolar disorder Hypertension Anxiety and fear Chronic pain Early psychosis Post-traumatic stress disorder Anorexia nervosa Gastroparesis and functional dyspepsia Anxiety in advanced breast cancer Traumatic brain injury Tobacco cessation Social anxiety disorder Rheumatoid arthritis Diabetes Chronic pain Endometriosis pain Social anxiety disorder • Radiculopathy Sleep disturbance Insomnia Prevention aGVHD Prader-Willi syndrome Musculoskeletal pain
Lenabasum CB ₂ R/CB ₁ R agonist	Cystic fibrosis Dermatomyositis Systemic lupus erythematosus	
Olorinab CB ₂ R agonist	Crohn's disease Abdominal pain	
RG7774 CB ₂ R agonist CNTX-6016 CB ₂ R agonist	Chronic pain Nociceptive pain Pain	Diabetic retinopathy Painful diabetic neuropathy
EHP-101 CB ₂ R agonist PPAR _γ agonist		Diffuse cutaneous systemic sclerosis

^aStudies with the status "not yet recruiting, recruiting," "enrolling by invitation," "active, not recruiting," and "completed" were included in this table.

^bSee Table 4 for respective CB₁R data.

Initial aminoalkylindoles were structurally simplified. Furthermore, CB₂R selectivity was improved to lead to CB₂R agonists such as A-796260 (Fig. 9) (Frost et al., 2008), which achieved efficacy in various rodent pain models upon intraperitoneal-injection administration (Yao et al., 2008). Importantly, these antihyperalgesic effects could be blocked by pretreatment with a CB₂R antagonist.

Bicyclic (het)aryl scaffolds were investigated for CB₂R selectivity or minimal CB₁R efficacy. Several high throughput screening campaigns were conducted in the search for potent, selective, and orally bioavailable CB₂R agonists, e.g., providing benzimidazole (Pagé et al., 2008) and triazolopyrimidine (Nettekoven et al., 2016) derived starting points. Subsequent lead optimization efforts provided development candidates such as




Fig. 15. Chemical structure and CB_2R binding affinity of THC, *N*-arachidonylethanolamine, and 2-arachidonoyl glycerol. ^aConsensus human CB_2R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017). ^b CB_2R selectivity ($10^{(pK_i CB_2R - pK_i CB_1R)}$).

dual CB_1R/CB_2R agonist ART-27.13 (AZD-1940) (Pagé et al., 2010) (Fig. 18). This molecule is currently assessed as oral treatment of cachexia in phase 2 and cancer-related anorexia in phase 1 trials (Clarivate, 2022a; <https://artelobio.com/pipeline/>). However, due to CNS-related side effects, phase 2 studies for the treatment of nociceptive and neuropathic pain were terminated (Kalliomäki et al., 2013; <https://www.astrazenecaclinicaltrials.com/study/D3120C00006/>).

Phase 2 clinical trials for the oral treatment of osteoarthritic knee pain were conducted with CB_2R agonist LY-2828360 (Fig. 17), but they were terminated despite an acceptable side-effect profile (Hollinshead et al., 2013; <https://clinicaltrials.gov/ct2/show/NCT01319929>; Clarivate, 2022f). The imidazopyrimidine is brain penetrant and exhibits an excellent selectivity over CB_1R (ratio CB_1R/CB_2R EC_{50} for $GTP\gamma S$ binding was $> 5'000$). Recently reported triazolopyrimidine-derived CB_2R agonist (at 1 nM) RG7774 (Fig. 17) is under active development in phase 2 as an innovative oral treatment of diabetic retinopathy exhibiting very high selectivity over CB_1R (ratio CB_1R/CB_2R EC_{50} for cAMP $> 6'940$) (Grether, 2022). Further bicyclic (het)aryl derived ligands reached advanced preclinical stages and were successfully explored in various disease models with an inflammatory pathology. PF-0355009 6 (Kikuchi et al., 2008) and RQ-00202730 (Iwata et al., 2015) were tested in 2,4,6-trinitrobenzene sulfonic acid-induced colonic pain rat models, and RO6871304 was tested in rodent models of kidney ischemia–reperfusion, renal fibrosis, and endotoxin-induced uveitis (Nettekoven et al., 2016; Porter et al., 2019).

Multiple organizations developed bicyclic aliphatic (het)aryl arrays with at least one aliphatic ring. Five-five, five-six, and five-seven systems were elaborated, and four of these CB_2R agonists made it into clinical trials.

Tedalinab was investigated for the oral treatment of neuropathic pain and osteoarthritis (Clarivate, 2022n) (Fig. 19). The CB_2R -selective pyrazole carboxamide exhibits similar binding affinities for human and rat CB_2R (human CB_2R K_i = rat CB_2R K_i ≈ 12 nM) and bioavailabilities $> 50\%$ across species. Despite favorable safety and tolerability data in single ascending dose (doses up to 1200 mg) and multiple ascending dose studies (doses up to 300 mg once daily for 14 days), development was halted for unknown reasons.

Lead optimization toward olorinab was guided by a β -arrestin efficacy assay (Han et al., 2017). This highly potent CB_2R full agonist is a peripherally acting molecule that is devoid of psychotropic effects (<https://adisinsight.springer.com/drugs/800039670>; <https://clinicaltrials.gov/ct2/show/NCT04043455>). Olorinab (Fig. 19) was clinically assessed as an oral treatment of pain related to irritable bowel syndrome in phase 2. While the drug was well tolerated, it did not meet the primary efficacy endpoint of statistically significant improvement in the overall average abdominal pain score (Pharma Intelligence, 2022). The ligand exhibits a short human half-life and was therefore administered three times a day (Clarivate, 2022i). Dual CB_1R/CB_2R agonist TAK-937 (Fig. 19) was developed as an injectable for the treatment of stroke after observing cerebroprotective effects in rat and nonhuman primate in vivo efficacy studies (Suzuki et al., 2012; Clarivate, 2022m). Yet, due to a narrow safety margin, development was halted. CB_2R -selective agonist dihydro-benzofuran NTRX-07 (Fig. 19) is being explored in phase 1 as an oral drug for the treatment of memory loss in Alzheimer's disease, cognitive disorder, and neuropathic pain (Clarivate, 2022h; <https://www.neurotherapia.com/research>). Follow-up studies targeting MS and amyotrophic lateral sclerosis




Fig. 16. Chemical structure and CB_2R binding affinity of noladin ether and synthetic eCB analogs. ^aBinding to spleen cannabinoid receptor. ^bWith phenylmethanesulfonyl fluoride.




Fig. 17. Chemical structure, CB_2R binding affinity and selectivity of representative classic cannabinoids. ^aConsensus human CB_2R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017). ^b CB_2R selectivity ($10^{(pK_i CB_2R - pK_i CB_1R)}$).

are foreseen. NTRX-07 preserves CB_2R potency across species and showed efficacy in multiple rodent efficacy studies (Naguib et al., 2008). The (*S*)-enantiomer is the active stereoisomer (Diaz et al., 2009).

CB_2R modulators containing aromatic and aliphatic five-, six-, and seven-membered central cores have been described by multiple organizations. Pyrimidine-based agonist GW-842166X displays high CB_2R selectivity over CB_1R , and favorable pharmacokinetic properties, translating into potent analgesic effects (ED_{50} = 0.1 mg/kg) in the Complete Freund's adjuvant rat model of inflammatory pain without initiating tetrad-like effects such as catalepsy or hypothermia (Giblin et al., 2007) (Fig. 20). The ligand reached phase 2 clinical trials for pain associated with osteoarthritis (<https://clinicaltrials.gov/ct2/show/NCT00479427>) and dental pain (<https://clinicaltrials.gov/ct2/show/NCT00444769>).

Disubstituted phenyl derivative KN 387271 (Fig. 20) is a dual CB_1R/CB_2R agonist. Neuroprotective effects in rat models of cerebral ischemia and traumatic brain injury (Mauler et al., 2002; Mauler et al., 2003) enabled phase 1 stroke and phase 2 traumatic brain injury studies in humans (Clarivate, 2022e). The selective orally bioavailable CB_2R agonist S-777469 exhibited efficacy in rodent models of scratching and skin inflammation (Odan et al., 2012; Haruna et al., 2015, 2017). However, these effects did not translate into therapeutic benefits in phase 2a trials with patients suffering from atopic dermatitis and pruritus (Clarivate, 2022l; [\[shionogi.com/content/dam/shionogi/global/investors/pdf/e_p090803.pdf\]\(https://www.shionogi.com/content/dam/shionogi/global/investors/pdf/e_p090803.pdf\)\). Many additional \$CB_2R\$ modulators with different central cores such as pyrazoles \(Ohta et al., 2007\), thiazoles \(Yao et al., 2009\), diazepanes \(Zindell et al., 2011\), piperidines \(Bartolozzi et al., 2015\), pyrrolidones \(Riether et al., 2015\), imidazoleidine-2,4-diones \(Mukhopadhyay et al., 2016\), pyridines \(Porter et al., 2019\), and 4-oxo-1,4-dihydropyridines \(El Bakali et al., 2014\) have been evaluated in detail. In some cases, minor structural changes triggering a switch from agonism to inverse agonism have been reported \(Sellitto et al., 2010; Porter et al., 2019\). Insights on how to design \$CB_2R\$ agonists with favorable kinetic profiles were disclosed in a structure kinetics relationship study on a biaryl imidazoleidine-2,4-dione-based scaffold \(Soethoudt et al., 2018b\). An adamantyl-derived series was investigated for functional activity on the Q63R variant of \$CB_2R\$ \(Nettekoven et al., 2013\), which is associated with the risk of schizophrenia \(Ishiguro et al., 2010\) and an increased risk of celiac disease and liver damage in obese children \(Rossi et al., 2011\).](https://www.</p>
</div>
<div data-bbox=)

2. Cannabinoid Receptor 2 Antagonists and Allosteric Ligands. Selective CB_2R antagonist/inverse agonist SR144528 (human CB_2R selectivity ratio = 129; mouse CB_2R selectivity ratio $10^{(pK_i CB_2R - pK_i CB_1R)}$ = 6'026) (Rinaldi-Carmona et al., 1998; Portier et al., 1999; Soethoudt et al., 2017) is an important pharmacological tool for antagonizing effects




Fig. 18. Chemical structure, CB_2R binding affinity or functional activity, and selectivity of clinically evaluated bicyclic (het)aryl derived CB_2R ligands.




Fig. 19. Chemical structure, CB_2R binding affinity or functional activity, and selectivity of clinically evaluated bicyclic aliphatic (het)aryl arrays.

triggered by CB_2R agonists in vitro and in vivo (Nackley et al., 2003). Interestingly, the ligand shows a bias in suppressing different signal transduction pathways. It effectively blocks the modulation of cAMP signaling but is less potent with regard to antagonizing CB_2R -mediated signal transduction pathways (Soethoudt et al., 2017).

Few ligands targeting postulated CB_2R allosteric sites (Feng et al., 2014; Pandey et al., 2020) are known. An allosteric CB_2R interaction has been suggested for CBD (Martinez-Pinilla et al., 2017). Conversely, it was also experimentally shown that CBD acts as an orthosteric partial agonist (Tham et al., 2019), although it does not follow a simple one-site competition model. An overlap of allosteric and orthosteric binding pockets might provide a suitable explanation for these findings. In contrast, 1,1'-dimethyl heptyl CBD was shown to act as a pathway-specific CB_2R allosteric modulator (Fig. 21). While positively modulating the cAMP response, it negatively modulated β -arrestin1 recruitment by CP55940 and SR144528. Interaction with a high-affinity allosteric binding site has been postulated by 5XRA- and 5TGZ-based in silico docking studies.

Endogenously occurring RVD-hemopressin peptide pepcan-12 (Fig. 21) exhibits positive allosteric modulation of CB_2R (Petrucci et al., 2017). It was shown to increase binding of orthosteric ligands and to potentiate 2-AG- and CP55940-induced CB_2R signaling. Synthetic ligand C2 shows positive allosteric modulation of CB_2R in vitro (Gado et al., 2019). Importantly, these effects translated into dose-dependent efficacy in a mouse model of neuropathic pain upon oral administration. Neither an X-ray crystal nor a cryo-electron microscopy structure of a CB_2R allosteric modulator in complex with the receptor has been reported. Therefore, the design of novel ligands is mostly aided by in silico predictions including molecular dynamics simulations that can lead to the identification and ranking of multiple putative allosteric binding sites (Yuan et al., 2022). Furthermore, molecular dynamics simulations suggest that cholesterol exerts an allosteric effect on the intracellular CB_2R regions that interact with the G-protein complex, thus altering the recruitment of G-protein (Yeliseev et al., 2021). Therefore, cholesterol levels might influence the screening for novel allo- and orthosteric CB_2R ligands, which should be taken into account in designing selective drugs directed toward CB_2R .




Fig. 20. Chemical structure, CB_2R binding affinity or functional activity, and selectivity of clinically evaluated CB_2R agonists and CB_2R inverse agonists SR144528 containing five- and six-membered central cores. ^aConsensus human CB_2R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017). ^b CB_2R selectivity ($10^{(pK_i CB_2R - pK_i CB_1R)}$).

3. Cannabinoid Receptor 2 Chemical Probes for Research and Diagnostics. A labeled chemical probe is a small molecule that is a ligand for a respective target and carries a reporter unit, e.g., a radio, fluorescent, or biotin label that allows characterization of ligand-target interactions. Optionally a linker connects the target recognition element and reporter unit (Prevet and Collins, 2019). Labeled probes are of utmost importance for all research and discovery phases (Guberman et al., 2022). Due to a major debate regarding the specificity of CB₂R antibodies (Cécyre et al., 2014; Marchalant et al., 2014; Zhang et al., 2019), labeled chemical CB₂R probes are highly important tools for determining CB₂R protein expression. While radioligands are generally used for studying binding affinity (Cascio et al., 2016) or drug-target binding kinetics (Martella et al., 2017) of unlabeled ligands, positron emission tomography tracers focus on determining receptor expression in tissues and noninvasively measuring the distribution and receptor occupancy of drug candidates in patients (Honer et al., 2014). Nonselective [³H]CP55940 and [³H]WIN55212-2 are the most relevant probes for measuring equilibrium binding affinities of novel CB₂R ligands applying radioligand competition-binding assays. Selective CB₂R inverse agonist [³⁵S]SCH225336 (Lavey et al., 2005; Gonsiorek et al., 2006) was successfully applied for quantifying CB₂R expression in various cell lines and hemopoietic cells making use of the superior specific activity of its ³⁵S reporter unit, as compared with tritiated cannabinoids (> 1'400 versus ~20 Ci/mmol) (Fig. 22).

Tritiated pyridine [³H]RO6957022 exhibits high binding selectivity targeting CB₂R (Martella et al., 2017). The CB₂R inverse agonist was used for studying drug-target binding kinetics. Its ¹¹C-labeled analog [¹¹C]RSR-056 carrying the carbon-11 reporter unit at the methoxy group is a CB₂R-specific brain-penetrant positron emission tomography tracer that displayed a higher brain radioactivity in mice with lipopolysaccharide-induced neuroinflammation than in the control group (Slavik et al., 2015). 2-Oxoquinoline-derived [¹¹C]NE40 is the first tracer that has been used for CB₂R in vivo positron emission tomography in humans (Ahmad et al., 2013). In agreement with the known expression of CB₂R, major uptake was observed in lymphoid tissue. Despite a rapid brain uptake and washout, no CB₂R upregulation was detected in the brains of Alzheimer's

disease patients (Ahmad et al., 2016). [¹⁸F]RoSMA-18-d6 exhibits subnanomolar affinity for CB₂R across species and a remarkable selectivity factor of > 12'000 over CB₁R (Haider et al., 2020). It showed specific and reversible target binding in vitro and in vivo and was successfully used for detecting CB₂R upregulation on post-mortem human amyotrophic lateral sclerosis spinal cord tissues.

Fluorescently labeled CB₂R ligands are highly versatile tools for studying receptor-ligand interactions and cellular trafficking, e.g., applying techniques such as flow cytometry, confocal fluorescence microscopy, and time-resolved fluorescence resonance energy transfer. *N*-Alkyl isatin acylhydrazone NMP6 was among the first fluorescently labeled ligands that showed selectivity for CB₂R over CB₁R (Petrov et al., 2011). In flow cytometry and confocal microscopy studies, specific binding to endogenously expressed CB₂R in CD4+ T cells and B-lymphocytes was demonstrated. Cy5-labeled (Cy5-) probe is a CB₂R inverse agonist with an extended linker moiety showing low levels of nonspecific fluorescence in live-cell experiments (Singh et al., 2019). Combination of favorable structural elements of the two cannabinoid ligands HU-308 and AM841 provided a privileged chimera motif that was functionalized with a range of fluorophores while retaining excellent affinity and selectivity for CB₂R (Sarott et al., 2020; Westphal et al., 2020). Coumarin fluorophore-labeled DY480-XL probe allowed for setting up a novel assay based on fluorescence resonance energy transfer, able to characterize equilibrium and kinetic binding constants and visualize in real-time CB₂R in endogenously expressing murine splenocytes and human macrophages. The reverse-design approach, in which small molecules previously optimized in medicinal chemistry programs form the basis for the generation of high-quality probes (Guberman et al., 2022), was applied for the generation of cell-permeable agonist-based SiR probe that was used for real-time in vivo tracing of CB₂R in zebrafish larvae (Gazzi et al., 2022). Near-infrared fluorophores are best suited for in vivo imaging in higher species due to their deeper light penetration of biologic tissues (Hong et al., 2017). Pyrazolopyrimidine derivative NIR760-XLP6 displays high selectivity over CB₁R and improved specific binding as compared with predecessors such as NIR760-mbc94 and therefore




Fig. 21. Chemical structure of validated CB₂R allosteric modulators.




Fig. 22. Chemical structure, CB_2R binding affinity, and selectivity of CB_2R radioligands, PET tracers, fluorescent and pAfbPP probes.

holds promise for visualizing CB_2R in in vivo imaging studies (Ling et al., 2015). Alternatively to fluorescent probes, biotinylated CB_2R ligands have been applied for visualization of the receptor after conjugation with streptavidin-AlexaFluor488 (Martin-Couce et al., 2012).

While reversible noncovalent interaction with CB_2R can easily be disrupted under experimental conditions, resulting in the washout of the probe from the binding site, a covalent attachment can surmount these issues (Weichert and Gmeiner, 2015; Yang et al., 2019). The water-stable isothiocyanate group, which reacts preferentially with the nucleophilic amino acid side chains of cysteines, was exploited to covalently attach cannabinoids to CB_2R (Szymanski et al., 2011; Mallipeddi et al., 2017). Furthermore, CB_2R -selective photoaffinity probes carrying benzophenone (Dixon et al., 2012) or azide (Szymanski et al., 2018) groups as photoreactive moiety have been reported. Two-step photoaffinity-based protein profiling probe LEI121 elegantly

combines the covalently modifying photoaffinity technique with a click chemistry approach, allowing for target engagement studies in live human cells by covalent SDS-PAGE visualization, flow cytometry, and mass spectrometry-based proteomics (Soethoudt et al., 2018a).

C. Summary of Clinical Status of Cannabinoid Receptor 1 and Cannabinoid Receptor 2 Agonists

In summary, three phytocannabinoid preparations (dronabinol, nabiximols, and CBD) are currently available for treatment of diseases via stimulation of CB_1R , CB_2R , both, or neither (Table 6). Although the need for selective full agonist stimulation of CB_1R is limited due to side effects, selective CB_2R agonists are in phase 2 clinical trials. We are at the stage of defining which human diseases can best be treated with these CB_2R agonists. Mixed $\text{CB}_1\text{R}/\text{CB}_2\text{R}$ -directed agonist preparations and numerous selective CB_2R ligands are either

on the market or under clinical development (reported in Table 6). Overall, more than 20 new molecular entities that activate CB₂R have been investigated in humans for a wide range of indications. Structurally, they cover a huge chemical space including fatty acid derivatives, classic and nonclassic cannabinoids, as well as multiple diverse synthetic ligands, thus resulting also in the coverage of a broad range of physicochemical properties.

Dronabinol, nabilone, and CBD, exerting their action through both CB₁R and CB₂R activation, have been introduced to the market. Oral THC is used for the treatment of anorexia, cachexia, and chemotherapy-induced emesis (Clarivate, 2022d). Buccal THC has been launched for cancer pain (<https://adisinsight.springer.com/drugs/800027102>). Other routes of administration, e.g., inhalable and sublingual formulations, are under exploration. Nabilone was launched for treating patients who suffer from chemotherapy-induced nausea and vomiting (<https://adisinsight.springer.com/drugs/800025856>). Clinical trials for the treatment of Parkinson's disease and pain are in advanced stages. CBD, a nonclassic cannabinoid for which the main mode of action is still a matter of debate, is marketed for the treatment of infantile severe myoclonic epilepsy, Dravet and Lennox-Gastaut syndrome, and tuberous sclerosis (Clarivate, 2022b). As reported in Table 2, combinations of CBD and THC have been approved for treating MS-associated spasticity and pain management, while glioblastoma trials and studies targeting further indications are ongoing (Clarivate, 2022g;

<https://citeline.informa.com/drugs/details/175074>). Nonpsychoactive dual CB₁R/CB₂R agonist Lenabasum (Zurier et al., 1998) is in phase 3 trials for the treatment of systemic sclerosis and dermatomyositis (<https://adisinsight.springer.com/drugs/800007180>; Corbus Pharmaceuticals, 2022). Most advanced selective CB₂R agonists are the synthetic cannabinoids olorinab (<https://adisinsight.springer.com/drugs/800039670>) and RG7774 (Grether, 2022). Clinical focus of olorinab is on pain related to irritable bowel syndrome, as such or with predominant constipation or diarrhea. RG7774 aims to provide an oral treatment for patients suffering from diabetic retinopathy (Clarivate, 2022k). AA analog CMX-020 is studied in phase 2 trials for the treatment of pain, osteoarthritis, and diabetic neuropathy using both oral and intravenous formulations (<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371547&isReview=true>). Pain, in particular neuropathic pain, is also the focus of the selective synthetic CB₂R agonists CNTX-6016, whose structure has not been yet disclosed (<https://centrexion.com/science/pipeline/>; <https://clinicaltrials.gov/ct2/show/NCT04857957>), and NTRX-07 (<https://www.neurotherapia.com/research>; Clarivate, 2022h). CNTX-6016 is in phase 2 and NTRX-07 in phase 1 trials. Dual CB₁R/CB₂R agonist ART-27.13 is in phase 2 trying to provide treatment options for cachexia and cancer-related anorexia (<https://artelobio.com/pipeline/>). CBD derivative EHP-101, which activates both PPAR γ and CB₂R, is aimed at MS and scleroderma patient populations in phase 2 clinical trials (EMA, 2022). Ten additional new

TABLE 6
CB₂R agonist that are launched or under active clinical development

Drug	Chemical Class	Mode of Action	CB ₂ R/CB ₁ R in vitro Pharmacology	Indication(s)	Highest Phase of Development
Dronabinol (THC, Syndros, Marinol)	Classic cannabinoid	CB ₂ R/CB ₁ R agonist	$pK_i = 8.16/8.48^a$	Appetite loss, CINV, anorexia, cancer pain	Launched
Nabilone (Cesamet) Lenabasum (Ajulemic acid)	Classic cannabinoid Classic cannabinoid	CB ₂ R/CB ₁ R agonist CB ₂ R/CB ₁ R agonist	$K_i = 1.84/2.19$ nM $K_i = 51/628$ nM	CINV CF, SLE, RA, systemic sclerosis, dermatomyositis	Launched Phase 3 (systemic sclerosis since 2017; dermatomyositis since 2018)
Olorinab (ADP-371)	Tricyclic 3,5,5-fused pyrazole 3-carboxamide	CB ₂ R agonist	$EC_{50} = 6.2/>10^4$ nM ^b	IBS-related pain, IBS with predominant constipation or diarrhea	Phase 2b (since 2017)
CMX-020	Arachidonic acid analog	CB ₂ R/CB ₁ R agonist, TRPV1 agonist	$K_i = 150/21$ nM	Pain, OA, DnP	Phase 2 (since 2015)
RG7774	Triazolopyrimidine	CB ₂ R agonist	$EC_{50} = 1/>10^4$ nM ^c	DR	Phase 2 (since 2020)
CNTX-6016	Piperidine based ligand	CB ₂ R agonist	—	Pain Np, DnP	Phase 2 (since 2020)
ART-27.13 (AZD-1940)	Benzimidazole	CB ₂ R/CB ₁ R agonist	$K_i = 0.9/12$ nM	Pain, cachexia, CINV	Phase 2 (since 2021)
EHP-101 (VCE-004.8)	Cannabidiol derivative	CB ₂ R agonist, PPAR γ agonist	$K_i = 170/>4 \times 10^4$ nM	MS, ScD	Phase 2 (since 2020)
NTRX-07 (MDA-7)	2,3-Dihydro-1-benzofuran	CB ₂ R agonist	$K_i = 422/>10^4$ nM	AD, Np pain, cognitive disorder	Phase 1 (since 2019)

AD, Alzheimer's disease; CF, cystic fibrosis; CINV, chemotherapy induced nausea and vomiting; DnP, diabetic neuropathy; DR, diabetic retinopathy; IBS, irritable bowel syndrome; LGS, Lennox Gastaut syndrome; MS, multiple sclerosis; Np, neuropathic; OA, osteoarthritis; RA, rheumatoid arthritis; ScD, scleroderma; SLE, systemic lupus erythematosus.

^aConsensus human CB₂R binding affinity values from a multicentric collaborative profiling effort between multiple independent academic laboratories and industry (Soethoudt et al., 2017).

^bFunctional activity in β -Arrestin-2 assay on human cannabinoid receptors (Han et al., 2017).

^cFunctional activity in cAMP assay on human cannabinoid receptors (Grether, 2022).

chemical entities were investigated in phase 1 and 2 clinical trials for different pain indications (neuropathic, dental, pain associated with osteoarthritis of the knee), postherpetic neuralgia, pruritis, atopic dermatitis, stroke, traumatic brain injury, coronary artery bypass graft, and ocular hypertension (Brennecke et al., 2021). Dual CB₁R/CB₂R agonist TAK-937 was terminated due to a narrow safety margin (Clarivate, 2022m), S-777469 due to the lack of a pharmacological effect (Clarivate, 2022l; https://www.shionogi.com/content/dam/shionogi/global/investors/pdf/e_p090803.pdf), while for KN 387271 (Clarivate, 2022e) and PRS-211375 13 (Clarivate, 2022j) business reasons were reported.

It is clear from this summary that there are many therapeutic opportunities for both CB₁R and CB₂R agonists (Pacher and Kunos, 2013), yet the untoward effects of the CB₁R at the CNS have limited the clinical progression of CB₁R agonists that penetrate the blood-brain barrier and preclude their use in the nonhospitalized population. Tissue and cell-type selectivity for therapeutic responses is a challenge, as many cannabinoid and aminoalkylindole agonists have been relegated to research rather than clinical use. Development of dual-target compounds that act by inhibiting CB₁R-mediated side effects while simultaneously activating CB₂R-mediated beneficial responses is also ongoing. Current development of peripherally restricted agonists and antagonists that fail to cross the blood-brain barrier will open avenues for treatment of diseases in organs outside of the brain. Research on “biased agonists” that promote cannabinoid receptor conformations that favor G-protein versus β -arrestin signaling is an approach that offers treatment opportunities if one pathway dominates in treatment while the alternative pathway is responsible for side effects. Researchers are screening for allosteric modulators based on the notion that their effects would be limited to only those receptors simultaneously engaged with an eCB agonist in the disease process. Thus, a positive allosteric modulator could potentiate responses if eCBs are understimulating the receptors. In contrast, a negative allosteric modulator would impart noncompetitive antagonism in a situation of excessive eCB tone. Research findings not discussed in the present review have recognized the presence of CB₁R and CB₂R receptor heterodimers with a wide range of GPCRs, as well as receptor complexes with other associated proteins. As these studies gain maturity, the understanding of the impact of such receptor combinations within the same cell can open avenues for novel therapeutic compounds. Although the present use of pCB and small molecule agonists is meeting unmet needs of many diseases, particularly those involving inflammation, the future for cannabinoid receptor pharmacotherapeutics must advance to agonists, antagonists, and modulators that exhibit greater selectivity to improve treatments and eliminate unwanted side effects.

III. Therapeutic Potential of Metabolic Enzymes of AEA

A. Enzymes of AEA Production

AEA is produced upon demand from the membrane phospholipid precursor *N*-arachidonoyl-phosphatidylethanolamine via two enzyme-mediated reactions (Fig. 3).

1. *NAT and iNAT.* The first step is the formation of NArPE, which occurs through *N*-acylation of phosphatidylethanolamine, mediated by Ca²⁺-dependent or independent *N*-acyl transferase (NAT and iNAT). It should be noted that the acyl donor is another phospholipid molecule, such as phosphatidylcholine, rather than acyl-CoA. The presence of *N*-arachidonoyl-phosphatidylethanolamine in mammalian tissues and the *N*-acyl-transferase activity responsible for its production were first reported in the late 1990s (Cadas, et al., 1997) and later molecularly identified as cytosolic phospholipase A_{2c} (cPLA_{2c}) (Ogura et al., 2016). Members of the phospholipase A and acyltransferase (PLAAT) family (Jin et al., 2007; Uyama et al., 2012) were identified as Ca²⁺-dependent and -independent NAT, respectively. cPLA_{2c} belongs to the cPLA₂ family with a serine residue as catalytic nucleophile. Since for *N*-acylation of phosphatidylethanolamine cPLA_{2c} selectively abstracts an acyl chain from the *sn*-1 position of the glycerol backbone of glycerophospholipid, which is abundant in saturated and mono-unsaturated fatty acids rather than poly-unsaturated fatty acids like AA, *N*-arachidonoyl-phosphatidylethanolamine and AEA account for a small percentage of the *N*-acyl-phosphatidylethanolamine (NAPE) and fatty acid ethanolamides present in cells. The analysis of cPLA_{2c}-deficient mice revealed the central role of this enzyme in the accumulation of NAPEs and *N*-acylethanolamines in an imiquimod-induced psoriasis model (Liang et al., 2022), as well as in an ex vivo model of brain ischemia (Rahman et al., 2022). The NAPE-forming activity of cPLA_{2c} in skin was suggested to be protective against skin inflammation such as psoriasis by producing anti-inflammatory *N*-acylethanolamines. On the other hand, PLAAT enzymes compose a small protein family with a cysteine residue as catalytic nucleophile (Uyama et al., 2017). Among the five members (1–5) in humans, PLAAT1, 2, and 5 exhibit relatively high NAT activity over the coexisting PLA₁/A₂ activity (Uyama et al., 2012). Since without any cellular stimulus the NAT activity is easily detected in the cells where recombinant PLAAT is expressed, the role of PLAATs is presumed to maintain the basal levels of NAPEs and *N*-acylethanolamines in unstimulated cells. However, their contribution to the formation of NAPEs in vivo remains unclarified.

2. *N-Acyl Phosphatidylethanolamine-Specific Phospholipase D.* NAPE-phospholipase D (PLD) catalyzes the second step of AEA formation (Fig. 3). The enzyme releases AEA and other fatty acid ethanolamides from their corresponding NAPEs in a PLD-type hydrolytic

reaction (Okamoto et al., 2004). However, NAPE-PLD is a member of the metallo- β -lactamase superfamily and shows no sequence similarity to classic PLDs converting phosphatidylcholine to phosphatidic acid. Multiple aspartic acid and histidine residues, highly conserved among the family members, are essential for catalytic activity, and metal analysis suggested the presence of Zn^{2+} coordinated by these amino acid residues (Wang et al., 2006). The crystal structure of human NAPE-PLD clarified the formation of homodimers adapted to associate with phospholipids and the presence of a binuclear Zn^{2+} center at the active site (Magotti et al., 2015). Purified recombinant NAPE-PLD selectively hydrolyzes NAPE among various phospholipids (Wang et al., 2006). However, the enzyme does not distinguish *N*-acyl species in NAPE, explaining why the composition of naturally occurring fatty acid ethanolamides is similar to the *N*-acyl composition of NAPEs. Recently, the role of NAPE-PLD in energy metabolism has received much attention. A common NAPE-PLD haplotype was reported to be protective against obesity (Wangensteen et al., 2011). Conditional knockout of adipocyte, intestinal, or hepatic NAPE-PLD showed the tendency to induce obesity (Geurts et al., 2015; Everard et al., 2019; Lefort et al., 2020). Moreover, LEI-401, the first brain-active NAPE-PLD inhibitor, was instrumental in demonstrating the distinctive role of NAPE-PLD in AEA biosynthesis in the brain (Mock et al., 2020). LEI-401 activated the hypothalamus-pituitary-adrenal axis and impaired fear extinction, thereby emulating the effect of a CB_1R antagonist and suggesting the presence of an endogenous AEA tone controlling emotional behavior (Mock et al., 2020).

3. Alternative Pathways. The analysis of NAPE-PLD-deficient mice revealed the existence of alternative pathways for fatty acid ethanolamide biosynthesis in brain (Leung et al., 2006; Tsuboi et al., 2011) and peripheral tissues (Inoue et al., 2017). Among the proposed multistep pathways (Fig. 3), the route via *lyso*-NAPE and glycerophospho-*N*-acylethanolamines appears to be the most important, whereby either α/β -hydrolase domain protein 4 (Simon and Cravatt, 2006) or cPLA_{2 γ} (Guo et al., 2021) generates glycerophospho-*N*-acylethanolamines from NAPE via *lyso*-NAPE in two consecutive esterase reactions. The resultant compound is further hydrolyzed to generate *N*-acylethanolamines by glycerophosphodiesterase 1 (Simon and Cravatt, 2008) and 4 (Tsuboi et al., 2015; Rahman et al., 2016). The glycerophosphodiesterase family is composed of seven proteins (1–7) in mammals (Yanaka, 2007), and isoforms 4 and 7 also show *lyso*-PLD activity directly producing *N*-acylethanolamines from *lyso*-NAPE (Tsuboi et al., 2015; Rahman et al., 2016). It is not fully elucidated how much these alternative pathways contribute to the generation of AEA and other *N*-acylethanolamines in the tissues of wild-type mice.

The physiologic significance in human tissues also remains unclarified.

B. Enzymes of N-Arachidonyl Ethanolamine Degradation

The major pathway of AEA degradation is hydrolysis to AA and ethanolamine, which is mediated by FAAH (Desarnaud et al., 1995; Hillard et al., 1995; Cravatt et al., 1996), two isoforms of which have been described: FAAH-1 and FAAH-2 (Wei et al., 2006). It should be noted that FAAH-2, sharing 20% sequence identity with FAAH-1, is expressed in humans but not in rodents (Wei et al., 2006), making its complete understanding difficult. Different from FAAH-1, which is found in the endoplasmic reticulum and the nucleus, FAAH-2 may be localized to lipid droplets (Kaczocha et al., 2010). NAAA and acid ceramidase also hydrolyze AEA, albeit with low activity (Ghidini et al., 2021; Tsuboi et al., 2021). In addition to hydrolytic degradation, AEA can be oxygenated by lipoxygenases (5-, 12-, 15-LOX), COX-2, or CYP450 (Fig. 4), all of which have been fully characterized as eicosanoid-generating oxygenase enzymes (Rouzer and Marnett, 2011; Fezza et al., 2014; Simard et al., 2022). The physiologic significance of these AEA oxygenation pathways remains unclear.

1. Fatty Acid Amide Hydrolase. FAAH-1, which is often referred to simply as FAAH, is widely distributed in mammalian tissues with high expression in liver, brain, and small intestine of rats (Katayama et al., 1997). The analysis of FAAH-1-deficient mice revealed increased endogenous AEA levels and hence the central role of FAAH-1 in AEA degradation (Cravatt et al., 2001). FAAH deletion reduced pain sensation, and when AEA was administered, FAAH-1-deficient mice exhibited intense hypomotility, antinociception, catalepsy, and hypothermia in a CB_1R -dependent manner. Although FAAH-1 is highly active with AEA, the enzyme shows broad substrate specificity, hydrolyzing other fatty acid ethanolamides, *N*-acyl taurines, and primary fatty acid amides such as oleamide. FAAH-1 can also catalyze the reverse reaction in which AEA is formed from AA and ethanolamine. However, the equilibrium constant demonstrated the predominance of the hydrolytic action of AEA (Katayama et al., 1999). FAAH-1 is an integral membrane protein functioning as a serine hydrolase and belongs to the amidase signature family characterized by the Ser-Ser-Lys catalytic triad (McKinney and Cravatt, 2005). Rat FAAH was crystallized as a homodimer. In common with bacterial enzymes of the same family, the structure exhibits a core fold comprised of a twisted β -sheet consisting of 11 mixed strands surrounded by a number of α -helices (Bracey et al., 2002). Remarkably, the FAAH dimer is stabilized by the lipid bilayer and shows a higher enzymatic activity within membranes containing cholesterol (Dainese et al., 2014) according to allosteric kinetics (Dainese et al., 2020). Additionally, colocalization of cholesterol, AEA, and FAAH in mouse neuroblastoma cells suggests a

mechanism by which cholesterol increases the substrate accessibility of FAAH (Dainese et al., 2014); yet, the pathophysiological implications of these findings remain to be understood. C385A polymorphism of the FAAH-1 gene (rs324420) results in the formation of P129T mutant, which is associated with the reduction of FAAH activity and cellular expression as well as increased risk for substance use disorders (Sipe et al., 2002). This polymorphism also affects susceptibility to various diseases (Hosseinzadeh Anvar and Ahmadalipour, 2023).

2. *N*-Acylethanolamine Acid Amide Hydrolase. NAAA is a lysosomal hydrolase (Tsuboi et al., 2007a; Ueda et al., 2010) that shows 33% amino acid identity with acid ceramidase, which hydrolyzes ceramide to sphingosine and fatty acid. Similar to other members of the N-terminal nucleophile hydrolase family (Linhorst and Lübke, 2022), NAAA is synthesized as a catalytically inactive precursor and then matured to heterodimer, consisting of α and β subunits, by post-translational autoproteolytic cleavage (Zhao et al., 2007). This reaction proceeds *in vitro* only at acidic pH, suggesting that the maturation occurs only after its migration to endosomes/lysosomes from the endoplasmic reticulum via the Golgi apparatus. The resultant N-terminal cysteine residue of the β subunit (Cys-126 in human NAAA, Cys-131 in rodents) functions as the catalytic nucleophile. Importantly, this cysteine residue is also indispensable for the autoproteolytic cleavage. The crystal structures of NAAA elucidated that autoproteolysis exposes the buried active site to enable catalysis (Gorelik et al., 2018). NAAA hydrolyzes various fatty acid ethanolamides *in vitro*, but its highest reactivity is for *N*-palmitoylethanolamine (Ghidini et al., 2021). The fact that NAAA is highly expressed in macrophages (Tsuboi et al., 2007b) and other immune cells (Ribeiro et al., 2015) suggests that this enzyme may regulate fatty acid ethanolamide levels at the site of inflammation. In fact, in dermatitis induced by treatment of mice with 2,4-dinitrofluorobenzene, NAAA-deficient mice showed elevated *N*-palmitoylethanolamine, but not *N*-oleoylethanolamine, levels in ear tissue relative to wild-type controls and exhibited a strong reduction in the inflammatory reaction (Sasso et al., 2018). Furthermore, NAAA deficiency in mice increased *N*-palmitoylethanolamine and AEA levels in bone marrow and macrophages and AEA levels in lungs (Xie et al., 2022).

C. Fatty Acid Amide Hydrolase Inhibitors

The first potent, selective, and systemically active FAAH inhibitor was the *N*-biphenylcarbamate derivative URB597, shown in Fig. 23 (Kathuria et al., 2003; Tarzia et al., 2003). This agent acts by forming a carbamoyl adduct with FAAH's catalytic serine (Mileni et al., 2010) and exhibits robust anxiolytic-like and antidepressant-like properties, which depend on indirect CB₁R

activation by accumulated anandamide (Kathuria et al., 2003; Gobbi et al., 2005; Bortolato et al., 2007).

Importantly, unlike direct-acting CB₁R agonists such as THC, URB597 is not rewarding to nonhuman primates, suggesting a lack of abuse potential (Justinova et al., 2008). An exploration of its scaffold unexpectedly led to the identification of the first peripherally restricted FAAH inhibitor, URB937 (Fig. 23), which strongly attenuates pain-related responses in animal models (Clapper et al., 2010). The promising pharmacological profile of URB597 prompted efforts by both academe and industry to create more advanced inhibitors. Reviews of this considerable body of work are available (Tuo et al., 2017; Fazio et al., 2020; Piomelli and Mabou Tagne, 2022), but one especially significant chemical class, the piperidine/piperazine-ureas, should be mentioned here. High-throughput screening of a chemical library led scientists at Johnson & Johnson to discover JNJ-1661010 (Fig. 23), which inhibits human FAAH with nanomolar potency (IC₅₀ = 33 nM) and through a covalent mechanism (Keith et al., 2008). Further optimization identified the compound JNJ-42165279, a slowly reversible FAAH inhibitor that was selected for clinical testing. Concomitant work at Pfizer produced several nanomolar piperidine/piperazine-urea covalent FAAH inhibitors (Ahn et al., 2007) and eventually led to PF-04457845 (Fig. 23), which was also moved to clinical development. There are several possible therapeutic indications for which FAAH inhibitors have been or are currently being tested, including anxiety disorders, substance use disorders, and pain.

Building on the observation that URB597 exerts profound anxiolytic-like and antidepressant-like effects in mice and rats, animal and human experiments have shown that AEA signaling at CB₁R modulates the emotional response to stress via regulation of prefrontal cortical-amygdala circuits (Patel et al., 2017). For example, subjects carrying the loss-of-function *faah* gene polymorphism C385A (rs324420) display enhanced fronto-amygdalar connectivity and cued fear extinction (Dincheva et al., 2015). This conclusion was later confirmed by several other human experimental medicine studies. For instance, Paulus and coworkers found that JNJ-42165279 (100 mg) dampens amygdala activity




Fig. 23. Chemical structures of representative inhibitors of FAAH.

during an emotion face-processing task, an effect that is associated positively with plasma AEA concentrations (Paulus et al., 2021). A lower dose of the drug (25 mg) was tested in a multicenter, placebo-controlled phase 2 trial in patients with social anxiety disorder. The study reported statistically detectable signs of efficacy, but the dosage was considered insufficient to fully inhibit FAAH (Schmidt et al., 2021). Additional clinical testing in anxiety and allied conditions is clearly warranted.

The impact of FAAH inhibitors on tobacco and cannabis use disorders exemplifies well the promise offered by these agents but also their complex actions. URB597 was shown to reduce nicotine reward and to prevent reinstatement of nicotine use in animal models (Justinova et al., 2015), an effect that was associated with reduced burst firing of dopamine neurons in the midbrain and dopamine release in the terminal field of such neurons (Melis et al., 2004). Unexpectedly, the effects of URB597 on nicotine reward were prevented by PPAR α rather than CB $_1$ R blockade, leading to the suggestion that they were mediated by PPAR α agonists, such as *N*-oleoylethanolamine and *N*-palmitoylethanolamine, rather than by AEA acting at CB $_1$ R. With regard to cannabis, a phase 2 clinical trial demonstrated that PF-04457845 is effective in reducing cannabis use and alleviating cannabis withdrawal symptoms in men (D'Souza et al., 2019).

There is strong preclinical evidence indicating that eCBs are critical regulators of pain sensation (for review, see Finn et al., 2021). The analgesic phenotype of individuals carrying loss-of-function FAAH mutations (C385A, *faah-out*) supports this conclusion (Habib et al., 2019), but the results of clinical trials have been disappointing (Huggins et al., 2012; Wagenlehner et al., 2017). Possible explanations for this discrepancy include species-specific differences, selection of inadequate clinical pain conditions, inconsistencies between preclinical and clinical study design, and lack of predictive validity of current animal models. Other pathologies where FAAH inhibitors might be clinically useful include chronic cough (Wortley et al., 2017) and urinary tract dysfunction (Wagenlehner et al., 2017). Overall, several FAAH inhibitors have been patented for their potential therapeutic use, as summarized in Table 7 (Fazio et al., 2020).

Several compounds (URB597, PF-04457845, SSR411298, APD8477, V158866, BIA 10-2474, and JNJ-42165279) have also been tested in clinical trials (Table 8). Of note, the FAAH inhibitor BIA 10-2474 led to adverse neurologic side effects and the death of one healthy volunteer in a phase 1 clinical trial (Kerbrat et al., 2016). Since the other FAAH inhibitors tested in clinical trials did not elicit any adverse neurologic effects and BIA 10-2474 was shown to have multiple off-targets, inhibition of FAAH is considered to be safe.









D. *N*-Acylethanolamine Acid Amide Hydrolase

The search for potent, selective, and systemically active NAAA inhibitors started in 2009 with the identification of the β -lactone derivative *N*-[(3*S*)-2-oxo-3-oxetanyl]-3-phenylpropanamide [(*S*)-OOPP] shown in Fig. 24, which inhibits rat NAAA with submicromolar potency (IC $_{50}$ = 420 nM on rat NAAA) via a noncompetitive and partially reversible mechanism (Solorzano et al., 2009).

Due to the opening of its β -lactone ring, (*S*)-OOPP undergoes rapid hydrolytic deactivation, which makes it unsuitable for systemic administration. The compound has, however, two interesting properties (Solorzano et al., 2009). First, it is selective for NAAA over other functionally (FAAH) or structurally (acid ceramidase) related lipid amidases. Second, its inhibitory effect is stereospecific, allowing researchers to leverage the enantiomer (*R*)-OOPP (IC $_{50}$ = 6 μ M) as a negative control in pharmacological experiments. These experiments showed that incubation with *S*-OOPP increases *N*-palmitoylethanolamine levels in RAW264.7 macrophages stimulated with bacterial endotoxin, whereas (*R*)-OOPP does not (Solorzano et al., 2009). Moreover, subdermal application of (*S*)-OOPP, but not (*R*)-OOPP, blocked carrageenan-induced neutrophil infiltration and plasma extravasation in mice, two effects that are prevented by genetic PPAR α ablation and are mimicked by administration of PPAR α agonists. These findings identified NAAA as a druggable target for the treatment of inflammation and encouraged efforts to discover inhibitors with greater potency and stability. The first notable outcome of this search was another β -lactone derivative, ARN077 (also known as URB913), in which the amide group of (*S*)-OOPP is replaced by a carbamate moiety and a syn-methyl group is introduced at the β position of the lactone ring (Fig. 24).

Compared with (*S*)-OOPP, ARN077 exhibits better chemical stability and greater NAAA inhibitory potency (IC $_{50}$ = 50 nM on rat NAAA) (Ponzano et al., 2013). ARN077 was found to be selective for NAAA when assessed in a broad panel of potential off-targets. Importantly, topical application of ARN077 on the mouse or rat skin attenuated inflammation and pain-related responses (Sasso et al., 2013, 2018). Despite these significant steps forward, the low chemical and enzymatic stability of the β -lactone ring remained a challenge to the systemic use of ARN077 and other chemically related inhibitors. Efforts were thus undertaken to overcome this problem, which led to the discovery of several new classes of NAAA inhibitors, including β -lactam derivatives (e.g., ARN726) (Ribeiro et al., 2015), isothiocyanate derivatives (e.g., AM9023) (Alhouayek et al., 2015), azetidone-nitrile derivatives (Malamas et al., 2020), and benzothiazole derivatives

TABLE 7
Potential therapeutic use of patented FAAH inhibitors^a

Compound	Potential Therapeutic Use
<p>Oxazole Derivatives</p> 	Treatment of different types of pain: postoperative pain, chronic pain, cancer pain, cancer chemotherapy, neuralgia, nociception pain, inflammatory pain
<p>Urea Derivatives</p> 	Treatment of depression, analgesia, and cannabis use disorders
<p>Urea/Carbamate</p> 	Treatment of pain, inflammation, neuropathy, neurodegenerative diseases, anxiety, motor function disorder, infertility, eating disorders, THC dependence, metabolic disorders, movement disorders, chemotherapy-induced nausea and vomiting, and cancer
<p>ARN2508</p> 	Treatment of intestinal inflammation where a pure FAAH inhibitor was weakly active and the pure COX inhibitor flurbiprofen aggravated inflammation Simultaneous blockade of FAAH and COX-1/COX-2 results in a combination of profound anti-inflammatory and tissue protective actions
<p>Oxazolyl-ketones [replacement of the phenyl hexyl group of OL-135 with a piperidine ring]</p> 	Treatment of anxiety, pain, sleep disorders, eating disorders, inflammation, or movement disorders (e.g., in multiple sclerosis)
<p>JNJ-42119779</p> 	Effective in the spinal nerve ligation (Chung) model of neuropathic pain
<p>JNJ-40413269</p> 	Effective in the rat spinal nerve ligation (Chung) model of neuropathic pain
<p>2,3,4-Tetrahydro-2,6-naphthyridines</p> 	Treatment of pain, anxiety, depression, inflammation, cognitive disorders, weight and eating disorders, Parkinson's disease, Alzheimer's disease, spasticity, addiction, glaucoma

^aFor further details see Fazio et al. (2020).

(e.g., ARN19702) (Migliore et al., 2016), shown in Fig. 24. The discovery, inhibitory properties, and mechanism of action of these agents were recently reviewed (Piomelli et al., 2020). Thus far, three main therapeutic indications have emerged for NAAA inhibitors: inflammation, pain, and neuroinflammation/neurodegeneration.

A chemically diverse set of NAAA inhibitors exhibit notable anti-inflammatory properties in animal models. For example, topical application of the β -lactone ARN077 was shown to suppress skin inflammation elicited by

exposure to UV B-radiation in rats or phorbol ester in mice (Sasso et al., 2013). The compound also attenuated itch and skin inflammation in sensitized mice challenged with 2,4-dinitrofluorobenzene (Sasso et al., 2018). Confirming that ARN077 acts by protecting *N*-palmitoylethanolamine from NAAA-mediated hydrolysis, the effects of ARN077 were accompanied by restoration of normal *N*-palmitoylethanolamine content in inflamed skin tissue and were dependent on PPAR α activation (Sasso et al., 2013, 2018). The striking effects produced by ARN077 on critical mediators of the allergic response (e.g.,

TABLE 8
Diseases/symptoms for treatment with FAAH inhibitors registered with
ClinicalTrials.gov^a

Generic Name Brand Name Class/Efficacy	Completed Clinical Trials	Ongoing Clinical Trials
FAAH inhibitors		
PF-04457845	Tourette syndrome Cannabis withdrawal Fear conditioning Acute pain • Chronic pain • Knee osteoarthritis	Cannabis use disorder
URB597		Schizophrenia
SSR411298	Major depressive disorder Cancer pain	
APD8477	Peripheral neuropathic pain	
V158866	Neuropathic pain	
JNJ-42165279	Major depressive disorder Social anxiety disorder Autism	

^aStudies with the status “not yet recruiting, recruiting,” “enrolling by invitation,” “active, not recruiting,” and “completed” were included in this table.

interleukin 4 and immunoglobulin E) (Sasso et al., 2018) and the efficacy demonstrated by *N*-palmitoylethanolamine as an adjuvant treatment of eczema (Eberlein et al., 2008) encourage further evaluation of NAAA as a target for the treatment of the atopic diathesis, a disease cluster that includes atopic dermatitis, bronchial asthma, hay fever, and allergic rhinitis. Other inflammatory diseases in which NAAA inhibitor might find clinical use, as suggested by animal model studies, include osteoarthritis (Bonezzi et al., 2016; Zhou et al., 2019b) and colitis (Alhouayek et al., 2015; Xiu et al., 2020).

In addition to inflammation, NAAA inhibitors may also be effective in the treatment of pain and neuroinflammation/neurodegeneration. For example, the systemically active NAAA inhibitor ARN19702 exhibited a broad antinociceptive profile in mouse models of acute and chronic pain (Fotio et al., 2021a) and alleviated symptoms of

neuroinflammation in mouse models of multiple sclerosis (Migliore et al., 2016) and Parkinson's disease (Palese et al., 2022). Similarly, the topically active β -lactone derivative ARN077 alleviated hypersensitivity in mouse and rat models of neuropathic pain (Sasso et al., 2013), while the oxazolidinone imide derivative F96 (Fig. 24) attenuated acetic acid-induced writhing and tactile allodynia evoked by sciatic nerve injury in mice (Yang et al., 2015). No NAAA-targeting compound has yet reached clinical trials.

IV. Therapeutic Potential of Metabolic Enzymes of 2-AG

A. Metabolism of 2-Arachidonoylglycerol

The endocannabinoid 2-AG can be produced via two distinct biologic pathways. The metabolic pathway uses *sn*-2 arachidonoyl-containing triglycerides, which are hydrolyzed by hormone-sensitive lipase, carboxyl esterases, or other lipases toward *sn*-2 arachidonoyl DAGs (Baggelaar et al., 2018). The signaling pathway utilizes phosphatidylinositol-4,5-bisphosphate, which is converted by PLC β in the CNS or PLC γ 2 in immune cells. The PLC enzymes are activated by Ca²⁺ ions and integrate G_q protein-coupled receptor activation and extracellular Ca²⁺ influx via ionotropic receptors and voltage-gated Ca²⁺-channels, thereby also producing DAGs. The diglycerides activate protein kinase C and are the central precursors for the production of 2-AG in both the metabolic and signaling pathways. The *sn*-1 acyl group from DAGs is predominantly hydrolyzed by two isoenzymes, diacylglycerol lipase- α and - β (DAGL α and DAGL β , also termed diacylglyceride lipases), which produce 2-AG and other *sn*-2 acylglycerides. The DAGLs were discovered by Doherty's group in 2003 (Bisogno et al., 2003), and the generation of genetically modified animals lacking *dagl* α and *dagl* β , the genes encoding the DAGL proteins, demonstrated that these enzymes are essential for 2-AG production in the brain (Gao et al., 2010; Tanimura et al., 2010). Of note, the DAGLs also terminate protein kinase C signaling by hydrolyzing DAGs; thus, these enzymes are an important hub to connect lipid and kinase signaling.

Termination of 2-AG signaling at CB₁R or CB₂R occurs through hydrolysis of the ester bond, thereby generating AA and glycerol. MAGL (also termed monoglyceride lipase) is the main enzyme responsible for the inactivation of 2-AG in the brain (Dinh et al., 2002), whereas α/β -hydrolase domain protein 6 and 12 may play a role in 2-AG hydrolysis in specific cell types (Marrs et al., 2010; Blankman et al., 2007). In various tissues, including the brain, 2-AG is responsible for the main supply of AA, which is the central precursor for proinflammatory signaling lipids, such as the prostaglandins (Nomura et al., 2010). Thus, MAGL is a central node that connects endocannabinoid and eicosanoid signaling. Modulators of




Fig. 24. Chemical structures of representative inhibitors of NAAA.

2-AG metabolism are listed in Table 9, and in the next sections their therapeutic potential is described. For an extensive review on chemical probes of the endocannabinoid system, see also Punt et al. (2023).

B. Therapeutic Potential of Diacylglycerol Lipase- α

DAGL α belongs to the family of serine hydrolases, and is responsible for the production of 2-AG in the CNS (Bisogno et al., 2003), where it is primarily found in the dendrites and soma of neurons and to a lower extent in astrocytes, but not in microglial cells. DAGL α is expressed in various brain regions, such as cortex, hippocampus, cerebellum, and striatum, and its activity is highest in the cerebellum (Baggelaar et al., 2017). DAGL α is a 120 kDa integral plasma membrane protein with multiple domains (Fig. 25) and has four transmembrane helices followed by a lipase domain, which contains the catalytic triad Ser, His, Asp (Bisogno et al., 2003).

DAGL α produces 2-AG on demand as a retrograde messenger upon depolarization of the post-synaptic neuron or by stimulation of G $_{q/11}$ -coupled metabotropic receptors, with or without activation of ionotropic receptors at both excitatory and inhibitory synapses (Gao et al., 2010; Tanimura et al., 2010). Animals with constitutive genetic disruption of DAGL α show a variety of neurologic phenotypes, including impaired synaptic transmission, disturbed memory and learning, compromised adult neurogenesis (Gao et al., 2010), hypophagia (Powell et al., 2015), enhanced anxiety and fear responses (Shonesy et al., 2014; Jenniches et al., 2016), and susceptibility to spontaneous seizures (Powell et al., 2015). Multiple selective pharmacological tools have been developed to modulate DAGL α (as well as DAGL β) activity in an acute and temporary manner (Baggelaar et al., 2018; Punt et al., 2023). LEI-105, DO34, and DH376 are currently widely used DAGL inhibitors to study the involvement of these enzymes in physiologic processes (Baggelaar et al., 2015; Ogasawara et al., 2016). For example, the same inhibitors were instrumental, in conjunction with genetic models, to unequivocally demonstrate that 2-AG production is “on demand,” i.e., when and where needed upon stimuli during short-term synaptic plasticity, such as depolarization-induced suppression of inhibition or excitation (DSE) in hippocampal and cerebellar slices (Baggelaar et al., 2015; Ogasawara et al., 2016). DAGL inhibitors also contributed to our understanding of the role of 2-AG in cocaine seeking (McReynolds et al., 2018), alcohol addiction, food intake (Deng et al., 2017), neuroinflammation (Ogasawara et al., 2016), anxiety and stress (Bluett et al., 2017), learning and memory (Schurman et al., 2019), pain sensation (Wilkerson et al., 2017), and voluntary movement (Farrell et al., 2021). It should be noted that DO34 and DH376, but not LEI-105, also inhibited other serine hydrolases suABHD6. Thus, it is advisable to include DO53 as a negative control

in the experimental design when using DO34 or DH376 (Deng et al., 2017).

DAGL α is very well conserved throughout evolution. Human DAGL α has 97% homology with its mouse ortholog, whereas it has only 79% homology to DAGL β . DAGL α has a long unstructured C-terminal tail, which contains many phosphorylation sites that regulate its activity and subcellular localization through protein-protein interactions. It has been shown that CaMKII phosphorylates Ser782 and Ser808, thereby reducing the enzyme activity (Shonesy et al., 2013). On the other hand, protein kinase A, which is activated by cAMP, has been shown to phosphorylate multiple sites in the C-terminus of DAGL α , including Ser798, thereby activating the enzyme (Shonesy et al., 2020). It has been suggested that the opposing actions of protein kinase A and CaMKII on DAGL α activity may be important in setting the level of tonic 2-AG signaling. Of note, cAMP-induced phosphorylation of Ser738 of DAGL α has been shown to enhance the interaction of DAGL α with ankyrin-G, a scaffolding protein in dendritic spines (Yoon et al., 2021). This led to increased spine size and decreased DAGL α surface diffusion. Repeated strong excitatory dendritic spine stimulation resulted in a feedback signal that promoted the growth of an inhibitory γ -aminobutyric acid bouton onto the same dendrite in a DAGL-dependent manner. The C-terminus also contains the consensus motif PPxxF, needed to bind the coiled-coil domain of Homer proteins, which are adapter proteins that localize DAGL α close to the post-synaptic density in the vicinity of metabotropic glutamate receptor 5 (Jung et al., 2007). Interestingly, the surface localization of DAGL α was shown to be a dynamic process controlled by protein kinase C. DAGL α colocalized with β -tubulin and cycled between the plasma membrane and endosomal compartments via EEA1- and Rab5-positive early endosomes in a clathrin-independent pathway (Zhou et al., 2016). This process could be disrupted by protein kinase C inhibitors but not by protein kinase A inhibitors. In a mouse model of Fragile X syndrome, which is the most commonly known genetic cause of autism, aberrant subcellular localization of DAGL α was found to cause a disruption in glutamatergic signaling, thereby impairing long-term depression (Jung et al., 2012). Recently, the first clinical evidence was presented that a *dagl α* variant, which led to a disrupted cellular localization of the protein, was connected to a human genetic disorder. Nine children from eight families with heterozygous de novo truncating variants in the last exon of DAGL α exhibited developmental delay, ataxia, and complex oculomotor abnormalities (Bainbridge et al., 2022). Altogether, these observations demonstrate that the post-translational regulation of DAGL α activity and its subcellular localization enable a tight spatiotemporal control on 2-AG-dependent synaptic transmission. Disturbances in the

TABLE 9
Modulators of 2-AG metabolism

Name	Target	Phase	Structure	Reference
LEI-105	DAGL	Preclinical		Baggelaar et al., 2015
DO34	DAGL	Preclinical		Ogasawara et al., 2016
DH376	DAGL	Preclinical		Ogasawara et al., 2016
DO53	Negative control compound	Preclinical		Ogasawara et al., 2016
KT109	DAGL	Preclinical		Hsu et al., 2012
JZL184	MAGL	Preclinical		Long et al., 2009
MJN110	MAGL	Preclinical		Niphakis et al., 2013
ABX-1431 (Lu-AG06466)	MAGL	Phase 2		

subcellular localization of DAGL α and its activity result in abnormal neurotransmission and neurologic disorders. Unfortunately, pharmacological inhibition of DAGL α in the CNS is unlikely to be of therapeutic value due to on-target toxicity.

C. Therapeutic Potential of Diacylglycerol Lipase- β

DAGL β is the main enzyme responsible for the production of 2-AG in immune cells, including microglia that are the brain resident macrophages. DAGL β is a 70 kDa multidomain, integral membrane serine




Fig. 25. (A) Structured part of the AlphaFold model for human DAGL α , residues 1-681; red: transmembrane domain, blue: catalytic domain, green: regulatory loop. (B) Unstructured tail region from the AlphaFold model, residues 682–1042 highlighting potential phosphorylation sites, as discussed in the text, and Homer binding domain. (C) Schematic representation with highlighted regions and relevant serines shown.

hydrolase that lacks the unstructured C-terminal tail observed in DAGL α . This suggests that the activity and subcellular localization of DAGL β is differently regulated. DAGL β has a similar substrate preference as DAGL α , but it is also capable of hydrolyzing polyunsaturated fatty acid-specific triacylglycerides (Shin et al., 2020). DAGL β knockout mice show 50% reduction in 2-AG levels in the brain, whereas in the liver, a > 90% reduction was observed (Gao et al., 2010). DAGL β is not involved in the regulation of depolarization-induced suppression of inhibition or DSE in hippocampal or cerebellar slices (Gao et al., 2010), and in the developing brain, it is detected in the axonal growth cone of neurons (Bisogno et al., 2003). DAGL β is transported to the cone via the adaptor protein complex AP-4 (Davies et al., 2022). A patient deficient in AP-4 was shown to accumulate DAGL β in the *trans*-Golgi network of cells, and AP-4 knockout mice had reduced eCB levels in the brain (Davies et al., 2022). Recently, a specific subset of nigral dopaminergic neurons in the adult brain was found to express DAGL β . This expression was implicated in the inhibition of γ -aminobutyric acid release from dorsal striatal spiny projection neurons and is supposed to be involved in locomotor skill learning across sessions (Liu et al., 2022). Multiple homozygous loss-of-function mutations in DAGL β were linked to sporadic, early-onset autosomal recessive Parkinsonism in Chinese families (Liu et al., 2022). PLC γ_2 , for which activating mutations are associated with autoimmune disorders and Alzheimer's disease, has recently been shown to serve as the principal enzyme providing the DAG pool for DAGL β -MAGL axis in human innate immune cells and microglia (Jing et al., 2021). Mouse microglia lacking PLC γ_2 displayed a suppressed endocannabinoid-eicosanoid cross-talk and an impaired in vivo inflammatory response to lipopolysaccharide that led to reduced CD68-expression but not to release of proinflammatory cytokines. These findings extend the previous observations that genetic and pharmacological

inhibition of DAGL β exerts anti-inflammatory properties in mouse macrophages and microglia (Hsu et al., 2012; Viader et al., 2016). Overall, it was suggested that selective inhibitors of DAGL β (and MAGL) may be therapeutically of interest for immune pathologies caused by activation of PLC γ_2 .

Currently, no selective DAGL β inhibitors are available. KT-109 was originally reported as a selective DAGL β inhibitor (Hsu et al., 2012), which displayed analgesic efficacy in an inflammatory and neuropathic pain model (Wilkerson et al., 2016; Shin et al., 2018), as well as in a sickle cell disease model (Khasabova et al., 2023). However, it should be noted that KT109 also inhibits DAGL α to the same extent as DAGL β (Deng et al., 2017); thus care should be taken in the interpretation of the effects of this compound. As noted earlier, nonselective dual DAGL inhibitors, such as DO34 and DH376, have anti-neuroinflammatory properties (Ogasawara et al., 2016; Viader et al., 2016). They reduced production of proinflammatory cytokines and prostaglandins in microglia and impaired lipopolysaccharide-induced hypothermia in mice. In summary, selective compounds are still required to test the therapeutic potential of DAGL β inhibition in neuroinflammatory diseases and inflammatory pain.

D. Therapeutic Potential of Monoacylglycerol Lipase

MAGL is a membrane-associated serine hydrolase, which was cloned in 1997, and consists of two tissue-specific splice-variants with a molecular weight of 33 kDa and 36 kDa. It has the typical catalytic triade Ser122, Asp239, and His269 and uses monoacylglycerols with different chain length and saturation, including 2-AG, as a substrate (Dinh et al., 2002). Oxidation of two noncatalytic cysteines (C201 and C208) reduces its enzymatic activity (Dotsey et al., 2015). MAGL is abundantly expressed in various tissues (e.g., brain, lung, liver, spleen, kidney, heart, and intestines) and is active in different brain regions including hippocampus,

cerebellum, cortex, and striatum (Baggelaar et al., 2017). MAGL is found in neurons and astrocytes, and to a lesser extent in microglia (Viader et al., 2016), and notably is localized at the presynaptic site along with the CB₁ receptor and opposed to DAGL α . This lipase terminates the retrograde eCB signaling mediated by 2-AG, and indeed mice lacking the *mgll* gene that encodes for MAGL show robust elevations of 2-AG in the brain and less pronounced elevations in liver, spleen, and thymus (Long et al., 2009). This observation suggests that other esterases may participate in the hydrolysis of 2-AG at the periphery. MAGL knockout mice also have significantly reduced AA levels in their brain, which indicates that the DAGL-MAGL axis is responsible for the pool of free AA in the brain (Nomura et al., 2010). Furthermore, MAGL knockout animals have a desensitized CB₁R, and show impaired eCB-dependent synaptic plasticity and physical dependence (Schlosburg et al., 2010).

Several *in vivo* active MAGL inhibitors, including JZL184 and MJN110, have been described in the literature (Long et al., 2009; Niphakis et al., 2013). Together with the MAGL knockout animals, these inhibitors have been instrumental in studies of the therapeutic potential of MAGL inhibition in a broad range of diseases, spanning from cancer (Nomura et al., 2011), Parkinson's disease (Nomura et al., 2010), Alzheimer's disease (Chen et al., 2012), and MS (Hernández-Torres et al., 2014) to inflammatory and neuropathic pain (Hohmann et al., 2005; Kinsey et al., 2009), acute liver injury (Cao et al., 2013), and anxiety and depression (Bluett et al., 2017; Zhang et al., 2015a). For recent reviews, see Gil-Ordóñez et al. (2018), Deng and Li (2020), and Van Egmond et al. (2021). Of note, chronic, high dosing of MAGL inhibitors caused desensitization and downregulation of CB₁R, and behavioral tolerance to CB₁R agonists. A therapeutic window for antinociceptive efficacy without CB₁R desensitization was observed upon acute and chronic low dosing. In this respect, MAGL inhibition may have therapeutic potential for treating inflammatory and neuropathic pain, as well as neurodegenerative diseases accompanied by neuroinflammation like MS, Alzheimer's, and Parkinson's diseases. Several pharmaceutical companies, including Johnson & Johnson, Lundbeck, Takeda Pharmaceuticals, Pfizer, and Hoffman-LaRoche, have filed patents describing a diverse range of chemotypes of MAGL inhibitors (Bononi et al., 2021). Among these compounds, the covalent, irreversible MAGL inhibitor Lu-AG06466, developed by Lundbeck (formerly ABX-1431 from Abide Therapeutics), is the most advanced experimental drug. It has been reported that Lu-AG06466 exerts adverse effects in the CNS and appeared ineffective in a phase 2 clinical trial for Tourette syndrome (Müller-Vahl et al., 2021, 2022), yet this compound is currently being investigated in phase 2 trials for other indications, such as post-traumatic

stress disorder and spasticity in multiple sclerosis. Clinical trials for Lu-AG06466 listed in ClinicalTrials.gov at the date of this review are shown in Table 10.

Overall, it is hypothesized that reversible MAGL inhibitors may avoid some of the adverse effects observed with covalent, irreversible inhibitors (Van Egmond et al., 2021). However, another strategy to avoid CNS-mediated side effects could be to generate peripherally restricted MAGL inhibitors for the potential treatment of cancer, tissue ischemic-reperfusion injury, and/or antinociception.

V. Therapeutic Potential of Transmembrane, Intracellular, and Extracellular Transporters

While translational efforts toward the development of ECS modulators have been primarily dedicated to eCB degradation inhibitors, in particular FAAH and MAGL blockers (Blankman and Cravatt, 2013; Fowler, 2021; van Egmond et al., 2021), translating research on inhibitors of eCB cellular uptake or cellular trafficking remains slow. The development of such transport inhibitors has been convoluted by the fact that extra- and intracellular eCB-binding proteins are promiscuous, as well as by the lack of a concrete target responsible for plasma membrane transport, whose identity remains elusive. Nevertheless, RT126, a FABP inhibitor that competes with eCB binding for FABP4 and FABP5, and SYT510, a selective eCB reuptake inhibitor (SERI) which increases extracellular eCB levels in the brain by targeting the putative eCB membrane transporter, are under development by the pharmaceutical industry (<https://ir.artelobio.com/news-events/press-releases/detail/90/artelobiosciences-reports-positive-pre-clinical-results>, <https://www.synendos.com>). Unlike active cellular transport mechanisms that are energy-driven, the lipophilic eCBs seem to traffic between membranes and across aqueous barriers through interactions with binding proteins and pass the plasma membrane by energy-independent mechanisms (Fig. 7). Among these, facilitated diffusion is influenced by both the interaction of eCBs with extra- and intracellular binding proteins and their metabolic enzymes. The measurement of facilitated diffusion and plasma membrane lipid transport is challenging and demands special phenotypic assays not easily accessible for routine screening (Oddi et al., 2010; Fowler, 2013; Rau et al., 2016; Reynoso-Moreno et al., 2023). A major challenge has been to differentiate FAAH and AEA uptake inhibitors as these processes are intrinsically coupled (Fowler et al., 2004; Vandevorde and Fowler, 2005; Hillard et al., 2007). Therefore, only recently selective and potent eCB cellular uptake inhibitors have been developed (Chicca et al., 2017).

In 2009, the identification of intracellular carrier proteins, primarily FABPs, and lipid droplets as potential sequestration domains for AEA provided a new

TABLE 10
Clinical trials for MAGL inhibitor Lu-AG06466 listed in ClinicalTrials.gov

Identifier	Status	Condition	Title
NCT04597450	Ongoing	PTSD	Lu-AG06466 in Participants With Post Traumatic Stress Disorder
NCT04990219	Ongoing	Multiple sclerosis	A Study of Lu-AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
NCT05028673	Completed	Healthy	A Study to Evaluate a New Tablet Formulation of Lu-AG06466 in Healthy Participants
NCT04713254	Completed	Healthy	Drug Drug Interaction Study With Lu-AG06466 in Young Healthy Men
NCT04405323	Completed	Healthy	Study That Evaluates the Effect of CYP3A4 Inhibition on Lu-AG06466 in Healthy Men and Women
NCT04419636	Completed	Healthy	Binding of Lu-AG06466 in the Brain in Healthy Men
NCT05081518	Terminated	Focal epilepsy	A Study of Lu-AG06466 in Participants With Treatment Resistant Focal Epilepsy
NCT05201092	Completed	Healthy	A Study Investigating Lu-AG06466 in Healthy Men
NCT05219838	Completed	Healthy	Binding and Effects of Lu-AG06466 in the Brain of Healthy Men
NCT04974359	Terminated	Fibromyalgia	A Study to Evaluate Lu-AG06466 in Participants With Fibromyalgia
NCT05177029	Terminated	Healthy	Safety and Tolerability Study of Lu-AG06466 in Healthy Young Japanese and Caucasian Participants

perspective in AEA transport research (Oddi et al., 2008, 2009; Kaczocha et al., 2009). FABPs facilitate the spatial organization of eCBs into domains and enable the trafficking between plasma and intracellular membranes. In this section, an update on previous reviews on the topic (Fowler, 2013; Nicolussi and Gertsch, 2015; Reynoso-Moreno and Gertsch, 2021) is provided, focusing on the molecular pharmacology and possible implications for therapeutic intervention of using the diverse eCB transport inhibitors shown in Fig. 26. Since such inhibitors show CB₁R/CB₂R-dependent indirect cannabimimetic effects like analgesia, anti-inflammatory, and anxiolytic effects, they constitute a new class of pharmacological inhibitors that indirectly activate the ECS, showing a differential effect on the system compared with FAAH and MAGL inhibitors.

A. Endocannabinoid Trafficking and Transport

Although 2-AG is the major eCB in tissues such as the brain and is generally more soluble in water than AEA (1400 ng/ml versus 250 ng/ml, respectively; see Tetko et al., 2005), most research on eCB transporters has been carried out on AEA. Intriguingly, almost 30 years after the identification of AEA in porcine brain (Devane et al., 1992b), the mechanisms of eCB membrane transport (i.e., release into the extracellular space and cellular reuptake) remain only partially understood. However, different hypothetical models have been proposed and reviewed for AEA uptake and trafficking (Felder et al., 2006; Yates and Barker, 2009; Nicolussi and Gertsch, 2015), as shown in Fig. 7. The currently the best substantiated model of facilitated diffusion is discussed here in the context of the emerging specific pharmacological modulators.

In the 1990s, the first reports on the cellular uptake of AEA designated a temperature- and time-dependent transport, which was linked to the enzymatic hydrolysis by FAAH in C6 glioma cells, N18TG2 neuroblastoma cells, and primary neuronal cells (Deutsch and

Chin, 1993; Di Marzo et al., 1994). This cellular uptake process of AEA was rapid ($t_{1/2} = 2.5$ minutes), saturable, and, importantly, did not compete with closely related *N*-acylethanolamines such as *N*-stearoylethanolamine, *N*-linoleoylethanolamine, or *N*-palmitoylethanolamine, shown in Table 3 (Di Marzo et al., 1994). Since all *N*-acylethanolamines compete for FAAH hydrolysis, being ideal substrates for this enzyme, the fact that they showed no competition for cellular AEA uptake clearly suggested a mechanism independent of AEA metabolism (Chicca et al., 2012).

The early investigations in the 1990s suggested a carrier-mediated uptake process for AEA that was not dependent on either ATP or coupled to ion (Na^+ , Cl^- , H^+) gradients (Beltramo et al., 1997; Hillard et al., 1997; Hillard and Jarrachian, 2000). The transport process of AEA displayed high-affinity Michaelis-Menten constants in astrocytes ($K_m = 0.3 \mu\text{M}$), cortical neurons ($K_m = 1.2 \mu\text{M}$), and human neuroblastoma CHP100 cells ($K_m = 0.2 \mu\text{M}$) (Beltramo et al., 1997; Maccarrone et al., 1998), with values comparable to those obtained with the transporters of serotonin ($K_m = 0.3\text{--}0.5 \mu\text{M}$), dopamine ($K_m = 0.9\text{--}1.2 \mu\text{M}$), and noradrenaline ($K_m = 0.4 \mu\text{M}$) (Masson et al., 1999; Piomelli, 2003). Among more than 25 cell lines, and considering different assay protocols and confounding factors such as sticking of lipids to plastic and vials, the range of the apparent K_m values for AEA uptake diverges dramatically, from $0.1 \mu\text{M}$ to $45 \mu\text{M}$ (Felder et al., 2006; Oddi et al., 2010). Although different routes of AEA catabolism exist (Fig. 4), which in principle can influence AEA cellular uptake, their contribution seems insignificant compared with that of FAAH. In an experiment on [³H]AEA uptake competition in U937 cells, different eCBs congeners (AEA, 2-AGE, *O*-AEA, and NADA, shown in Table 3) competed with [³H]AEA uptake, suggesting that a common cellular membrane uptake mechanism seemingly competes for one target related to cellular eCB uptake (Chicca et al., 2012).




Fig. 26. Model of eCB membrane transport and trafficking showing druggable targets. Molecular pharmacology and possible implications for therapeutic intervention of using diverse eCB transport inhibitors are shown. See text for details and abbreviations.

Albumin and Hsp70 have been identified as cytosolic AEA-binding proteins in mouse skin keratinocytes using proteomics and functional assays (Oddi et al., 2009). Another candidate in the list of intracellular carrier proteins for AEA is the reported FAAH-like AEA transporter (FLAT) (Fu et al., 2011). The latter was proposed to be a partially cytosolic, catalytically silent variant of the AEA-degrading enzyme FAAH. The role and existence of FLAT as an AEA transporter were subsequently questioned, as no expression in either mouse brain, spinal cord, or dorsal root ganglia could be detected by independent groups (Leung et al., 2013; Fowler, 2014). Furthermore, a certain enzymatic activity could still be detected in artificial FLAT-transfected HeLa cells (Leung et al., 2013). On the other hand, an inhibitor of FLAT (ARN272) showed promising indirect cannabimimetic effects in a mouse model of nausea and vomiting (O'Brien et al., 2013).

In a docking study, the sterol carrier protein 2 (SCP2) was shown to be yet another potential eCB carrier protein (Liedhegner et al., 2014). Although an increase of AEA accumulation could be detected in SCP2-transfected HEK-293 cells, competition experiments with AM404 and 2-AG did not show a significant difference in their IC_{50} values between SCP2-expressing and wild-type cells. It was concluded that SCP2 is a low affinity binding protein for AEA and that it might facilitate AEA cellular uptake to a minor degree. A fluorescent probe displacement assay was developed to screen for SCP2 inhibitors, which might help to elucidate the role of SCP2 in eCB transport. Using this assay, the binding affinities of AEA ($K_i = 0.68 \pm 0.05 \mu\text{M}$) and 2-AG ($K_i = 0.37 \pm 0.02 \mu\text{M}$) to SCP2 were calculated (Hillard et al., 2017). The binding affinities of a library of previously reported SCP2 inhibitors were tested along with a new series of analogs, where SCPI-1 was the most potent probe with a $K_i = 1.0 \pm 0.1 \mu\text{M}$ (Hillard et al., 2017). SCP-2/SCP-x gene ablation in FABP1 null (LKO) mice antagonized the impact of LKO and high-fat diet on brain AA and, subsequently, on eCB levels, suggesting that both FABP1 and SCP-2 directly or indirectly participate in regulating the ECS (Martin et al., 2019). In principle, any protein with hydrophobic surfaces/cavities may serve as an acceptor for lipids like AEA and other eCBs. This is confirmed by the recent crystal structure of cellular retinol-binding protein in complex with 2-AG (Lee et al., 2020). Currently, the pharmacological competition of eCBs at extracellular binding proteins like albumin, Hsp70, SCP2, or extracellular FABPs by synthetic ligands has not been studied in sufficient detail to allow conclusions regarding their druggability; i.e., it remains unclear whether competing for extracellular AEA protein binding would exert robust cannabimimetic effects, as well as diverse CB_1R/CB_2R -dependent pharmacological effects. Therefore, the current focus is on plasma membrane-associated and intracellular processes.

Notably, the involvement of FABPs in the transport of eCBs was suggested already in the context of intracellular PPAR activation (Sun et al., 2008). Consequently, FABP5 and FABP7 were shown to mediate AEA intracellular transport from the plasma membrane to FAAH in COS-7-FAAH-eGFP and N18TG2 neuroblastoma cells (Kaczocha et al., 2009).

As shown in Fig. 1, membrane-derived AEA and 2-AG can initiate cellular signaling at both extracellularly accessible (e.g., CB and other GPCRs) and intracellularly accessible (e.g., TRPVs, TRPs, and PPARs) sites (Ross, 2003; Watanabe et al., 2003; Goodfellow and Glass, 2009; Sigel et al., 2011; Baur et al., 2013). Because any eCB agonist needs to be removed from the orthosteric binding site of its receptor targets, the evolution of a membrane protein that facilitates reuptake and CB_1R/CB_2R clearance would make sense. The interference with the movement of eCBs through competitive inhibition at binding sites or the putative eCB membrane transporter, therefore, has great potential to modulate pathophysiological processes through the ECS, with a range of possible therapeutic applications like FAAH and MAGL inhibitors.








B. Evolution of Pharmacological Inhibitors of N-Arachidonyl Ethanolamine Transport

In the 1990s, the first AEA uptake inhibitors were synthesized. Based on the observed substratespecificity, initially mainly structural analogs of AEA were synthesized and tested for [^3H]AEA uptake inhibition in rat brain neurons and astrocytes (Khanolkar et al., 1996; Beltramo et al., 1997). The first inhibitor of AEA cellular uptake was the *N*-(4-hydroxyphenyl)-arachidonamide AM404, which exhibited an IC_{50} value $\sim 1 \mu\text{M}$ in neurons and an IC_{50} value $\sim 5 \mu\text{M}$ in astrocytes (see Table 11) (Beltramo et al., 1997).

This probe, which was later discovered to be a bioactive AA conjugated metabolite of paracetamol (also known as acetaminophen) (Högstätt et al., 2005), was initially reported to be selective toward uptake inhibition over FAAH inhibition ($IC_{50} > 30 \mu\text{M}$). AM404 was later suggested to be a competitive inhibitor of AEA uptake and was found to be transported as a pseudo-substrate of the postulated AEA transporter (Beltramo and Piomelli, 1999). Yet, independent groups showed that AM404 inhibits FAAH with IC_{50} values close to those obtained for AEA uptake inhibition (Table 11), thus questioning the selectivity of this compound. In addition, AM404 may also interact with other targets of the ECS. The reversed amide analog AM1172 apparently solved the problem of selectivity by being an equally potent inhibitor of AEA uptake as AM404 but resistant to hydrolysis by FAAH (Fegley et al., 2004). Yet, it was subsequently reported that AM1172 also inhibits FAAH (Hillard et al., 2007).







The quest for better AEA cellular uptake inhibitors continued with the aim to increase their

TABLE 11
Potent inhibitors of AEA cellular uptake relative to inhibition of AEA degradation (by FAAH) or intracellular transport (by FABP5)

Compound	AEA Cellular Uptake Inhibition			FAAH IC ₅₀ value (μ M)	FABP5 K _i value (μ M)
	IC ₅₀ (μ M)	Cell Type	AEA Cellular Uptake Kinetics		
 <p>Thiazolidinone-type second-generation selective endocannabinoid reuptake inhibitors (SERIs) Patent ES2845636T3</p>	0.08-0.50	U937	ND	>10	>10
 <p>WOBE437 Chicca et al., 2017</p>	0.01 0.137 0.055 ~1 [50% inh.]	U937 HMC- α Neuro2A Rat cortical neurons	$K_m = 0.25 \mu$ M, $V_{max} = 67.4$ fmol/min/cell in U937 cells	>10	>50
 <p>RX-055 Chicca et al., 2017</p>	0.014 ~1 [35% inh.]	U937 Neuro2A	ND	4.0	ND
 <p>Guineensine Nicolussi et al., 2014b</p>	1.32 0.29 0.62	U937 U937 HMC-1 α	ND	46.8	>100
 <p>Macamide 7 Hajdu et al., 2014</p>	0.67	U937	ND	4.1	ND
 <p>Farinosone-C derivative (BSL-34) Burch et al., 2013</p>	0.23	U937	ND	>10	ND
 <p>AM404</p>	1.0 5.0 2.2 10.2 10.9 8.1 10.2 4 $K_i \approx 14$ 14.9 20 1.8 4.9 >100 44.4	Rat cortical neurons Rat cortical astrocytes Astrocytoma C6 glioma RBL-2H3 RBL-2H3 RBL-2H3 RBL-2H3 RBL-2H3 RBL-2H3 U937 Cerebellar granular neurons HMC- α HeLa α	$K_m = 1.2 \mu$ M, $V_{max} = 90.9$ pmol/min/mg in neurons $K_m = 0.32 \pm 0.1 \mu$ M, $V_{max} = 171$ pmol/min/mg in astrocytes $K_m = 0.6 \pm 0.1 \mu$ M, $V_{max} = 14.7 \pm 1.5$ pmol/min/mg in astrocytoma $K_m = 0.7 \pm 0.1 \mu$ M, $V_{max} = 0.39$ fmol/min/cell in C9 glioma cells $K_m = 11.4 \pm 2.3 \mu$ M, $V_{max} = 17.5 \pm 2.1 \times 10^{-17}$ mol/min/cell in RBL-2H3 cells $K_m = 0.13 \pm 0.01 \mu$ M, $V_{max} = 140 \pm 15$ pmol/min/mg in U937 cells	5.9 3.6 0.5 0.8 >30 $K_i = 0.60$ 6 2.1	0.39


(continued)

TABLE 11—Continued

AEA Cellular Uptake Inhibition					
Compound	IC ₅₀ (μM)	Cell Type	AEA Cellular Uptake Kinetics	FAAH IC ₅₀ value (μM)	FABP5 K _i value (μM)
 AM1172 Fegley et al., 2004; Dickason-Chesterfield et al., 2006; Kaczocha et al. 2006; Hillard et al., 2007	2.5	Astrocytoma	ND	>5	ND
	2.1	Rat cortical neurons		K _i ≈ 3.2	
	24.0	Cerebellar granular neurons		>100	
	86.6	RBL-2H3		>50	
	68.9	HeLa ^a			
 VDM11 De Petrocellis et al., 2000; Fowler et al., 2004; Vandevoorde and Fowler, 2005; Dickason-Chesterfield et al., 2006; Kaczocha et al., 2006; Hillard et al., 2007; Kaczocha et al., 2012; Nicolussi et al., 2014a	10.2	C6 glioma	ND	2.0	1.75
	6.1	C6 glioma		1.2	
	11.2	RBL-2H3		0.4	
	9.9	RBL-2H3		K _i ≈ 0.44	
	1.1	U937		11.1 ⁷⁴	
	5.5	Cerebellar granular neurons		5 ¹¹¹	
	>100	HMC-1 ^a		1.6 - 2.9	
	23.8	HeLa ^a			
 OMDM-1/2 Ortar et al., 2003; Fowler et al., 2004; Dickason-Chesterfield et al., 2006; Kaczocha et al., 2006; Hillard et al., 2007; Chicca et al., 2012; Kaczocha et al., 2012; Nicolussi et al., 2014a	K _i ≈ 3	RBL-2H3	ND	>50	3.85
	16.6	C6 glioma		54	>100
	3.2	RBL-2H3		23.4	
	9.1	RBL-2H3		>100	
	3.93	U937		K _i ≈ 9.7	
	5.2	U937 ⁶⁴		>100	
	3.2	U937		>50	
	3.1	HMC-1 ^a			
	>100	HeLa ^a			
	4.9	Cerebellar granular neurons			
 UCM707 López-Rodríguez et al., 2003a; Fegley et al., 2004; Fowler et al., 2004; Dickason-Chesterfield et al., 2006; Kaczocha et al., 2006; Hillard et al., 2007; Chicca et al., 2012; Nicolussi et al., 2014a	0.8	U937	K _m = 1.1 μM, V _{max} = 151 pmol/min/mg in WT cortical neurons	30	25.8
	1.34	U937		8.32	
	1.8	U937	K _m = 1.3 μM, V _{max} = 157 pmol/min/mg in FAAH ^{-/-} cortical neurons	>100	
	41	C6 glioma		K _i ≈ 3.7	
	25	RBL-2H3		20.5	
	20.1	RBL-2H3		50	
	3.6	HMC-1 ^a			
	56.4	HeLa ^a			
	30.3	Cerebellar granular neurons			
	4	Cortical neurons			
3	Cortical neurons FAAH ^{-/-}				
 LY2183240 Moore et al., 2005; Alexander and Cravatt, 2006; Dickason-Chesterfield et al., 2006; Ortar et al., 2008; Nicolussi, 2014; Nicolussi et al., 2014a	0.000270	RBL-2H3	K _m = 4.69 ± 0.46 μM, V _{max} = 0.02 fmol/min/cell in RBL-2H3 cells	0.014	ND
	0.015	RBL-2H3		0.0021	
	0.00095	U937		0.0124	
	1.93	HMC-1 ^a		0.001	
	29.7	HeLa ^a			
 WOBE492 Nicolussi et al., 2014	0.000005	U937	ND	0.000014	ND
	0.12	HMC-1			

(continued)

TABLE 11—Continued

Compound	AEA Cellular Uptake Inhibition		AEA Cellular Uptake Kinetics	FAAH	FABP5
	IC ₅₀ (μM)	Cell Type		IC ₅₀ value (μM)	K _i value (μM)
 WOBE498 Nicolussi et al., 2014	0.00005 0.25 ^a	U937 HMC-1	ND	0.000015	ND

ND, not determined.

^aCells lacking FAAH-activity.

potency and generate structure-activity relationship studies for the postulated transporter target (Jarrahian et al., 2000; Di Marzo et al., 2004). Since the inhibition of FAAH also leads to the inhibition of [³H]AEA uptake, the aspect of selectivity over FAAH became a crucial differentiation criterion (Day et al., 2001; Deutsch et al., 2001). Besides the well-studied AEA uptake inhibitor VDM11 (De Petrocellis et al., 2000), more selective inhibitors such as the oleic acid derivatives OMDM-1 and OMDM-2 (Ortar et al., 2003) or UCM707 (López-Rodríguez et al., 2001, 2003a) were synthesized (Table 11). Despite their initially published selectivity over FAAH, some of these inhibitors were later found to inhibit FAAH with similar or even identical IC₅₀ values obtained for AEA uptake inhibition (Fowler et al., 2004; Vandevoorde and Fowler, 2005; Hillard et al., 2007). Unfortunately, almost nothing is known about the pharmacokinetics and tissue distribution of these compounds, and pharmacological effects are difficult to attribute to either FAAH inhibition or AEA transport inhibition. UCM707 was investigated in neuronal preparations of FAAH^{-/-} mice and still showed an IC₅₀ = 3 ± 1 μM for AEA accumulation (Ortega-Gutiérrez et al., 2004). This finding agreed with its selectivity for AEA uptake inhibition over FAAH (López-Rodríguez et al., 2003b). A direct comparison of the data obtained with neuronal cells of FAAH^{+/+} mice demonstrated that AEA cellular uptake is a facilitated process in which a specific “UCM707-binding protein” was proposed to participate with a relative contribution of at least 30% (Ortega-Gutiérrez et al., 2004). FABP5 as an intracellular eCB carrier protein (Kaczocha et al., 2012; Sanson et al., 2014) was therefore a possible candidate. However, the affinity of UCM707 to FABP5 was measured (Table 11) and resulted in a K_i = 25.8 μM (19.5–44.7 μM) (Nicolussi, 2014). This low affinity interaction of UCM707 with FABP5 clearly does not match the determined IC₅₀ value for AEA cellular uptake. Moreover, given that UCM707 still works in FAAH-lacking cells and synergizes with FAAH inhibitors for AEA uptake inhibition and inhibits AEA efflux (Chicca et al., 2012), the possibility that UCM707 targets a membrane transport mechanism is still

valid. Unsurprisingly, the highly potent FAAH inhibitors LY2183240 and URB597 (Table 11) resulted in pronounced AEA cellular uptake inhibition in different cell types (Mor et al., 2004; Moore et al., 2005; Dickason-Chesterfield et al., 2006) and were essentially representative of all FAAH inhibitors. The unexpected and paradoxical inhibition of passive diffusion by small organic molecules, as the primary evidence of the carrier-mediated model, was readily refuted because inhibitors like AM404 did not inhibit AEA cellular uptake at short incubation times (< 40 seconds) and inhibited FAAH (Glaser et al., 2003). Ligresti and colleagues convincingly showed saturable AEA uptake within 90 seconds not only in RBL-2H3 and C6 glioma cell lines but also in mouse brain synaptosomes from FAAH^{-/-} mice (Ligresti et al., 2004). In the study by Glaser and colleagues (Glaser et al., 2003), where simple diffusion of AEA was measured, very high nonphysiologic AEA concentrations (1–100 μM) were used, which may easily mask the transport kinetics seen with concentrations of 50 to 500 nM (as a note, at ≥ 1 μM AEA simple diffusion kinetics can be measured). Yet, such high AEA concentrations are not found in tissues, and much less is needed for receptor activation. Eli Lilly developed the highly potent tetrazole inhibitor called LY2183240 with an astonishing IC₅₀ = 270 ± 29 pM for AEA cellular uptake in RBL-2H3 cells (Moore et al., 2005; Ortar et al., 2008) (Table 11). Using the modified radiolabeled probe [¹²⁵I]-LY2318912, a high-affinity membrane binding site involved in the transport of AEA could be identified, curiously also in FAAH-lacking HeLa cells (K_d = 7.06 ± 1.69 nM, B_{max} = 32.2 ± 2.98 fmol/mg). In human FAAH-transfected HeLa cells, neither the binding affinity (K_d) nor the B_{max} value changed significantly, indicating that one binding site is independent of FAAH (Moore et al., 2005). Having raised hopes for the molecular identification of the postulated AEA transporter, shortly afterward, LY2183240 was shown to be an ultrapotent, irreversible, and nonspecific inhibitor of FAAH, MAGL, and other serine hydrolases (Alexander and Cravatt, 2006).

Additional indirect evidence for the existence of a transporter-mediated (facilitated) AEA uptake

mechanism was provided by the demonstration of AEA uptake in synaptosomes from human, mouse, and rat brain (Battista et al., 2002) and in neuronal preparations of FAAH knockout mice (Fegley et al., 2004; Ligresti et al., 2004; Ortega-Gutiérrez et al., 2004). Known AEA uptake inhibitors like UCM707 still reduced the accumulation of AEA, but the uptake efficacy was much lower in cells lacking FAAH compared with those from wild-type mice (Fegley et al., 2004; Ligresti et al., 2004; Ortega-Gutiérrez et al., 2004). However, FAAH activity alone did not seem to be causative of all AEA uptake phenomena (Ligresti et al., 2004). In agreement with the view that FAAH is not the only player in AEA transport, cells lacking FAAH like HMC-1 cells (Maccarrone et al., 2000; Nicolussi et al., 2014b) show robust AEA uptake kinetics, although with a lower V_{max} than in FAAH-expressing cells. Moreover, an energy-independent and saturable export of [3H]AEA was demonstrated in human endothelial cells (Maccarrone et al., 2002). Obviously, hydrolysis by FAAH has no impact on AEA efflux. Additionally, it was demonstrated that the transport inhibitor VDM11 inhibited the release of de novo-generated AEA in HEK-293 cells (Ligresti et al., 2004). Taken together, these studies pointed toward a bidirectional membrane transport mechanism for AEA shown by independent groups (Hillard et al., 1997; Maccarrone et al., 2002; Ligresti et al., 2004; Chicca et al., 2012). In this context, the release of AEA and 2-AG was assessed in an electrophysiological study measuring striatal long-term depression in acute brain slice preparation, where postsynaptic blockage of eCB membrane transport using VDM11 achieved a disruption of eCB release (Ronesi et al., 2004). In another study, OMDM-2 and AM404 increased activity-dependent AEA and 2-AG levels in the hypothalamus and inhibited the synaptically driven spiking activity in postsynaptic neurons upon enhanced retrograde signaling (Di et al., 2005). In urethane-anesthetized rats, VDM11 inhibited the micturition reflex at least in part through CB₁R (Honda et al., 2016), suggesting a possible therapeutic role of AEA transport inhibitors in disturbances of the storage function of the bladder or disturbances of the emptying function. The only pharmacological study that uses AEA release inhibition as an explanation for the effect was the comparison of OMDM-2 versus the FAAH inhibitor URB597 on social withdrawal in rodents (Seillier and Giuffrida, 2018). Systemic administration of OMDM-2 reduced social interaction, but, in contrast to URB597-induced social deficit, this effect was not reversed by the TRPV1 antagonist capsazepine. Conversely, the CB₁R antagonist AM251, which did not affect URB597-induced social withdrawal, exacerbated OMDM-2 effect (Seillier and Giuffrida, 2018). The infusion of OMDM-2 and VMD11 in both cases reduced the extracellular levels of dopamine collected from nucleus accumbens and

suggested a role for AEA transport in sleep modulation (Murillo-Rodriguez et al., 2013). Interestingly, AM404 but not VDM11 reduced the acute freezing response in male mice in a strong auditory-cued fear memory via CB₁R- and TRPV1-mediated mechanisms (Llorente-Berzal et al., 2015). Finally, in nonhuman primates, AM404 reinforced anandamide or cocaine self-administration behavior and induced reinstatement of drug-seeking behavior in abstinent monkeys by a CB₁R-dependent mechanism (Schindler et al., 2016a).

C. Preclinical Development of Selective Endocannabinoid Reuptake Inhibitors

The *N*-isobutylamide guineensine from *Piper* species (Table 11) was identified as a nanomolar and strongly selective inhibitor of AEA cellular uptake over FAAH inhibition and other ECS targets (Nicolussi et al., 2014b). Guineensine did not show a relevant inhibition of FAAH activity ($IC_{50} > 50 \mu M$) or FABP5 binding ($K_i > 100 \mu M$) and dose-dependently induced cannabimimetic effects in BALB/c mice shown by strong catalepsy, hypothermia, reduced locomotion, and analgesia in the hot plate test. The catalepsy and analgesia were blocked by the CB₁R antagonist rimonabant (SR141716A) (Reynoso-Moreno et al., 2017). The pharmacological evidence of indirect cannabimimetic effects strongly suggests that guineensine also targets eCB cellular reuptake in vivo (Reynoso-Moreno et al., 2017). An efficient total synthesis of guineensine was published that may facilitate the provision of this rare natural product for research (Bartholomäus et al., 2019). Another compound in the list of plant-derived natural AEA uptake inhibitors is the *N*-benzyl-(9*Z*,12*Z*)-octadecadieneamide (macamide 7, shown in Table 11), which exhibited a nanomolar IC_{50} value for AEA uptake inhibition but also inhibits FAAH at low micromolar concentrations (Hajdu et al., 2014). Furthermore, an analog of the natural product farinosone-C (BSL-34, Table 11) was found to be a more selective inhibitor of AEA uptake ($IC_{50} = 232 \text{ nM}$) over FAAH inhibition ($IC_{50} > 10 \mu M$), with close structural similarity to OMDM-2 (Burch et al., 2013).

Building on previous work on *N*-alkyl-2,4-dodecadienamides from *Echinacea purpurea*, which have been shown to interact with the ECS (Raduner et al., 2007; Chicca et al., 2009), a series of derivatives and analogs were synthesized. Diverse *N*-alkylcarbamates were also synthesized and tested in U937 cells for their ability to inhibit AEA hydrolysis and uptake, showing ultrapotent FAAH inhibition that led to hyperpotent AEA uptake inhibition (Nicolussi et al., 2014a). Interestingly, some of these *N*-alkylcarbamates (e.g., WOB492 and WOB498) showed a FAAH-independent AEA uptake inhibition in HMC-1 cells with IC_{50} values below 300 nM (Nicolussi et al., 2014a). This study led to the identification of (2*E*,4*E*)-*N*-[2-(3,4-dimethoxyphenyl)

ethyl] dodeca-2,4-dienamide (WOBE437, shown in Table 11) as a highly potent and selective eCB uptake inhibitor, which was extensively profiled (Chicca et al., 2017). For instance, WOBE437 inhibits AEA and 2-AG uptake in U937 cells with IC_{50} values of 10 ± 8 nM and 283 ± 121 nM, respectively (Chicca et al., 2017). Furthermore, WOBE437 was tested in Neuro2a mouse neuroblastoma cells, primary rat cortical neurons, and FAAH-deficient HMC-1 cells, showing differential but significant inhibition of AEA uptake in all the cell lines. WOBE437 did not inhibit FAAH, MAGL, α/β -hydrolase domain proteins 6 and 12, or COX-2, nor did it show a significant interaction with CB₁R/CB₂R, FABP5, or any of 45 relevant CNS-related receptors/transporters/ion channels/enzymes tested (Chicca et al., 2017). Moreover, in C57BL/6/J male mice WOBE437 was found to be orally bioavailable (Reynoso-Moreno et al., 2018), and in a clinically relevant mouse model of MS-like experimental autoimmune encephalomyelitis, it significantly reduced disease severity and accelerated recovery through CB₁R/CB₂R-dependent mechanisms (Reynoso-Moreno et al., 2021). A structure-activity relationship study on the WOBE437 scaffold for cellular AEA uptake inhibition was recently published (Mäder et al., 2021). However, using a clickable analog of the WOBE437-derived photoaffinity probe RX-055 (Table 11), saccharopine dehydrogenase-like oxidoreductase, vesicle amine transport 1, and ferrochelatase were identified as low affinity (10 μ M) off-targets of WOBE437 in Neuro-2a cells (Gagestein et al., 2022), calling for attention on the therapeutic exploitation of this inhibitor at higher doses.

Currently, a new class of SERIs, the thiazolidinones (Table 11), are being developed for the treatment of psychiatric or neurologic disorders and inflammation at Synendos Therapeutics, though their target protein has not yet been published.

D. Preclinical Development of Fatty Acid Binding Protein Inhibitors



In liver, it has been shown that FABP1 not only acts as an eCB and pCB binding protein but also regulates hepatic eCB levels (Huang et al., 2018). Studies using FABP1 knockout mice revealed a markedly diminished impact of a high-fat diet on brain eCB levels, especially in male mice, suggesting the involvement of FABP1 in the biosynthesis of these lipids (Martin et al., 2017). FABPs seem to be generally involved in modulating AEA trafficking as the overexpression of FABP5 and FABP7 in COS-7-FAAH-eGFP cells increased AEA uptake and hydrolysis by 32% and 35%, respectively (Kaczocha et al., 2009). N18TG2 cells showed an increase of 36% upon FABP5 and 42% upon FABP7 overexpression. In the same cells, a reduction of AEA uptake and hydrolysis could be monitored after

preincubation with the FABP4/5 inhibitor BMS309403 (Table 12). While BMS309403 exhibited a $K_i = 350 \pm 3$ nM for FABP5 binding, a concentration of 100 μ M of this probe was needed to reach ~50% inhibition of cellular AEA uptake (Sulsky et al., 2007; Furuhashi and Hotamisligil, 2008; Kaczocha et al., 2009). FABP5 was suggested as the main target of the AEA uptake inhibitors OMDM-2, VDM11, and AM404, because these blockers showed binding affinities to FABP5 comparable to the published K_i values for AEA-FABP5 binding (Kaczocha et al., 2012; Nicolussi et al., 2014a).

Surprisingly, AA also showed a strong affinity to FABP5 (Kaczocha et al., 2012). It is generally accepted that AA does not affect AEA cellular uptake up to a concentration of 100 μ M (Beltramo et al., 1997; Hillard et al., 1997; Piomelli et al., 1999), a finding that would challenge the role of FABP5 in AEA transport. The development of potent and specific FABP5 inhibitors with the aim to modulate AEA cellular transport is ongoing (Berger et al., 2012; Zhou et al., 2019a), and a first in vivo evaluation of SBFI-26 (one of these compounds shown in Table 12) was reported (Kaczocha et al., 2014). SBFI-26 is an α -truxillic acid 1-naphthyl monoester, originally identified using a computational docking protocol and synthesized as a mixture of both the (*S*) and (*R*) enantiomers (Berger et al., 2012). SBFI-26 produced antinociceptive and anti-inflammatory effects in mice and inhibited the activities of FABP5 and FABP7 with K_i values of 0.9 μ M and 0.4 μ M, respectively (Berger et al., 2012; Kaczocha et al., 2014). In FABP5, SBFI-26 was unexpectedly found to bind at the substrate entry portal region in addition to binding at the canonical ligand-binding pocket (Hsu et al., 2017). However, it is noted that the high concentrations needed in vitro for AEA cellular uptake inhibition experiments do not match the reported FABP5 affinity of SBFI-26. In rodents, SBFI-16 showed peripheral and supraspinal analgesic effects (Peng et al., 2017) and abrogated pulmonary artery remodeling in pulmonary hypertension secondary to left heart disease and improved cardiac function (Lei et al., 2022). Yet, the involvement of the ECS in these effects was not elucidated. As already pointed out above, the K_i values obtained for AEA binding to FABP5 are not in agreement with the K_m values in many cells that show AEA transport. Recently, it was demonstrated that FABP5 both promotes the hydrolysis of AEA to AA and thus reduces brain eCB levels and directly shuttles AA to the nucleus, where it delivers it to PPAR β/δ , enabling its activation (Yu et al., 2014). Interestingly, in adult neurons, neither FABP5 nor FABP7 seems to be expressed in significant amounts (Liedhegner et al., 2014).

The first evidence for intracellular carriers of 2-AG was provided by two independent groups. The known

TABLE 12
Additional and less potent inhibitors of AEA cellular uptake relative to inhibition of AEA degradation (by FAAH)
or intracellular transport (by FABP5)

Compound	AEA Cellular Uptake Inhibition			
	IC ₅₀ (μM)	Cell Type	FAAH IC ₅₀ Value (μM)	FABP5 K _i Value (μM)
 BMS309403 Sulsky et al., 2007; Kaczocha et al., 2009; Berger et al., 2012; Kaczocha et al., 2012; Nicolussi et al., 2014a	~100 [57% inh.]	N18TG2	>100	0.35
	>100 [48% inh.]	COS7-FAAH-eGFP U937 HMC-1*	>100	0.75 0.89
 SBFI-26 (RT26) Berger et al., 2012; Zhou et al., 2019a	24.7 >100 [30% inh.]			
	~20 [40% inh.]	HeLa ^a	>50	0.9

^aCells lacking FAAH-activity.

cytosolic FABP5, which is an AEA carrier and binds numerous highly abundant fatty acids, was also shown to bind 2-AG. Using fluorescence polarization and a labeled fatty acid probe that was displaced from FABP5, a K_i = 8.7 μM was determined (Nicolussi, et al., 2014a). Simultaneously, a crystallographic study of FABP5 as an intracellular carrier protein of eCBs confirmed the binding data (Sanson et al., 2014). Of note, the K_d for 2-AG binding to FABP5 more closely matches the K_m for 2-AG transport than in the case of AEA.

It was recently reported that FABP5 could act as a synaptic (i.e., extracellular) transporter of 2-AG and control the retrograde signaling by this eCB (Haj-Dahmane et al., 2018). Using dorsal raphe neurons incubated with SBFI-26 (a FABP5 and FABP7 inhibitor) or from FABP5^{-/-} mice, it was shown that FABP5 inhibition or absence prevented DSE, which under normal conditions occurs after depolarization of postsynaptic neurons and phasic 2-AG release, followed by presynaptic CB₁R activation, reduction of glutamate release, and a reduction in excitatory postsynaptic currents. Furthermore, FABP5 inhibition or absence prevented the increase seen in excitatory postsynaptic currents after incubation with AM251 (a CB₁R antagonist/inverse agonist), showing that by acting as a carrier FABP5 modulates the effect of phasic and tonic levels of 2-AG in the control of retrograde signaling. Additionally, in a coculture of primary hippocampal astrocytes and neurons, it was shown that FABP5 is

secreted by astrocytes to the extracellular media in a time-dependent manner, supporting its role as an extracellular synaptic transporter of 2-AG. In FABP5^{-/-} neurons, no changes were observed in the protein expression of CB₁R, DAGLα (the neuronal isoform) or MAGL, concluding that there are no changes in either CB₁R activation or 2-AG metabolism. Although nonsignificant changes in 2-AG levels were observed after incubation with SBFI-26, the opposite occurred in FABP5^{-/-} neurons, which showed a significant increase. Furthermore, dorsal raphe neurons incubated with SBFI-26 showed an increase in AEA levels, which agrees with previous reports (Kaczocha et al., 2009; 2014); however, there were no changes in AEA levels measured in FABP5^{-/-} neurons compared with wild-types. These contradictions raise a question regarding other possible changes in the metabolic pathways of 2-AG and AEA, respectively, that might not be observed at the protein level. As shown recently, deletion of FABP5 impaired tonic 2-AG and AEA signaling at striatal γ-aminobutyric acid synapses of medium spiny neurons and blunted phasic 2-AG mediated short-term synaptic plasticity without altering CB₁R expression or function (Fauzan et al., 2022). Based on the expression of FABP5 in TRPV1-positive nociceptors, a conditional knockout strategy was employed that showed that deletion of FABP5 specifically in nociceptors augments AEA levels, resulting in antinociceptive effects mediated by CB₁R (Bogdan et al., 2022). Given that the concentration of free fatty acids including

AA may be much higher in the synaptic cleft and in neuronal membranes, it is intriguing that FABP5 binds 2-AG in a physiologic environment, which is found at significantly lower concentrations and competes for the same binding site as AA in this protein, especially because there are not multiple lipid binding sites in FABP5. Overall, it cannot be ruled out that the effects observed with FABP KO mice may also be related to AA metabolism.

E. Translational Implications of Endocannabinoid Transport Inhibitors

The different models of eCB cellular uptake and trafficking offer different druggable sites, that are schematically depicted in Fig. 26. The identification of intracellular carrier proteins for AEA has clearly provided a missing link to explain how eCBs are able to cross the cytosol, which constitutes a hydrophilic barrier for these lipophilic compounds (Hillard and Jarrhian, 2003; Fegley et al., 2004; Glaser et al., 2005; Hillard et al., 2007; Kaczocha et al., 2009; Oddi et al., 2009; Fowler, 2012, 2013).

To date, different AEA transport inhibitors and detailed pharmacological assessment of their *in vivo* effects have led to a better understanding of the druggability of such processes within the ECS. However, only a few inhibitors used in pharmacological experiments have been studied for their bioavailability, tissue distribution, and overall pharmacokinetics; thus *in vivo* effects of such inhibitors are difficult to interpret. As yet, only FABP5 inhibitors AT26 and SYT510 have shown efficacy in models of pain, anxiety, and inflammation through mechanisms involving the ECS and are drug candidates in a late preclinical stage (Table 13).

The new generation of selective inhibitors for AEA uptake (WOBE437, RX-055, guineensine) also blocks 2-AG uptake but does not interact with any of the known metabolic enzymes or AEA binding proteins, suggesting an additional common target that is competitive with eCB membrane transport. This observation has inspired the development of thiazolidinones like SYT510 that act as SERIs for the treatment of neuropsychiatric disorders—in a manner that is comparable to MAGL inhibitors—and are in early clinical development (Table 13). Based on the pharmacological profiles of these SERIs, it can be expected that they are more specific and do not interfere with metabolic classes. Moreover, unlike FAAH, MAGL, and FABP5 inhibitors, SERIs rather

selectively inhibit the uptake of both AEA and 2-AG, without modulating other lipids (Chicca et al., 2017). Remarkably, their mild modulation of the eCB tone may be beneficial when it comes to issues related to the desensitization of CB₁R (Reynoso-Moreno et al., 2021).

VI. Therapeutic Potential of Additional Targets Within the “Endocannabinoidome”

A. Definition of the Endocannabinoidome

Two realizations during the past 20 years have brought to the attention of the scientific community that the ECS should be considered as part of a much wider signaling system, now referred to as the endocannabinoidome (eCBome) (Balvers et al., 2009; Piscitelli et al., 2011; Di Marzo, 2018; Cristino et al., 2020): (1) the discovery that several endogenous congeners of AEA and 2-AG, *i.e.*, the *N*-acyl-ethanolamines and 2-monoacylglycerols, respectively, and other eCB analogs like long chain fatty acid derivatives are present in tissues and biologic fluids, although they seldom share with eCBs the capability of modulating the activity of CB₁R and CB₂R (while often being biosynthesized and/or degraded by the same enzymes) (Di Marzo, 2018), and (2) the finding that most plant cannabinoids other than THC, such as cannabidiol, cannabigerol, cannabidivarine, and cannabichromene, to name a few, also do not share with THC, AEA, and 2-AG their activity at cannabinoid receptors, although they often interact, among others, with several receptors of the aforementioned eCB-like molecules (Di Marzo, 2018). The main components of the eCBome are summarized in Table 14.

In particular, beyond *N*-acyl-ethanolamines and 2-monoacylglycerols, whose existence was known even before the discovery of AEA and 2-AG, several other subfamilies of eCB-like molecules have been recently discovered, including (1) primary amides of long chain fatty acid, of which the sleep-inducing factor oleamide is the prototypical member; (2) amides between long chain fatty acids and several amino acids, such as *N*-acyl-taurines, -glycines, and -serines (Huang et al., 2001; Milman et al., 2006; Saghatelian et al., 2006); (3) amides of long chain fatty acids with neurotransmitters and other amines, such as *N*-acyl-dopamines and -serotonines (Huang et al., 2002; Verhoeckx et al., 2011), and (4) oxidation products (usually, but not necessarily, produced by the action of “arachidonate

TABLE 13
Drug candidates that target eCB transport in late preclinical stage

Name	Company	Indication(s)	Target
RT26	Artelo Biosciences	Prostate cancer Chemotherapy-Induced Peripheral Neuropathy	FABP5 inhibitor
SYT510	Synendos Therapeutics	Neuropsychiatric Disorders	SERI, undisclosed target

SERI, selective eCB reuptake inhibitor.

cascade” enzymes COX-2 and LOXs) of the di- and polyunsaturated members of the aforementioned families (namely *N*-acyl-ethanolamines and 2-monoacylglycerols), a subfamily of lipids that we can refer to as the “oxyendocannabinoidome” (oxyeCBome) (reviewed in Simard et al., 2022). Therefore, considering that several long chain fatty acids exist, from the C16-containing and completely saturated palmitic acid, to the C22-containing hexa-unsaturated docosahexaenoic acid, it can be reckoned that, in principle, hundreds of such eCBome mediators exist. However, the actual occurrence of only a few dozens of them has been ascertained so far, through the use of bidimensional liquid chromatography mass spectrometry approaches (Piscitelli et al., 2011; Leishman et al., 2016; Kantae et al., 2017; Lacroix et al., 2019).

Importantly, each different member of these subfamilies, depending on its fatty acid and amine moieties, can modulate the activity of one or more different receptors that in a few cases, have been suggested to be also targeted by AEA or 2-AG (Table 14), although often at concentrations higher than those required to activate CB₁R and CB₂R (Di Marzo, 2018; Gómez-Cañas et al., 2023). In fact, at least three classes of receptors have been suggested to act as targets for eCBome mediators (Morales and Reggio, 2017; Muller et al., 2019; Lago-Fernandez et al., 2021): (1) GPCRs, like CB₁R and CB₂R and beyond, and including some orphan GPCRs like GPR18, GPR55, GPR110, GPR119, and GPR130 or GPCRs that are known to be activated or inhibited by other mediators, such as some serotonin receptors; (2) ligand-activated ion channels, such as (i) TRP channels of the V1-4, A1, and M8 types and T-type Ca²⁺ (Ca_{v3}) channels, which have been suggested to be modulated also by other lipid mediators, and (ii) amino acid neurotransmitter-activated targets, such as γ -aminobutyric acid or glycine receptors; and (3) nuclear PPARs. However, for some eCBome mediators, such as the primary amides, the molecular targets are still unknown, although for oleamide evidence of it being a weak agonist of CB₁R (Leggett et al., 2004) and a TRPV2 antagonist (Schiano Moriello et al., 2018) exist. Additionally, some eCB-like molecules have also been shown to produce some of their pharmacological actions by interacting with eCB metabolic enzymes. While stimulation of DAGLs by *N*-palmitoylethanolamine, which possibly explains why this mediator can enhance 2-AG levels in vitro and in vivo, has been only recently shown (Petrosino et al., 2019), inhibition of FAAH leading to increased levels of AEA and other endogenous substrates for these enzymes (e.g., *N*-acyl-taurines and, under certain circumstances, 2-AG) has been suggested as the basis of some of the pharmacological effects of other NAEs and unsaturated *N*-acyl-serotonins, -glycines, and -alanines (Jonsson et al., 2001; Petrosino and Di Marzo, 2017; Bashashati et al., 2017; Ayoub et al., 2020). Interestingly, the capability of inhibiting FAAH is shared

also by the noneuphoric cannabinoid CBD (Watanabe et al., 1996; Bisogno et al., 2001).

As mentioned, several non-THC cannabinoids, as well as AEA and 2-AG, have also been suggested to influence the activity of the aforementioned eCBome receptors, including (1) orphan GPCRs, particularly for CBD, which antagonizes GPR55 and seems to modulate some opioid and serotonin receptor subtypes (reviewed by de Almeida and Devi, 2020); (2) TRPV1-4 or TRPA1 channels, which are activated by several noneuphoric cannabinoids—with TRPV1 now being widely considered also as an alternative physiopathological target for AEA, unsaturated NAEs, and 2-AG—and TRPM8, which is antagonized by all tested cannabinoids (with the only exception of cannabichromene) as well as by both AEA and 2-AG (Zygmunt et al., 1999; De Petrocellis et al., 2007; De Petrocellis et al., 2011; De Petrocellis et al., 2012; Muller et al., 2019); 3) Ca_{v3.3} channels and glycine receptors, which can be variedly inhibited by THC, cannabidiol, and several types of eCBome mediators, as well as by AEA and some *N*-acylethanolamines, whereas some subunits of the γ -aminobutyric acid receptor are instead activated by 2-AG and CBD (Sigel et al., 2011; Baur et al., 2013; Chemin et al., 2014; Bakas et al., 2017; Mirlohi et al., 2022); and (4) PPARs, which can be activated by CBD and cannabigerol, particularly in their acidic forms normally found in cannabis flowers, as well as, particularly in the case of PPAR α , by some *N*-acylethanolamines, 2-palmitoyl-glycerol, and *N*-acyl-glycines (O’Sullivan, 2016; Donvito et al., 2019; D’Aniello et al., 2019; Tutunchi et al., 2020; Depommier et al., 2021; Lago-Fernandez et al., 2021). These eCBome receptors are schematically depicted in Fig. 27.

In summary, the eCBome and the oxyeCBome potentially include perhaps hundreds of mediators (several combinations of amides between long chain fatty acids and amino acids or bioactive amines and the plethora of oxidation products that can be generated from polyunsaturated eCBome mediators, to name a few) and dozens of receptors. Of the latter, however, many had been previously described as molecular targets for other mediators (neurotransmitters, fatty acids, etc.) and cannot be listed as “specific” eCBome receptors, at least not until their preferential role is ascertained as intermediates of the biologic effects of eCBome mediators, which, however, are often very promiscuous in their modulation of the activity of pharmacologically relevant proteins. While it is of crucial importance to know that AEA and 2-AG are accompanied in tissues by several congeners and metabolites with similar biochemistry and different pharmacology, a discussion of the pharmacological and therapeutic importance of these non-CB₁R, non-CB₂R receptors is too speculative and goes beyond the scope of this article.

Indeed, the existence of the eCBomes both opens new opportunities and raises new challenges for the

TABLE 14
Lipid signals from the eCBomes, their targets and metabolic enzymes

eCBome	Family	Most Studied Subfamily (If Applicable)	Most Studied And/Organism Abundant Members	Best Established Molecular Target(s)	Best Established Anabolic Enzyme(s)	Best Established Catabolic Enzyme(s)	Main Potential Therapeutic Applications (Based On The Best Established Pharmacological Actions)	References
NAEs (AEA and its congeners)			N-Arachidonoyl-ethanolamine (anandamide)	CB ₁ R (1), CB ₂ R (1), TRPV1 (1), TRPV2 (4), TRPM8 (1), Cav3.3 (4)	NAPE-PLD, ABHD4+GDE1	FAAH-1	Chronic and inflammatory pain; anxiety; depression; (neuro)inflammatory disorders; cancer. <i>Obesity, NASH and type 2 diabetes</i>	Mechoulam, 2023
			N-Docosahexaenoyl-ethanolamine	GPR110 (1), CB ₂ R (1)		FAAH-1	Inflammation; neurodegenerative disorders; cancer.	Watson et al., 2019
			N-Oleoyl-ethanolamine	PPAR α (1), TRPV1 (1), GPR119 (1)		FAAH-1, FAAH-2	Obesity; type 2 diabetes, steatosis and related disorders	Bowen et al., 2017
MAGs (2-AG and its congeners)			N-Palmitoyl-ethanolamine	PPAR α (1), GPR55 (1)		NAAA, FAAH-1	Chronic and inflammatory pain; eczema, neuroinflammatory disorders; migraine; COVID-19	Petrosino and Di Marzo, 2017
			2-Arachidonoyl-glycerol	CB ₁ R (1), CB ₂ R (1), TRPV1 (1), TRPM8 (1)	DAGL α , DAGL β	MAGL, ABHD6, ABHD12	Chronic and inflammatory pain; anxiety; depression; (neuro)inflammatory disorders, obesity and type 2 diabetes	Baggelaar et al., 2018
			2-Oleoyl- and 2-Linoleoyl-glycerol 1- or 2-Palmitoyl-glycerol	GPR119 (1), TRPV1 (1), PPAR α (1)			Type 2 diabetes	Hansen and Vana, 2019
Primary amides			Oleamide	TRPV3 (1), CB ₁ R (?)(1)	GLYATL3 + PAM	FAAH-1	Obesity; type 2 diabetes, steatosis and related disorders	Depommier et al., 2021
			N-Oleoyl-glycine	PPAR α (1), FAAH-1 (1), Cav3.3 (1), N-Arachidonoyl-glycine	GLYATL3	PAM, FAAH-1	Sleep disorders	Leggett et al., 2004; Schiano Moriello et al., 2018
			N-Oleoyl-alanine	PPAR α (1), FAAH-1 (1), Cav3.3 (1), TRPV1 (1), Arachidonoyl-taurine			Brain trauma and its consequences, neuroprotection, nicotine and opiate addiction, pain	Huang et al., 2001; Foster et al., 2019; Donvito et al., 2019; Piscitelli et al., 2020
N-Acyl-amino acids (lipo-aminoacids)			N-Acyl-serine	TRPV1 (1), CB ₁ R (1), FAAH (1), Cav3.3 (1)			Nicotine and opiate addiction	Ayoub et al., 2020
			N-Acyl-taurines	TRPV1 (1), CB ₁ R (1), FAAH (1), Cav3.3 (1)			Osteoporosis	Milman et al., 2006
			N-Acyl-dopamines	TRPV1 (1), CB ₁ R (1), FAAH (1), Cav3.3 (1)			Skin wound healing, type 2 diabetes and dyslipidemia	Grevengeot et al., 2019; Sasso et al., 2016.
N-Acyl-neurotransmitters			N-Arachidonoyl-serotonin	TRPV1 (1), FAAH (1), Cav3.3 (1)		COMT, Cyp epoxygenases	Pain, cancer, nausea, neuroinflammatory and neurodegenerative disorders	De Petrocellis and Di Marzo, 2014
							Chronic and inflammatory pain, anxiety, depression, (neuro)inflammatory	

(continued)

TABLE 14—Continued

Family	Most Studied Subfamily (if Applicable)	Most Studied And/Or Most Tissue Abundant Members	Best Established Molecular Target(s)	Best Established Anabolic Enzyme(s)	Best Established Catabolic Enzyme(s)	Main Potential Therapeutic Applications (Based On The Best Established Pharmacological Actions)	References
OxyeCBome	COX-2 derivatives	Prostamide F _{2z}	FP/Alt4-FP heteromer (†)	COX-2 + PGFS	?	disorders, epilepsy, IBS	Woodward et al., 2013
	Prostaglandin-glycerol esters	Prostaglandin E ₂ -glycerol ester	P2Y6(†)	COX-2 + PGES	MAGL	Hypocampal excitotoxicity?	Brüser et al., 2017
	15-LOX derivatives	13-hydroxy-octadecanoylethanolamide	TRPV1(†)	15-LOX	?	?	Simard et al., 2022
	Anandamide derivatives	15-hydroxy-eicosatetraenoyl-ethanolamide	CB ₁ R(†), CB ₂ R (†), TRPV1(†)				
	Cyp epoxyeicosatrienoyl-ethanolamides	5,6-Epoxy-eicosatrienoyl-ethanolamide	CB ₂ R(†), TRPV4(?)(†)	Cyp epoxyexygenase	?	Cardiovascular disorders, hypertension, inflammation	Snider et al., 2009
	Epoxyeicosatrienoyl-neurotransmitters	Epoxyeicosatrienoyl-dopamine and -serotonin	CB ₁ R(†), CB ₂ R(†), TRPV1(†)		?	Neuroinflammation	Arnold et al., 2021
µbeCBome	Microbiota-derived N-Acyl-amides	Glycine and alanine derivatives	Commendamide, N-Myristoyl-alanine	Bacterial N-acyl-transferase (<i>choA/glsB</i>)	?	Cancer, intestinal inflammation	Cohen et al., 2017
		Diacylated glycine lipids	?	Bacterial N-acyl-transferase (<i>choA/glsB</i>) + and O-acyl-transferases (<i>choB/glsA</i>)	?	Intestinal fitness, eubiosis	Lynch et al., 2019
	Serinol derivatives	N-Oleoyl-serinol	GPR119(†)	Bacterial N-acyl-transferases	?	Type 2 diabetes	Cohen et al., 2017
	N-Acyl-tyramines, N-Acyl-tryptamines, N-Acyl-aminoacids	N-Lauroyl-tryptamine	GPR183(†)	Bacterial N-acyl-transferases	?	Immune disorders	Chang et al., 2021

The main potential therapeutic applications of the manipulation of their levels and activity is also shown. Upward and downward arrows denote agonism/activation or antagonism/inhibition. Endocannabinoid-like mediators derived from gut microbiota are also included. Notably, several receptors other than CB₁R and CB₂R have been found to be also modulated by non-euphoric plant cannabinoids such as cannabidiol, i.e., GPR55, GPR118, GPR132, TRPV1, TRPV2, TRPM8, PPARs, and Cav3.3. Potential therapeutic applications obtained from counteracting the action or the formation of the mediators are shown in italics. ABHD, *α/β*-hydrolase domain; Alt4-FP, splicing variant 4 of the FP receptor; Cav3.3, T-type Ca²⁺ channels; COMT, catechol-O-methyl transferase; Covid-19, coronavirus disease type 19; COX-2, cyclooxygenase-2; Cyp, cytochrome p450; DAGL, diacylglycerol lipase; eCBome, endocannabinoidome; FAAH, fatty acid amide hydrolase; FP, prostaglandin F receptor; GDE1, glycerodiesterase type 1; GLYATL3, glycine-N-Acyltransferase Like 3; GPR, orphan G-protein couple receptor; IBS, irritable bowel syndrome; MAGL, monoacylglycerol lipase; *µbeCBome*, microendocannabinoidome; NAPE-PLD, N-acyl-phosphatidylethanolamines-specific phospholipase D-like enzyme; *oxyeCBome*, oxendocannabinoidome; PAM, peptidyl-glycine alpha-amidating monooxygenase; PGES, prostaglandin E synthase; PGFS, prostaglandin F synthase; PPAR, peroxisome proliferator-activated receptor; TRPM8, transient receptor potential melastatin type-8; TRPV1, transient receptor potential vanilloid type-1; TRPV2, transient receptor potential vanilloid type-2.

development of new therapeutics from the study of the ECS. On the one hand, the recognition that some plant cannabinoids, which are devoid of the typical psychotropic and unwanted effects of THC, owe some of their pharmacological effects—and hence potential therapeutic actions—to modulation of the activity of eCBome receptors beyond CB₁R and CB₂R, widens their potential applications in medicine (Fig. 27). This same realization is also at the basis of the use of some eCBome mediators, such as *N*-palmitoylethanolamine and *N*-oleoylethanolamine, as either synthetic drugs, nutraceuticals, and tissue-targeted nanoparticles (Bowen et al., 2017; Petrosino and Di Marzo, 2017; Wu et al., 2021) or through diets rich in their fatty acid precursors (Sihag and Di Marzo, 2022) as potential new therapeutic approaches in inflammatory and metabolic disorders. On the other hand, the fact that several eCBome mediators that have noncannabinoid receptors as their main targets and share with AEA or 2-AG the capability of being inactivated by FAAH (as in the case of *N*-acyl-ethanolamines, -glycines and -taurines) or MAGL (as in the case of 2-monoacylglycerols), respectively, may limit the clinical applicability of FAAH and MAGL inhibitors. In fact, such drugs might concomitantly elevate the tissue levels not only of AEA or 2-AG, thus indirectly activating CB₁ and CB₂ receptors, but also of other eCBome mediators with targets whose functions in disease might also be opposite to those exerted by cannabinoid receptors in disease. A typical example of this potential problem might be represented by the failure, to date, of FAAH inhibitors to counteract inflammatory and chronic pain in clinical trials, when the fact that such molecules elevate the levels not only of AEA but also of *N*-palmitoylethanolamine and *N*-oleoylethanolamine, which may consequently act at targets such as TRPV1 and GPR55, may explain the lack of efficacy. Likewise, inhibitors of DAGLs, which have been proposed as a potential treatment of obesity and metabolic disorders through the impairment of 2-AG biosynthesis and subsequent CB₁R activation (Bisogno et al., 2013; Janssen and van der Stelt, 2016), might reduce the levels of 2-monoacylglycerols acting at CB₂R, GPR119, and TRPV1, which, unlike CB₁R, may have beneficial effects in such pathologic conditions (Di Marzo and Silvestri, 2019). In yet other pathologic conditions, however, where both cannabinoid and other eCBome receptors play similar functions (e.g., inflammation, neurodegeneration, and mood control), such an intrinsic lack of functional selectivity of inhibitors of eCB metabolism may provide additional advantages. It is, therefore, clear that the use of such inhibitors requires (1) first the understanding of what eCBome receptors are involved in a given disorder and (2) in case of conflicting effects being predicted for the blockade of a given enzyme, the development of multitarget drugs, capable also of modifying the activity of targets that exert opposing

roles in a given disorder (see, for review, Maione et al., 2013). The eCBome mediators and their synthetic analogs that are under clinical testing are listed in Table 15.

B. Interaction with the Gut Microbiome

An additional possibility that is attracting attention is to explore targeted nutritional strategies for the therapeutic manipulation of the eCBome, based on the concept that the content of different eCBome mediators is strongly affected by the presence of their fatty acid precursors in the diet (Castonguay-Paradis et al., 2020). Indeed, an important opportunity opened by the discovery of the eCBome lies in its capability of interacting, much more than the ECS does, with another fundamental player in mammalian physiology and pathology that, like the eCBome, is also strongly influenced by diet, medications, and other environmental and lifestyle as well as genetic factors: the gut microbiome (Di Marzo and Silvestri, 2019). Trillions of microorganisms, belonging to thousands of species from several phyla (bacteria, archaea, viruses, yeasts, eukaryote parasites), populate the mammalian gut and communicate with, and subsequently regulate, the activity of host cells, mostly through the production of a plethora of chemical signals that are capable of interacting with host targets. In particular, some small molecules typically produced by gut bacteria following the digestion (fermentation) of dietary macro- and micro-nutrients, have been well characterized and include, among others, (1) short chain fatty acids (derived from the processing of dietary complex carbohydrates), (2) branched chain fatty acids and amino acids (usually derived from the processing of dietary proteins), (3) tryptophan derivatives, and (4) secondary bile acids (Gold and Zhu J, 2022). These molecules usually act at receptors located in host cells (e.g., GPCRs and PPARs, in the case of branched chain fatty acids, and the aryl hydrocarbon receptor, in the case of some tryptophan derivatives), as recently reviewed (Ikeda et al., 2022; Wang et al., 2022). However, only recently it has become evident that some gut bacteria and yeasts can produce eCB-like molecules, such as *N*-acylated glycines, dopamines, tyramines, phenylethylamines, and tryptamines, as well as oxyeCBome mediators capable of binding to the same receptors as the host eCBome mediators (De Petrocellis et al., 2009; Cohen et al., 2017; Chang et al., 2021). This emerging “microbendocannabinoidome,” also summarized in Table 14, enlarges the span of microbe-host communication and expands it to the eCBome, as depicted in Fig. 28. It also adds to previous evidence suggesting that, reciprocally, the ECS modulates the gut microbiome.

This evidence came from experiments carried out in animal models of obesity, gut dysbiosis (i.e., perturbation of gut microbiota composition and function), and ensuing metabolic endotoxaemia using CB₁R antagonists and TRPV1 agonists (namely capsaicin) (Cluny




Fig. 27. The eCBome receptors as a pharmacological substrate for plant-derived cannabinoids and host or commensal bacteria-derived eCBs and eCB-like molecules. The elements of the ECS as part of the eCBome are shown squared in red. The chemical structures of commendamide, *N*-miristoyl-alanine, and *N*-oleoyl-serinol are shown from the top right and down. CBD, cannabidiol; THC, Δ^9 -tetrahydrocannabinol; THCV, Δ^9 -tetrahydrocannabivarin.

et al., 2015; Shen et al., 2017; Mehrpouya-Bahrami et al., 2017), as well as in mice where eCB metabolic enzymes were knocked out (Geurts et al., 2015; Dione et al., 2020). These interventions, together with the expected alterations of eCB and eCBome signaling, were found to lead to concomitant and interrelated modulation

of metabolic and inflammatory parameters and gut microbiota composition, with increases of the relative abundance of beneficial gut bacteria species, such as *Akkermansia muciniphila*. More recently, some therapeutic effects of pCBs were likewise found to be accompanied by corresponding beneficial actions on the gut microbiome. Clearly,

TABLE 15
Endocannabinoidome mediators and their synthetic analogs under clinical testing

Name	Company (and Commercial Name) when Available	Indication(s)	Main Proposed Target	Clinical Trials Gov Identifier
<i>N</i> -Palmitoylethanolamine (PEA)	Epitech Italy (Normast, Pelvilen, Gialia)	Neuropathic pain from spinal cord injury Covid-19 Fibromyalgia Chronic pain Chronic pelvic pain in endometriosis Frontotemporal Dementia Tourette's syndrome (in combination with dronabinol)	PPAR α GPR55 ^a TRPV1 ^b CB ₂ R ^b	NCT01851499 NCT04568876 NCT04488926 NCT02699281 NCT02372903 NCT04489017 NCT03066193
<i>N</i> -Oleoyl ethanolamine (OEA)	University of California Davis Davis, California, United States NutriForward LLC (RiduZone, 90% OEA)	Post-prandial inflammation Overweight and obesity	PPAR α TRPV1 GPR119	NCT05017428 NCT04614233
Bimatoprost (Prostamide F _{2x} analog)	Allergan (Lumigan)	Intraocular Pressure, Glaucoma, Ocular Hypertension Eyelash hypotrichosis, alopecia	FP/Alt4-FP heteromer FP ^a	Several completed studies Several completed studies

Reported studies are mostly completed (only in a few cases recruitment is still ongoing), and results of most of them have not been disclosed yet. An exception is the case of bimatoprost, which has proven to be very effective on eyelash hypotrichosis and promising on various forms of alopecia (Jha et al., 2018). *N*-Palmitoylethanolamine is often administered as the ultramicrosized solid, and/or in combination with other molecules, such as transpodydatin (in Pelvilen, for pelvic pain) or luteolin (Gialia, for some CNS disorders) (Petrosino and Di Marzo, 2017). Abbreviations: see Table 14.

^aStill controversial.

^bThese targets are activated indirectly via elevation of endogenous ligand levels or activity.




Fig. 28. Reciprocal modulation of the ECS and the gut microbiome. The emerging microbendocannabinoidome (μ beCBome), also summarized in Table 14, enlarges the span of microbe-host communication and expands it to the eCBome.

it is difficult to understand solely from these *in vivo* studies whether the effects observed on the gut microbiome were the direct consequence of the pharmacological and genetic manipulation of the eCBome or only an indirect and host-mediated effect of the latter.

In fact, there is now also accumulating *ex vivo* and *in vitro* evidence that host-derived eCB-like mediators can directly affect the composition and function of the gut microbiome. In particular, both *N*-acylethanolamines and 2-monoacylglycerols were found to affect the function (e.g., proliferation, biofilm formation, and virulence) of gut bacteria, clearly through mechanisms and at experimental concentrations that are quite different from those underlying their effects on host cells (Ellermann et al., 2020; Dione et al., 2020; Fornelos et al., 2020; Sionov and Steinberg, 2022). On the other hand, it was also shown that the manipulation of the gut microbiome, either in germ-free mice or following prolonged treatment of mice with antibiotics, directly affects the expression of eCBome receptors, metabolic enzymes, and mediators in the gut and other, more distal host tissues like the brain (Muccioli et al., 2010; Aguilera et al., 2015; Manca et al., 2020a, b). The mechanisms through which this influence is exerted are not yet known but are likely to be due to the action on host cells of the aforementioned microbiome-derived metabolites (i.e., short chain fatty acids) and may include epigenetic

regulation of genes encoding for eCBome proteins, since these changes can be reversed upon reinstatement of the gut microbiome.

Also, probiotics are known to affect the intestinal ECS and to potentially owe to this interaction part of their pharmacological actions (Rousseaux et al., 2007; Ringel-Kulka et al., 2014; Rossi et al., 2020; Cuzzo et al., 2021). Yet, it remains unclear whether these effects are due to a direct action of probiotic bacterial species on host cells or to their capability of modulating the gut microbiome. Interestingly *A. muciniphila*, a proposed gut microbiota-derived probiotic whose administration produces beneficial actions in both animal models of obesity and dysmetabolism and authentic obese subjects with metabolic syndrome (Everard et al., 2013; Plovier et al., 2017; Depommier et al., 2019), was found to increase the intestinal levels of pharmacologically active 2-monoacylglycerols (i.e., 2-AG, 2-palmitoyl-glycerol, and 2-oleoyl-glycerol) in mice with diet-induced obesity (Everard et al., 2013), as well as the circulating levels of 2-palmitoyl-glycerol—a PPAR α agonist with potential metabolic beneficial activity—in obese individuals (Depommier et al., 2021). Probiotics can also reverse the gut dysbiosis-induced alterations of *N*-acyl-serotonin and *N*-acylethanolamine concentrations in gut (Guida et al., 2018) or adipose tissue (Geurts et al., 2015), respectively, with a corresponding amelioration of dysmetabolism and mood disturbances, respectively; again

it is not clear whether these effects were exerted directly on eCBome mediator biosynthesis or degradation. Clearly, *in vitro* studies, using, for example, cocultures of commensal bacteria or probiotic species (or their culture media) with mammalian intestinal cells or organoids, are again needed to understand whether these *in vivo* effects are the consequence of direct bacterial interactions with host cells.

VII. Conclusion

Plant-derived cannabinoids and endocannabinoids represent two different but equally complex systems, so that the terms “(phyto)cannabinoids” and “endocannabinoids” are actually used to identify rather heterogeneous groups of lipophilic substances. It is striking how some of these molecules happened to share 3D structures, allowing exogenous pCBs to play so many biologic activities in our body, because they mimic eCBs. The additional layer of complexity brought about by these structural similarities makes extremely challenging the use of pCBs and ECS-oriented drugs as potential therapeutics to combat human diseases and requires deeper knowledge of the structural and functional details of their potential targets in the cell. Undoubtedly, a better understanding of these fine molecular clues will allow us to turn pCBs and ECS-oriented drugs from threats to a treasure trove for human health.

Among the various components of the ECS, CB₁R, CB₂R, and FAAH have been the most largely exploited to develop therapeutic drugs for human diseases.

Shortly after the discovery of CB₁R, many therapeutic opportunities identified it for its agonists and antagonists; yet, improvements in medicinal cannabinoids are continually meeting novel challenges (Pacher and Kunos, 2013). Selectivity for specific tissue responses is necessary to promote beneficial therapeutic responses while minimizing side effects. Developing agonists that are highly selective for CB₁R but devoid of activity at other receptors (e.g., CB₂R, GPR55) continues to remain a challenge. Organ-system selectivity is a second goal for minimizing CNS actions of CB₁R agonists and antagonists and is being met by the development of peripherally restricted ligands that have limited access to brain CB₁R (Amato et al., 2019). A third approach to selectivity involves tuning the functional outcome of ligands such as “biased agonists” that would modify the active CB₁R conformation to direct signaling preferentially through either G protein pathways or β -arrestin pathways and, further, to select for individual G protein subtypes (Gs or G_{12/13} versus Gi/o) and for β -arrestin 1 versus β -arrestin 2. A fourth mechanism for selectivity is to develop allosteric modulators whose effects would be limited to only those receptors concurrently being stimulated by an endogenous agonist. A positive allosteric modulator would augment the response to eCBs and could potentiate ongoing stimulatory signals, whereas a negative allosteric

modulator would be expected to provide noncompetitive inhibition to those receptors receiving an endocannabinoid signal. Additionally, future goals for antagonists would be the development of biased antagonists, negative allosteric modulators, as well as neutral antagonists that do not affect the basal activity of CB₁R. A still unexplored approach with therapeutic potential that is closer to the concept of polypharmacology involves specifically inhibiting CB₁R and activating CB₂R. Thus, the future for CB₁R pharmacotherapeutics can be predicted to move from phytocannabinoid preparations to agonists and antagonists that exhibit greater selectivity through one of these strategies.

Also, CB₂R is a key element of the ECS. It is highly expressed in immune cells, and its activation limits inflammation and associated tissue injury under multiple pathologic conditions. Efficacy in preclinical models of pain, neurodegenerative, cardiovascular, gastrointestinal, liver, kidney, and lung diseases has been demonstrated. Due to this enormous therapeutic potential, a multitude of CB₂R ligands has been developed that can be categorized as eCBs and related fatty acid derivatives, pCBs, or synthetic CB₂R ligands. The majority of these ligands include agonists, modulators, neutral antagonists, inverse agonists, allosteric ligands, as well as labeled chemical probes. Altogether, a large, structurally diverse chemical space is covered. Generally, early CB₂R modulators are dual CB₁R/CB₂R agonists that are mostly not quite “drug-like.” In contrast, recent ligands often combine high potency for CB₂R with favorable overall ADME profiles including low lipophilicity, aqueous solubility, and favorable plasma protein binding, which translate into excellent pharmacokinetic profiles and consequently improved developability. To overcome CB₁R-driven psychotropic effects, two strategies were followed: limiting exposure toward the periphery or enhancing the selectivity over CB₁R through excellent structure activity relationship work in the lead optimization phase, thus enabling clinical studies with more than 20 new molecular entities. First, trials focused on diseases of the CNS and pain. Most recent ligands and clinical studies focus on peripheral indications with a strong inflammatory/immunomodulatory and/or fibrotic background. Three phytocannabinoids (THC, nabilone, and cannabidiol) have been launched. Most advanced selective CB₂R agonists are in phase 2 clinical trials. While no CB₂R-related toxicity issues have been reported from clinical studies, the demonstration of target engagement and the identification of best-suited human disease condition(s) for the therapeutic use of CB₂R modulators still poses challenges for the development of CB₂R-based therapies. The generation of translational animal models and a better understanding of CB₂R and the ECS in general will help unlock the receptor’s full therapeutic potential. Recently discovered high-quality labeled chemical probes have enabled a better understanding of

CB₂R expression, mechanism of action, and translatability of results toward the human situation. The in-depth understanding of signaling bias as well as CB₂R receptor homo- and heterodimers might translate into different functional properties and ultimately tailor-made CB₂R therapeutics. Deeper insights into drug-target binding kinetics, their impact on receptor function, and, in particular, the recently reported structures of antagonist- and agonist-bound CB₂R and knowledge on allosterism will facilitate rational drug design. Together with the huge chemical space available to generate tailor-made CB₂R modulators, this will hopefully guide us to the discovery of potent, effective, and safe medicines for indications with a dire or even unmet need.

Finally, since the discovery of FAAH and MAGL many compounds have been developed starting from inhibitors of other known serine hydrolases to study enzyme activity, its regulation, and relevance in the pathophysiological process. Over the years, different approaches have been used to identify and synthesize new classes of single or dual inhibitors, paying more and more attention to the analysis of their selectivity, potency, and mechanism of action. The development of selective FAAH and MAGL inhibitors remains one of the major issues in drug discovery, as also demonstrated by the large number of research papers and review articles devoted to this topic. The main interest in this field is to develop a therapeutic alternative to the use of cannabinoid receptor agonists, able to prevent or minimize serious psychotropic side effects due to direct receptor activation. The possibility to increase eCB tone by reducing degradation, and to apply new multitarget strategies that include additional receptors and enzymes, have boosted FAAH and MAGL inhibition studies to generate therapeutics against peripheral and CNS-related pathologies. However, more details seem to be necessary on 3D structure, catalytic mechanism, and regulation of both hydrolases to design effective inhibitors devoid of off-target activity. Novel in silico approaches like computer-aided drug discovery may be useful to reach this goal. In this context, it has to be recalled the tragic use of BIA10-2474, a purported FAAH inhibitor that killed one volunteer and led four others to hospitalization in phase I clinical trials because of serious adverse neurologic events (Kerbrat et al., 2016). This BIA 10-2474 disaster clearly reminds us that accurate preclinical characterization of the biochemical profile of any new chemical entity must be performed, before claiming that a new selective drug has been discovered, and especially before allowing its use in clinical trials.

Overall, the same potentialities and limitations revealed by accumulated evidence in so many studies on CB₁R, CB₂R, FAAH, and MAGL are likely to apply also to the more recently characterized elements of the ECS and hopefully will be instructive to avoid making the same mistakes. In particular, a better

appreciation of the 3D structure of the desired targets, also via cryo-electron microscopy (Hua et al., 2020), and the application of powerful in silico tools like CADD, virtual screening (Stasiulewicz et al., 2022), and machine learning (Atz et al., 2023) hold promise to shorten the path from the bench to the patient's bed in drug discovery programs oriented toward the ECS. This knowledge of structural details will also help to decipher complex interactions between pCBs/eCBs and other bioactive lipids (e.g., eicosanoids and specialized pro-resolving mediators) that are receiving increasing attention for their therapeutic potential to treat human diseases (Maccarrone, 2023).

Acknowledgments

M.M. wishes to express gratitude to all colleagues who contributed over the last 30 years to his studies on the ECS and its implications for human health and disease. M.M. also thanks Cinzia Rapino (University of Teramo, Teramo, Italy) and Marina Fava (Campus Bio-Medico University of Rome, Rome, Italy) for their help in preparing Tables 1 to 3 and Figures 1 to 7, respectively. A.M. thanks Christos Iliopoulos Tsoutsouvas (Northeastern University, Boston, MA, USA) for his support in collecting information on CB₁R and preparing Table 4 and Figures 8 and 9. D.P. thanks Yannick Fotio (University of California, Irvine, CA, USA) for his support in preparing Figures 23 and 24. M.vd S. thanks Na Zhu and Anthe Janssen (Leiden University, Leiden, Netherlands) for preparing the schemes in Tables 1, 3, 7, and 9 and for Figure 25.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Maccarrone, Di Marzo, Gertsch, Grether, Howlett, Hua, Makriyannis, Piomelli, Ueda, Van der Stelt.

Note Added in Proof: Two mistakes were found in Figure 4 and Figure 6 published in the Fast Forward version published May 10, 2023. Figures 4 and 6 have now been corrected.

References

- Abrams DI and Guzman M (2015) Cannabis in cancer care. *Clin Pharmacol Ther* **97**:575–586.
- Adams R, MacKenzie Jr S, and Loewe S (1948) Tetrahydrocannabinol homologs with double branched alkyl groups in the 3-position. *J Am Chem Soc* **70**:664–668.
- Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A et al. (2008) The acyclic CB₁R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. *Cell Metab* **7**:68–78.
- Aghazadeh Tabrizi M, Baraldi PG, Borea PA, and Varani K (2016) Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB₂ receptor agonists. *Chem Rev* **116**:519–560.
- Aguilera M, Cerdà-Cuellar M, and Martínez V (2015) Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. *Gut Microbes* **6**:10–23.
- Ahmad R, Koole M, Evens N, Serdons K, Verbruggen A, Bormans G, and Van Laere K (2013) Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [¹¹C]-NE40 in healthy subjects. *Mol Imaging Biol* **15**:384–390.
- Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, and Van Laere K (2016) Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. *Eur J Nucl Med Mol Imaging* **43**:2219–2227.
- Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP et al. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. *Biochemistry* **46**:13019–13030.
- Alexander JP and Cravatt BF (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. *J Am Chem Soc* **128**:9699–9704.
- Alhouayek M, Bottemanne P, Subramanian KV, Lambert DM, Makriyannis A, Cani PD, and Muccioli GG (2015) N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. *FASEB J* **29**:650–661.

- Alhouayek M, Masquelier J, and Muccioli GG (2018) Lysophosphatidylinositols, from cell membrane constituents to GPR55 ligands. *Trends Pharmacol Sci* **39**:586–604.
- Al-Zoubi R, Morales P, and Reggio PH (2019) Structural insights into CB1 receptor biased signaling. *Int J Mol Sci* **20**:1837.
- Amato G, Khan NS, and Maitra R (2019) A patent update on cannabinoid receptor 1 antagonists (2015–2018). *Expert Opin Ther Pat* **29**:261–269.
- Amato GS, Manke A, Harris DL, Wieth RW, Vasukuttan V, Snyder RW, Lefever TW, Cortes R, Zhang Y, Wang S et al. (2018) Blocking alcoholic steatosis in mice with a peripherally restricted purine antagonist of the type 1 cannabinoid receptor. *J Med Chem* **61**:4370–4385.
- Amin MR and Ali DW (2019) Pharmacology of medical cannabis. *Adv Exp Med Biol* **1162**:151–165.
- Anagnostopoulos D, Rakiec C, Wood J, Pandarinathan L, Zvonok N, Makriyannis A, and Siafaka-Kapadai A (2010) Identification of endocannabinoids and related *N*-acylethanolamines in tetrahymena. A new class of compounds for Tetrahymena. *Protist* **161**:452–465.
- Anand P, Whiteside G, Fowler CJ, and Hohmann AG (2009) Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. *Brain Res Brain Res Rev* **60**:255–266.
- Archer RA, Blanchard WB, Day WA, Johnson DW, Lavagnino ER, Ryan CW, and Baldwin JE (1977) Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone. *J Org Chem* **42**:2277–2284.
- Arnold WR, Carnevale LN, Xie Z, Baylon JL, Tajkhorshid E, Hu H, and Das A (2021) Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. *Nat Commun* **12**:926.
- Atwood BK and Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. *Br J Pharmacol* **160**:467–479.
- Atwood BK, Wager-Miller J, Haskins C, Straiker A, and Mackie K (2012) Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. *Mol Pharmacol* **81**:250–263.
- Atz K, Guba W, Grether U, and Schneider G (2023) Machine learning and computational chemistry for the endocannabinoid system. *Methods Mol Biol* **2576**:477–493.
- Ayoub SM, Smoum R, Farag M, Atwal H, Collins SA, Rock EM, Limebeer CL, Piscitelli F, Iannotti FA, Lichtman AH et al. (2020) Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. *Psychopharmacology (Berl)* **237**:2753–2765.
- Baggelaar MP, Chameau PJ, Kantae V, Hummel J, Hsu KL, Janssen F, van der Wel T, Soethoudt M, Deng H, den Dulk H et al. (2015) Highly selective, reversible inhibitor identified by comparative chemoproteomics modulates diacylglycerol lipase activity in neurons. *J Am Chem Soc* **137**:8851–8857.
- Baggelaar MP, Maccarrone M, and van der Stelt M (2018) 2-Arachidonoylglycerol: a signaling lipid with manifold actions in the brain. *Prog Lipid Res* **71**:1–17.
- Baggelaar MP, van Esbroeck AC, van Rooden EJ, Florea BI, Overkleeft HS, Marsicano G, Chauloff F, and van der Stelt M (2017) Chemical proteomics maps brain region specific activity of endocannabinoid hydrolases. *ACS Chem Biol* **12**:852–861.
- Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, Burglen L, Cope H, Crawford A, Derksen A et al.; Rady Children's Institute for Genomic Medicine; Undiagnosed Disease Network (2022) Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. *Brain* **145**:3383–3390.
- Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, and Chebib M (2017) The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA_A receptors. *Pharmacol Rev* **119**:358–370.
- Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, and Vinod KY (2018) Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. *Neuropharmacology* **131**:200–208.
- Balvers MG, Verhoeckx KC, and Witkamp RF (2009) Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* **877**:1583–1590.
- Bari M, Battista N, Fezza F, Finazzi-Agrò A, and Maccarrone M (2005) Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. *J Biol Chem* **280**:12212–12220.
- Bartholomäus R, Nicolussi S, Baumann A, Rau M, Simão AC, Gertsch J, and Altmann KH (2019) Total synthesis of the endocannabinoid uptake inhibitor guineensine and SAR studies. *ChemMedChem* **14**:1590–1596.
- Bartolozzi A, Cirillo PF, Berry AK, Hickey ER, Thomson DS, Wu L, Zindell R, Albrecht C, Ceci A, Gemkow MJ et al. (2015) Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model. *Bioorg Med Chem Lett* **25**:587–592.
- Barutta F, Bellini S, Mastrocola R, Gambino R, Piscitelli F, di Marzo V, Corbetta B, Vemuri VK, Makriyannis A, Annaratone L et al. (2018) Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. *Br J Pharmacol* **175**:4371–4385.
- Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, and Gruden G (2017) Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. *Nephrol Dial Transplant* **32**:1655–1665.
- Basagni F, Rosini M, and Decker M (2020) Functionalized cannabinoid subtype 2 receptor ligands: fluorescent, PET, photochromic and covalent molecular probes. *ChemMedChem* **15**:1374–1389.
- Bashashati M, Fichna J, Piscitelli F, Capasso R, Izzo AA, Sibaev A, Timmermans JP, Cenac N, Vergnolle N, Di Marzo V et al. (2017) Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: a pharmacological intervention with *N*-arachidonoyl-serotonin (AA-5-HT). *Neurogastroenterol Motil* **29**:12.
- Battista N, Bari M, Finazzi-Agrò A, and Maccarrone M (2002) Anandamide uptake by synaptosomes from human, mouse and rat brain: inhibition by glutamine and glutamate. *Lipids Health Dis* **1**:PMC139962.
- Baur R, Gertsch J, and Sigel E (2013) Do *N*-arachidonoyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the β 2 subunit of GABAA receptors? *PeerJ* **1**:e149.
- Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann Jr JL, Wetzel JR, Rosi D, Philion RE, Daum SJ, Hlasta DJ et al. (1991) Antinociceptive (aminoalkyl)indoles. *J Med Chem* **34**:1099–1110.
- Beltramo M and Piomelli D (1999) Anandamide transport inhibition by the vanilloid agonist olvanil. *Eur J Pharmacol* **364**:75–78.
- Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, and Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* **277**:1094–1097.
- Berger WT, Ralph BF, Kaczocha M, Sun J, Balius TE, Rizzo RC, Haj-Dahmane S, Ojima I, and Deutsch DG (2012) Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. *PLoS One* **7**:e50968.
- Billings RE, Whitaker GW, and McMahon RE (1980) The stereoselective enzymic reduction of the synthetic 9-ketocannabinoid, nabilone, in vivo, in isolated liver cells and in liver homogenate. *Xenobiotica* **10**:33–36.
- Biró T, Tóth BI, Haskó G, Paus R, and Pacher P (2009) The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* **30**:411–420.
- Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, and Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol* **134**:845–852.
- Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* **163**:463–468.
- Bisogno T, Mahadevan A, Coccorello R, Chang JW, Allarà M, Chen Y, Giacobuzzo G, Lichtman A, Cravatt B, Moles A et al. (2013) A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. *Br J Pharmacol* **169**:784–793.
- Blankman JL and Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. *Pharmacol Rev* **65**:849–871.
- Blankman JL, Simon GM, and Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol* **14**:1347–1356.
- Bluett RJ, Báldi R, Haymer A, Gauden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC et al. (2017) Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. *Nat Commun* **8**:14782.
- Bogdan DM, Studholme K, DiBua A, Gordon C, Kanjiya MP, Yu M, Puopolo M, and Kaczocha M (2022) FAPP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain. *Sci Rep* **12**:9241.
- Bond RA and Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. *Trends Pharmacol Sci* **27**:92–96.
- Bonezzi FT, Sasso O, Pontis S, Realini N, Romeo E, Ponzano S, Nuzzi A, Fiasella A, Bertozzi F, and Piomelli D (2016) An important role for *N*-acylethanolamine acid amides in the complete Freund's adjuvant rat model of arthritis. *J Pharmacol Exp Ther* **356**:656–663.
- Bononi G, Poli G, Rizzolio F, Tuccinardi T, Macchia M, Minutolo F, and Granchi C (2021) An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018–present). *Expert Opin Ther Pat* **31**:153–168.
- Börner C, Smida M, Höllt V, Schraven B, and Kraus J (2009) Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. *J Biol Chem* **284**:35450–35460.
- Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, and Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. *Biol Psychiatry* **62**:1103–1110.
- Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, and Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* **214**:173–180.
- Bowen KJ, Kris-Etherton PM, Shearer GC, West SG, Reddivari L, and Jones PJH (2017) Oleic acid-derived oleylethanolamide: a nutritional science perspective. *Prog Lipid Res* **67**:1–15.
- Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G et al. (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. *Proc Natl Acad Sci USA* **112**:285–290.
- Bracey MH, Hanson MA, Masuda KR, Stevens RC, and Cravatt BF (2002) Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. *Science* **298**:1793–1796.
- Braillou GC, Delieu E, Marcu J, Hoffman NE, Console-Bram L, Zhao P, Madesh M, Abood ME, and Braillou E (2014) Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. *Biochemistry* **53**:4990–4999.
- Brennecke B, Gazzi T, Atz K, Fingerle J, Kuner P, Schindler T, Weck G, Nazare M, and Grether U (2021) Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. *Pharm Pat Anal* **10**:111–163.
- Brodie JS, Di Marzo V, and Guy GW (2015) Polypharmacology shakes hands with complex aetiopathology. *Trends Pharmacol Sci* **36**:802–821.
- Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, and Heys SD (2010) Cannabinoid receptor-dependent and -independent anti-

- proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. *Carcinogenesis* **31**:1584–1591.
- Brown I, Lee J, Sneddon AA, Cascio MG, Pertwee RG, Wahle KJW, Rotondo D, and Heys SD (2020) Anticancer effects of n-3 EPA and DHA and their endocannabinoid derivatives on breast cancer cell growth and invasion. *Prostaglandins Leukot Essent Fatty Acids* **156**:102024.
- Brüser A, Zimmermann A, Crews BC, Sliwoski G, Meiler J, König GM, Kostenis E, Lede V, Marnett LJ, and Schöneberg T (2017) Prostaglandin E₂ glyceryl ester is an endogenous agonist of the nucleotide receptor P2Y₆. *Sci Rep* **7**:2380.
- Burch P, Chicca A, Gertsch J, and Gademann K (2013) Functionally optimized neurotogenic farinosone C analogs: SAR r-study and investigations on their mode of action. *ACS Med Chem Lett* **5**:172–177.
- Cabral GA and Griffin-Thomas L (2008) Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. *Endocr Metab Immune Disord Drug Targets* **8**:159–172.
- Cabral GA, Raborn ES, Griffin L, Dennis J, and Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. *Br J Pharmacol* **153**:240–251.
- Cadas H, di Tomaso E, and Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. *J Neurosci* **17**:1226–1242.
- Calignano A, La Rana G, Giuffrida A, and Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. *Nature* **394**:277–281.
- Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonogo AB, Rodrigues NS, Galve-Roperh I, and Guimarães FS (2017) Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. *Front Pharmacol* **8**:269.
- Campos AC, Moreira FA, Gomes FV, Del Bel EA, and Guimarães FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. *Philos Trans R Soc Lond B Biol Sci* **367**:3364–3378.
- Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdélyi K, Hao E, Holovac E, Haskó G, Cravatt BF, Nomura DK et al. (2013) Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. *Gastroenterology* **144**:808–817.e15.
- Carlini EA and Cunha JM (1981) Hypnotic and antiepileptic effects of cannabidiol. *J Clin Pharmacol* **21**(Suppl 1):417S–427S.
- Cascio MG, Marini P, and Pertwee RG (2016) The displacement binding assay using human cannabinoid CB2 receptor-transfected cells. *Methods Mol Biol* **1412**:57–63.
- Castaneda JT, Harui A, and Roth MD (2017) Regulation of cell surface CB₂ receptor during human B cell activation and differentiation. *J Neuroimmune Pharmacol* **12**:544–554.
- Castonguay-Paradis S, Lacroix S, Rochefort G, Parent L, Perron J, Martin C, Lamarche B, Raymond F, Flamand N, Di Marzo V et al. (2020) Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. *Sci Rep* **10**:15975.
- Cecconi S, Rapino C, Di Nisio V, Rossi G, and Maccarrone M (2020) The (endo)cannabinoid signaling in female reproduction: what are the latest advances? *Prog Lipid Res* **77**:101019.
- Cécyre B, Thomas S, Ptitto M, Casanova C, and Bouchard JF (2014) Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. *Naunyn-Schmiedeberg Arch Pharmacol* **387**:175–184.
- Cencioni MT, Chirchì V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, and Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. *PLoS One* **5**:e8688.
- Centonze D, Finazzi-Agrò A, Bernardi G, and Maccarrone M (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. *Trends Pharmacol Sci* **28**:180–187.
- Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, and Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. *Am J Physiol Regul Integr Comp Physiol* **293**:R2185–R2193.
- Chang C-P, Huang H-L, Huang J-K, Hung M-S, Wu C-H, Song J-S, Lee C-J, Yu C-S, and Shia K-S (2019) Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist. *Bioorg Med Chem* **27**:216–223.
- Chang FY, Siuti P, Laurent S, Williams T, Glassey E, Sailer AW, Gordon DB, Hemmerle H, and Voigt CA (2021) Gut-inhabiting Clostridia build human GPCR ligands by conjugating neurotransmitters with diet- and human-derived fatty acids. *Nat Microbiol* **6**:792–805.
- Chemin J, Cazade M, and Lory P (2014) Modulation of T-type calcium channels by bioactive lipids. *Pflügers Arch* **466**:689–700.
- Chen Q and Tesmer JGG (2022) G protein-coupled receptor interactions with arrestins and GPCR kinases: the unresolved issue of signal bias. *J Biol Chem* **298**:102279.
- Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang YP, Teng Z, and Chen C (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. *Cell Rep* **2**:1329–1339.
- Chicca A, Marazzi J, Nicolussi S, and Gertsch J (2012) Evidence for bidirectional endocannabinoid transport across cell membranes. *J Biol Chem* **287**:34660–34682.
- Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Dalghi Gens M, Lutz B et al. (2017) Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. *Proc Natl Acad Sci USA* **114**:E5006–E5015.
- Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, and Gertsch J (2009) Synergistic immunopharmacological effects of N-alkylamides in *Echinacea purpurea* herbal extracts. *Int Immunopharmacol* **9**:850–858.
- Christensen R, Kristensen PK, Bartels EM, Bliddal H, and Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet* **370**:1706–1713.
- Ciarra Mellano F, Fanti F, Scipioni L, Maccarrone M, and Oddi S (2023) Endocannabinoid metabolism and transport as drug targets. *Methods Mol Biol* **2576**:201–211.
- Cinar R, Iyer MR, and Kunos G (2020) The therapeutic potential of second and third generation CB1R antagonists. *Pharmacol Ther* **208**:107477.
- Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM et al. (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. *Nat Neurosci* **13**:1265–1270.
- Clarivate (2022a) *Drug report on ART-27.13*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/54930> (accessed October 2022).
- Clarivate (2022b) *Drug report on cannabidiol*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/57457> (accessed October 2022).
- Clarivate (2022c) *Drug report on CMX-020*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/89531> (accessed October 2022).
- Clarivate (2022d) *Drug report on dronabinol*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/12866> (accessed October 2022).
- Clarivate (2022e) *Drug report on KN 387271*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/22439> (accessed October 2022).
- Clarivate (2022f) *Drug report on LY-2828360*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/70612> (accessed October 2022).
- Clarivate (2022g) *Drug report on nabiximols*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/94779> (accessed October 2022).
- Clarivate (2022h) *Drug report on NTRX-07*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/104592> (accessed October 2022).
- Clarivate (2022i) *Drug report on olorinab*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/70435> (accessed October 2022).
- Clarivate (2022j) *Drug report on PRS-211375*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/27212> (accessed October 2022).
- Clarivate (2022k) *Drug report on RG7774*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/121857> (accessed October 2022).
- Clarivate (2022l) *Drug report on S-777469*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/56044> (accessed October 2022).
- Clarivate (2022m) *Drug report on TAK-937*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/63642> (accessed October 2022).
- Clarivate (2022n) *Drug report on tedalinab*. Cortellis data base, <https://www.cortellis.com/intelligence/report/ci/nextgendrugall/55827> (accessed October 2022).
- Cluny NL, Keenan CM, Reimer RA, Le Foll B, and Sharkey KA (2015) Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with Δ⁹-tetrahydrocannabinol. *PLoS One* **10**:e0144270.
- Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A et al. (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. *Br J Pharmacol* **161**:629–642.
- Cohen K, Weizman A, and Weinstein A (2019) Positive and negative effects of cannabis and cannabinoids on health. *Clin Pharmacol Ther* **105**:1139–1147.
- Cohen LJ, Esterhazy D, Kim SH, Lemetre C, Aguilar RR, Gordon EA, Pickard AJ, Cross JR, Emiliano AB, Han SM et al. (2017) Commensal bacteria make GPCR ligands that mimic human signalling molecules. *Nature* **549**:48–53.
- Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, and Schram K (1991) Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacol Biochem Behav* **40**:701–708.
- Consroe P, Sandyk R, and Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. *Int J Neurosci* **30**:277–282.
- Cooper A, Singh S, Hook S, Tyndall JDA, and Vernal AJ (2017) Chemical tools for studying lipid-binding class A G protein-coupled receptors. *Pharmacol Rev* **69**:316–353.
- Corbus Pharmaceuticals (2022) *Drug report on lenabasum*. Adis Insight data base, <https://adisinsight.springer.com/drugs/800007180>.
- Correa F, Hernangómez-Herrero M, Mestre L, Loria F, Docagne F, and Guaza C (2011) The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. *Brain Behav Immun* **25**:736–749.
- Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci USA* **98**:9371–9376.
- Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* **384**:83–87.
- Cristino L, Bisogno T, and Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. *Nat Rev Neurol* **16**:9–29.
- Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, and Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology* **21**:175–185.
- Cuzzo M, Castelli V, Avagliano C, Cimini A, d'Angelo M, Cristiano C, and Russo R (2021) Effects of chronic oral probiotic treatment in paclitaxel-induced neuropathic pain. *Biomedicines* **9**:346.
- Dainese E, De Fabritiis G, Sabatucci A, Oddi S, Angelucci CB, Di Pancrazio C, Giorgino T, Stanley N, Del Carlo M, Cravatt BF et al. (2014) Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH. *Biochem J* **457**:463–472.
- Dainese E, Oddi S, Simonetti M, Sabatucci A, Angelucci CB, Ballone A, Dufursine B, Fezza F, De Fabritiis G, and Maccarrone M (2020) The endocannabinoid hydrolase FAAH is an allosteric enzyme. *Sci Rep* **10**:2292.

- D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC et al. (1992) Conformationally restrained analogues of pravadolol: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. *J Med Chem* **35**:124–135.
- D'Aniello E, Fellous T, Iannotti FA, Gentile A, Allarà M, Balestrieri F, Gray R, Amodeo P, Vitale RM, and Di Marzo V (2019) Identification and characterization of phytocannabinoids as novel dual PPAR α/γ agonists by a computational and in vitro experimental approach. *Biochim Biophys Acta, Gen Subj* **1863**:586–597.
- Davies AK, Alecu JE, Ziegler M, Vasilopoulou CG, Merciai F, Jumo H, Afshar-Saber W, Sahin M, Ebrahimi-Fakhari D, and Borner GHH (2022) AP-4-mediated axonal transport controls endocannabinoid production in neurons. *Nat Commun* **13**:1058.
- Day TA, Rakhshan F, Deutsch DG, and Barker EL (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. *Mol Pharmacol* **59**:1369–1375.
- de Almeida DL and Devi LA (2020) Diversity of molecular targets and signaling pathways for CBD. *Pharmacol Res Perspect* **8**:e00682.
- De Laurentiis A, Araujo HA, and Rettori V (2014) Role of the endocannabinoid system in the neuroendocrine responses to inflammation. *Curr Pharm Des* **20**:4697–4706.
- De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, and Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. *FEBS Lett* **483**:52–56.
- De Petrocellis L, Cascio MG, and Di Marzo V (2004) The endocannabinoid system: a general view and latest additions. *Br J Pharmacol* **141**:765–774.
- De Petrocellis L, Deva R, Mainieri F, Schaefer M, Bisogno T, Ciccoli R, Ligresti A, Hill K, Nigam S, Appendino G et al. (2009) Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. *J Lipid Res* **50**:658–666.
- De Petrocellis L and Di Marzo V (2014) N-Acyl-dopamines and N-acylserotonins: from synthetic pharmacological tools to endogenous multitarget mediators, in *The Endocannabinoidome: The World of Endocannabinoids and Related Mediators* (Di Marzo V, Wang J, eds) pp 67–84, Elsevier, Boston.
- De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, and Di Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* **163**:1479–1494.
- De Petrocellis L, Marini P, Matias I, Moriello AS, Starowicz K, Cristino L, Nigam S, and Di Marzo V (2007) Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. *Exp Cell Res* **313**:2993–3004.
- De Petrocellis L, Melck D, Bisogno T, Milone A, and Di Marzo V (1999) Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. *Neuroscience* **92**:377–387.
- De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, and Di Marzo V (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. *Acta Physiol (Oxf)* **204**:255–266.
- del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA et al. (2016) The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor- γ and CB2 pathways. *Sci Rep* **6**:21703.
- Delis F, Polissidis A, Pouliou N, Justinova Z, Nomikos GG, Goldberg SR, and Antoniou K (2017) Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and CB1 receptor antagonism in rats. *Int J Neuropsychopharmacol* **20**:269–278.
- Deng H and Li W (2020) Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. *Acta Pharm Sin B* **10**:582–602.
- Deng H, Kooijman S, van den Nieuwendijk AM, Ogasawara D, van der Wel T, van Dalen F, Baggelaar MP, Janssen FJ, van den Berg RJ, den Dulk H et al. (2017) Triazole ureas act as diacylglycerol lipase inhibitors and prevent fasting-induced refeeding. *J Med Chem* **60**:428–440.
- Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM et al. (2019) Supplementation with *Akkermansia muciniphila* in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat Med* **25**:1096–1103.
- Depommier C, Vitale RM, Iannotti FA, Silvestri C, Flamand N, Druart C, Everard A, Pelicaen R, Maiter D, Thissen JP et al. (2021) Beneficial effects of *Akkermansia muciniphila* are not associated with major changes in the circulating endocannabinoidome but linked to higher mono-palmitoyl-glycerol levels as new PPAR α agonists. *Cells* **10**:185.
- Desarnaud F, Cadas H, and Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. *J Biol Chem* **270**:6030–6035.
- Després JP, Golay A, and Sjöström L; Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N Engl J Med* **353**:2121–2134.
- Deutsch DG and Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. *Biochem Pharmacol* **46**:791–796.
- Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenberger RA, Hillard CJ, and Abumrad N (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. *J Biol Chem* **276**:6967–6973.
- Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, and Mechoulam R (1992a) A novel probe for the cannabinoid receptor. *J Med Chem* **35**:2065–2069.
- Devane WA, Dysarz 3rd FA, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* **34**:605–613.
- Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992b) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**:1946–1949.
- DeVullo MV, Hrelja KM, Petrie GN, Limebeer CL, Rock EM, Hill MN, and Parker LA (2020) Nausea-induced conditioned gaping reactions in rats produced by high-dose synthetic cannabinoid, JWH-018. *Cannabis Cannabinoid Res* **5**:298–304.
- Di Marzo V (2018) New approaches and challenges to targeting the endocannabinoid system. *Nat Rev Drug Discov* **17**:623–639.
- Di Marzo V and Fontana A (1995) Anandamide, an endogenous cannabinomimetic eicosanoid: “killing two birds with one stone.” *Prostaglandins Leukot Essent Fatty Acids* **53**:1–11.
- Di Marzo V and Piscitelli F (2015) The endocannabinoid system and its modulation by phytocannabinoids. *Neurotherapeutics* **12**:692–698.
- Di Marzo V and Silvestri C (2019) Lifestyle and metabolic syndrome: contribution of the endocannabinoidome. *Nutrients* **11**:1956.
- Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, and Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* **372**:686–691.
- Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járái Z, Fezza F, Miura GI, Palminter RD, Sugiura T et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* **410**:822–825.
- Di Marzo V, Ligresti A, Morera E, Nalli M, and Ortar G (2004) The anandamide membrane transporter. Structure-activity relationships of anandamide and oleylethanolamine analogs with phenyl rings in the polar head group region. *Bioorg Med Chem* **12**:5161–5169.
- Di Meo C, Tortolani D, Standoli S, Angelucci CB, Fanti F, Leuti A, Sergi M, Kadhim S, Hsu E, Rapino C et al. (2022) Effects of rare phytocannabinoids on the endocannabinoid system of human keratinocytes. *Int J Mol Sci* **23**:5430.
- Di S, Boudaba C, Popescu IR, Weng FJ, Harris C, Marcheselli VL, Bazan NG, and Tasker JG (2005) Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. *J Physiol* **569**:751–760.
- Diaz P, Phatak SS, Xu J, Fronczek FR, Astruc-Diaz F, Thompson CM, Cavasotto CN, and Naguib M (2009) 2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. *ChemMedChem* **4**:1615–1629.
- Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, and Felder CC (2006) Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. *Cell Mol Neurobiol* **26**:407–423.
- Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, Ra S, Gray JM, Yang R, DeGruccio AM et al. (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. *Nat Commun* **6**:6395.
- Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci USA* **99**:10819–10824.
- Dione N, Lacroix S, Taschler U, Deschênes T, Abolghasemi A, Leblanc N, Di Marzo V, and Silvestri C (2020) Mgl1 knockout mouse resistance to diet-induced dysmetabolism is associated with altered gut microbiota. *Cells* **9**:2705.
- DiPatrizio NV (2021) Endocannabinoids and the gut-brain control of food intake and obesity. *Nutrients* **13**:1214.
- Dixon DD, Tius MA, Thakur GA, Zhou H, Bowman AL, Shukla VG, Peng Y, and Makriyannis A (2012) C3-heteroaryl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. *Bioorg Med Chem Lett* **22**:5322–5325.
- Donvito G, Piscitelli F, Muldoon P, Jackson A, Vitale RM, D'Aniello E, Giordano C, Ignatowska-Jankowska BM, Mustafa MA, Guida F et al. (2019) N-oleoyl-glycine reduces nicotine reward and withdrawal in mice. *Neuropharmacology* **148**:320–331.
- Dotsey EY, Jung KM, Basit A, Wei D, Daglian J, Vacondio F, Armirotti A, Mor M, and Piomelli D (2015) Peroxide-dependent MGL sulfenylation regulates 2-AG-mediated endocannabinoid signaling in brain neurons. *Chem Biol* **22**:619–628.
- D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A et al. (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. *Lancet Psychiatry* **6**:35–45.
- Eberlein B, Eicke C, Reinhardt HW, and Ring J (2008) Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venerol* **22**:73–82.
- Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. *J Med Chem* **38**:3094–3105.
- Eissenstat MA, Bell MR, D'Ambra TE, Estep KG, Haycock DA, Olefirowicz EM, and Ward SJ (1990) Aminoalkylindoles (AALs): structurally novel cannabinoid-mimetics. *NIDA Res Monogr* **105**:427–428.
- El Bakali J, Muccioli GG, Body-Malapel M, Djouina M, Klupsch F, Ghinet A, Barczyk A, Renault N, Chavatte P, Desreumaux P et al. (2014) Conformational restriction leading to a selective CB2 cannabinoid receptor agonist orally active against colitis. *ACS Med Chem Lett* **6**:198–203.
- El Sohly MA and Gul W (2014) Constituents of Cannabis sativa, in *Handbook of Cannabis* (Pertwee RG, ed) pp 3–22, Oxford University Press, Oxford, U.K.
- El Sohly MA, Radwan MM, Gul W, Chandra S, and Galal A (2017) Phytochemistry of Cannabis sativa L. *Prog Chem Org Nat Prod* **103**:1–36.
- Ellermann M, Pacheco AR, Jimenez AG, Russell RM, Cuesta S, Kumar A, Zhu W, Vale G, Martin SA, Raj P et al. (2020) Endocannabinoids inhibit the induction of virulence in enteric pathogens. *Cell* **183**:650–665.e15.
- Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I et al. (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). *J Biol Chem* **290**:8711–8721.

- Elmes MW, Prentis LE, McGoldrick LL, Giuliano CJ, Sweeney JM, Joseph OM, Che J, Carbonetti GS, Studholme K, Deutsch DG et al. (2019) FABP1 controls hepatic transport and biotransformation of Δ^9 -THC. *Sci Rep* **9**:7588.
- European Medicines Agency (2022) Sativex (https://www.ema.europa.eu/en/medicines/search_api_views_fulltext=Sativex). Emerald Health Pharmaceuticals, <https://emeraldpharma.com/clinical-trials/> (accessed October 2022).
- Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM et al. (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA* **110**:9066–9071.
- Everard A, Plovier H, Rastelli M, Van Hul M, de Wouters d'Oplinter A, Geurts L, Druart C, Robine S, Delzenne NM, Muccioli GG et al. (2019) Intestinal epithelial N-acetylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. *Nat Commun* **10**:457.
- Farrell JS, Colangeli R, Dong A, George AG, Addo-Osafo K, Kingsley PJ, Morena M, Wolff MD, Dudok B, He K et al. (2021) In vivo endocannabinoid dynamics at the timescale of physiological and pathological neural activity. *Neuron* **109**:2398–2403.e4.
- Fasia L, Karava V, and Siafaka-Kapadai A (2003) Uptake and metabolism of [3H] anandamide by rabbit platelets. Lack of transporter? *Eur J Biochem* **270**:3498–3506.
- Fauzan M, Oubraim S, Yu M, Glaser ST, Kaczocha M, and Haj-Dahmane S (2022) Fatty acid-binding protein 5 modulates brain endocannabinoid tone and retrograde signaling in the striatum. *Front Cell Neurosci* **16**:936939.
- Fazio D, Criscuolo E, Piccoli A, Barboni B, Fezza F, and Maccarrone M (2020) Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold? *Expert Opin Drug Discov* **15**:765–778.
- Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, and Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. *Proc Natl Acad Sci USA* **101**:8756–8761.
- Felder CC, Dickason-Chesterfield AK, and Moore SA (2006) Cannabinoid biology. *Mol Interv* **6**:149–161.
- Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol Pharmacol* **48**:443–450.
- Feng Z, Alqarni MH, Yang P, Tong Q, Chowdhury A, Wang L, and Xie XQ (2014) Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. *J Chem Inf Model* **54**:2483–2499.
- Fernández-Ruiz J, Moro MA, and Martínez-Orgado J (2015a) Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. *Neurotherapeutics* **12**:793–806.
- Fernández-Ruiz J, Romero J, and Ramos JA (2015b) Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. *Handb Exp Pharmacol* **231**:233–259.
- Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, and Guzmán M (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? *Trends Pharmacol Sci* **28**:39–45.
- Fezza F, Bari M, Florio R, Talamonti E, Feole M, and Maccarrone M (2014) Endocannabinoids, related compounds and their metabolic routes. *Molecules* **19**:17078–17106.
- Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, and Rice ASC (2021) Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. *Pain* **162**(Suppl 1):S5–S25.
- Fong TM (2014) Constitutive activity in cannabinoid receptors. *Adv Pharmacol* **70**:121–133.
- Fornelos N, Franzosa EA, Bishai J, Annand JW, Oka A, Lloyd-Price J, Arthur TD, Garner A, Avila-Pacheco J, Haiser HJ et al. (2020) Growth effects of N-acyl ethanolamines on gut bacteria reflect altered bacterial abundances in inflammatory bowel disease. *Nat Microbiol* **5**:486–497.
- Foster JR, Ueno S, Chen MX, Harvey J, Dowell SJ, Irving AJ, and Brown AJ (2019) N-Palmitoylglycine and other N-acylamides activate the lipid receptor G2A/GPR132. *Pharmacol Res Perspect* **7**:e00542.
- Fotio Y, Jung KM, Palese F, Obenaus A, Tagne AM, Lin L, Rashid TI, Pacheco R, Jullienne A, Ramirez J et al. (2021b) NAAA-regulated lipid signaling governs the transition from acute to chronic pain. *Sci Adv* **7**:eabi8834.
- Fotio Y, Sasso O, Ciccioppo R, and Piomelli D (2021a) Antinociceptive profile of ARN19702, (2-ethylsulfanylphenyl)-[(2S)-4-(6-fluoro-1, 3-benzothiazol-2-yl)-2-methylpiperazin-1-yl] methanone, a novel orally active N-acyl ethanolamine acid amidase inhibitor, in animal models. *J Pharmacol Exp Ther* **378**:70–76.
- Fowler CJ (2012) Anandamide uptake explained? *Trends Pharmacol Sci* **33**:181–185.
- Fowler CJ (2013) Transport of endocannabinoids across the plasma membrane and within the cell. *FEBS J* **280**:1895–1904.
- Fowler CJ (2014) Has FLAT fallen flat? *Trends Pharmacol Sci* **35**:51–52.
- Fowler CJ (2021) The endocannabinoid system—current implications for drug development. *J Intern Med* **290**:2–26.
- Fowler CJ, Tiger G, Ligresti A, López-Rodríguez ML, Di Marzo V, López-Rodríguez ML, and Di Marzo V (2004) Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle. *Eur J Pharmacol* **492**:1–11.
- Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, and James I (2001) The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. *Pain* **92**:91–100.
- Franco R, Rivas-Santesteban R, Reyes-Resina I, Casanovas M, Pérez-Olives C, Ferreira-Vera C, Navarro G, Sánchez de Medina V, and Nadal X (2020) Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids. *Pharmacol Res* **158**:104801.
- Fride E and Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. *Eur J Pharmacol* **231**:313–314.
- Friedman D, French JA, and Maccarrone M (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. *Lancet Neurol* **18**:504–512.
- Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Miller LN, Li L, Yao BB et al. (2008) Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. *J Med Chem* **51**:1904–1912.
- Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, Lodola A, Armirotti A, Garau G et al. (2011) A catalytically silent FAAH-1 variant drives anandamide transport in neurons. *Nat Neurosci* **15**:64–69.
- Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G et al. (2003) Oleyl ethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature* **425**:90–93.
- Fulp A, Bortoff K, Zhang Y, Snyder R, Fennell T, Marusich JA, Wiley JL, Seltzman H, and Maitra R (2013) Peripherally selective diphenyl purine antagonist of the CB1 receptor. *J Med Chem* **56**:8066–8072.
- Furuhashi M and Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. *Nat Rev Drug Discov* **7**:489–503.
- Gabrielli M, Battista N, Riganti L, Prada I, Antonucci F, Cantone L, Matteoli M, Maccarrone M, and Verderio C (2015) Active endocannabinoids are sequestered on extracellular membrane vesicles. *EMBO Rep* **16**:213–220.
- Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomio M, Stevenson LA, Macchia M, Tuccinardi T, Ghelardini C et al. (2019) Identification of the first synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief. *J Med Chem* **62**:276–287.
- Gagestein B, Stevens AF, Fazio D, Florea BI, van der Wel T, Bakker AT, Fezza F, Dulk HD, Overkleeft HS, Maccarrone M et al. (2022) Chemical proteomics reveals off-targets of the anandamide reuptake inhibitor WOBE437. *ACS Chem Biol* **17**:1174–1183.
- Galiegue S, Mary S, Marchand J, Dussosoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* **232**:54–61.
- Galli JA, Sawaya RA, and Friedenberg FK (2011) Cannabinoid hyperemesis syndrome. *Curr Drug Abuse Rev* **4**:241–249.
- Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, Shen R, Zhang MY, Strassle BW, Lu P et al. (2010) Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. *J Neurosci* **30**:2017–2024.
- Gaoni Y and Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. *J Am Chem Soc* **86**:1646–1647.
- Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, and Thakur GA (2021) Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. *Bioorg Med Chem* **50**:116421.
- García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA, and Muñoz E (2018) EHP-101, an oral formulation of the cannabinoid aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. *Biochem Pharmacol* **157**:304–313.
- Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, Tremblay N, Weech PK, Metters KM, and Labelle M (1996) Structure activity relationships of tetrahydrocannabinol analogs on human cannabinoid receptors. *Bioorg Med Chem Lett* **6**:189–194.
- Gasperi V, Guzzo T, Topai A, Gambacorta N, Ciriaco F, Nicolotti O, and Maccarrone M (2023) Recent advances on type-2 cannabinoid (CB2) receptor agonists and their therapeutic potential. *Curr Med Chem* **30**:1420–1457.
- Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND and Makriyannis A (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. *Life Sci* **61**:191–197.
- Gazzi T, Brennecke B, Atz K, Korn C, Sykes D, Forn-Cuni G, Pfaff P, Sarott RC, Westphal MV, Mostinski Y et al. (2022) Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe. *Chem Sci (Camb)* **13**:5539–5545.
- Gérard C, Mollereau C, Vassart G, and Parmentier M (1990) Nucleotide sequence of a human cannabinoid receptor cDNA. *Nucleic Acids Res* **18**:7142.
- Gérard CM, Mollereau C, Vassart G, and Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. *Biochem J* **279**:129–134.
- Geurts L, Everard A, Van Hul M, Essaghir A, Duparc T, Matamoros S, Plovier H, Castel J, Denis RG, Bergiers M et al. (2015) Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. *Nat Commun* **6**:6495.
- Ghidini A, Scalvini L, Palese F, Lodola A, Mor M, and Piomelli D (2021) Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-acyl ethanolamine acid amidase. *J Enzyme Inhib Med Chem* **36**:1411–1423.
- Giblin GM, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP, Rawlings DA, Goldsmith P, Brown AJ, Haslam CP et al. (2007) Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. *J Med Chem* **50**:2597–2600.
- Gil-Ordóñez A, Martín-Fonchea M, Ortega-Gutiérrez S, and López-Rodríguez ML (2018) Monoacylglycerol lipase (MAGL) as a promising therapeutic target. *Biochem Pharmacol* **157**:18–32.
- Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, and Deutsch DG (2003) Evidence against the presence of an anandamide transporter. *Proc Natl Acad Sci USA* **100**:4269–4274.
- Glaser ST, Kaczocha M, and Deutsch DG (2005) Anandamide transport: a critical review. *Life Sci* **77**:1584–1604.

- Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proc Natl Acad Sci USA* **102**:18620–18625.
- Gobira PH, Oliveira AC, Gomes JS, da Silveira VT, Asth L, Bastos JR, Batista EM, Issy AC, Okine BN, de Oliveira AC et al. (2019) Opposing roles of CB₁ and CB₂ cannabinoid receptors in the stimulant and rewarding effects of cocaine. *Br J Pharmacol* **176**:1541–1551.
- Godlewski G, Offertaler L, Wagner JA, and Kunos G (2009) Receptors for acylethanolamides-GPR55 and GPR119. *Prostagl Other Lipid Med* **89**:105–111.
- Gold A and Zhu J (2022) Not just a gut feeling: a deep exploration of functional bacterial metabolites that can modulate host health. *Gut Microbes* **14**:2125734.
- Gómez-Cañas M, Rodríguez-Cueto C, Satta V, Hernández-Fisac I, Navarro E, and Fernández-Ruiz J (2023) Endocannabinoid-binding receptors as drug targets. *Methods Mol Biol* **2576**:67–94.
- Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J et al. (2006) Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. *J Biol Chem* **281**:28143–28151.
- Goodfellow CE and Glass M (2009) Anandamide receptor signal transduction. *Vitam Horm* **81**:79–110.
- Gorelik A, Gebai A, Illes K, Piomelli D, and Nagar B (2018) Molecular mechanism of activation of the immunoregulatory amidase NAAA. *Proc Natl Acad Sci USA* **115**:E10032–E10040.
- Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson KE, and Hedlund P (2010) Effects of cannabinoil, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. *Eur Urol* **57**:1093–1100.
- Grether U (2022) First disclosure of cannabinoid receptor type 2 agonist RG7774—an innovative oral treatment for diabetic retinopathy. XXVII EFMC International Symposium on Medicinal Chemistry, Nice, France.
- Grevingoed TJ, Trammell SAJ, McKinney MK, Petersen N, Cardone RL, Svenningsen JS, Ogasawara D, Næxø-Larsen CC, Knop FK, Schwartz TW et al. (2019) N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis. *Proc Natl Acad Sci USA* **116**:24770–24778.
- Gruden G, Barutta F, Kunos G, and Pacher P (2016) Role of the endocannabinoid system in diabetes and diabetic complications. *Br J Pharmacol* **173**:1116–1127.
- Guba W, Nazaré M, and Grether U (2020) Natural compounds and synthetic drugs to target type-2 cannabinoid (CB₂) receptor, in *New Tools to Interrogate Endocannabinoid Signaling. From Natural Compounds to Synthetic Drugs* (Maccarrone M, ed) pp 89–167, Royal Society of Chemistry, Cambridge, U.K.
- Guberman M, Kosar M, Omran A, Carreira EM, Nazare M, and Grether U (2022) Reverse design toward optimized labeled chemical probes—examples from the endocannabinoid system. *Chimia (Aarau)* **76**:425–434.
- Gueye AB, Prysławsky Y, Trigo JM, Pouliat N, Delis F, Antoniou K, Loureiro M, Laviolette SR, Vemuri K, Makriyannis A et al. (2016) The CB₁ neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. *Int J Neuropsychopharmacol* **19**:pyw068.
- Guida F, Tureo F, Iannotta M, De Gregorio D, Palumbo I, Sarnelli G, Furiano A, Napolitano F, Boccella S, Luongo L et al. (2018) Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. *Brain Behav Immun* **67**:230–245.
- Guindon J and Hohmann AG (2008) Cannabinoid CB₂ receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. *Br J Pharmacol* **153**:319–334.
- Guo Y, Uyama T, Rahman SMK, Sikder MM, Hussain Z, Tsuboi K, Miyake M, and Ueda N (2021) Involvement of the γ isoform of cPLA₂ in the biosynthesis of bioactive N-acyl ethanolamines. *Molecules* **26**:5213.
- Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, Gossage SJ, van Drimmelen M, Morena M, Houlden H et al. (2019) Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. *Br J Anaesth* **123**:e249–e253.
- Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering TJ, Muri D, Iding H, Bürkler M et al. (2020) Identification and preclinical development of a 2,5,6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors. *J Med Chem* **63**:10287–10306.
- Haj-Dahmane S, Shen R-YY, Elmes MW, Studholme K, Kanjiya MP, Bogdan D, Thanos PK, Miyauchi JT, Tsrirka SE, Deutsch DG et al. (2018) Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses. *Proc Natl Acad Sci USA* **115**:3482–3487.
- Hajdu Z, Nicolussi S, Rau M, Lorántfy L, Forgo P, Hohmann J, Csupor D, and Gertsch J (2014) Identification of endocannabinoid system-modulating N-alkylamides from *Heliosiph helianthoides* var. *scabra* and *Lepidium meyenii*. *J Nat Prod* **77**:1663–1669.
- Han S, Chen JJ, and Chen JZ (2014) Latest progress in the identification of novel synthetic ligands for the cannabinoid CB₂ receptor. *Mini Rev Med Chem* **14**:426–443.
- Han S, Thatte J, Buzard DJ, and Jones RM (2013) Therapeutic utility of cannabinoid receptor type 2 (CB₂) selective agonists. *J Med Chem* **56**:8224–8256.
- Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, Gaïdarov I, Unett DJ, Yoon WH, Barden J et al. (2017) Discovery of APD371: identification of a highly potent and selective CB₂ agonist for the treatment of chronic pain. *ACS Med Chem Lett* **8**:1309–1313.
- Hansen HS and Vana V (2019) Non-endocannabinoid N-acyl ethanolamines and 2-monoacylglycerols in the intestine. *Br J Pharmacol* **176**:1443–1454.
- Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, and Mechoulam R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB₁ receptor. *Proc Natl Acad Sci USA* **98**:3662–3665.
- Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, and Fride E (1999) HU-308: a specific agonist for CB₂, a peripheral cannabinoid receptor. *Proc Natl Acad Sci USA* **96**:14228–14233.
- Hanus LO, Meyer SM, Muñoz E, Tagliatela-Scafati O, and Appendino G (2016) Phytocannabinoids: a unified critical inventory. *Nat Prod Rep* **33**:1357–1392.
- Haruna T, Soga M, Morioka Y, Hikita I, Imura K, Furue Y, Yamamoto M, Imura C, Ikeda M, Yamauchi A et al. (2015) S-77469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission. *Pharmacology* **95**:95–103.
- Haruna T, Soga M, Morioka Y, Imura K, Furue Y, Yamamoto M, Hayakawa J, Deguchi M, Arimura A, and Yasui K (2017) The inhibitory effect of S-77469, a cannabinoid type 2 receptor agonist, on skin inflammation in mice. *Pharmacology* **99**:259–267.
- He X-H, Jordan CJ, Vemuri K, Bi G-H, Zhan J, Gardner EL, Makriyannis A, Wang Y-L, and Xi Z-X (2019) Cannabinoid CB₁ receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. *Acta Pharmacol Sin* **40**:365–373.
- Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj CG, Mechoulam R, Zalsman G, Weller A, and Shoval G (2018) Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. *Behav Brain Res* **351**:1–3.
- Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA* **87**:1932–1936.
- Hernández-Torres G, Cipriano M, Hedén E, Björklund E, Canales Á, Zian D, Feliú A, Mecha M, Guaza C, Fowler CJ et al. (2014) A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. *Angew Chem Int Ed Engl* **53**:13765–13770.
- Hillard CJ and Jarrahian A (2000) The movement of N-arachidonylethanolamine (anandamide) across cellular membranes. *Chem Phys Lipids* **108**:123–134.
- Hillard CJ and Jarrahian A (2003) Cellular accumulation of anandamide: consensus and controversy. *Br J Pharmacol* **140**:802–808.
- Hillard CJ, Edgemond WS, Jarrahian A, and Campbell WB (1997) Accumulation of N-arachidonylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. *J Neurochem* **69**:631–638.
- Hillard CJ, Huang H, Vogt CD, Rodrigues BE, Neumann TS, Sem DS, Schroeder F, and Cunningham CW (2017) Endocannabinoid transport proteins: discovery of tools to study sterol carrier protein-2. *Methods Enzymol* **593**:99–121.
- Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, and Campbell WB (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB₁). *J Pharmacol Exp Ther* **289**:1427–1433.
- Hillard CJ, Shi L, Tuniki VR, Falck JR, and Campbell WB (2007) Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. *J Mol Neurosci* **33**:18–24.
- Hillard CJ, Wilkison DM, Edgemond WS, and Campbell WB (1995) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. *Biochim Biophys Acta* **1257**:249–256.
- Högstätt ED, Jönsson BAG, Ermund A, Andersson DA, Björk H, Alexander JP, Cravatt BF, Basbaum AI, and Zygmunt PM (2005) Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. *J Biol Chem* **280**:31405–31412.
- Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. *Nature* **435**:1108–1112.
- Hollinshead SP, Tidwell MW, Palmer J, Guidetti R, Sanderson A, Johnson MP, Chambers MG, Oskins J, Stratford R, and Astles PC (2013) Selective cannabinoid receptor type 2 (CB₂) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. *J Med Chem* **56**:5722–5733.
- Honda M, Yoshimura N, Kawamoto B, Hikita K, Muraoka K, Shimizu S, Saito M, Chancellor MB, and Takenaka A (2016) Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats. *Int Urol Nephrol* **48**:1407–1412.
- Honer M, Gobbi L, Martarello L, and Comley RA (2014) Radioligand development for molecular imaging of the central nervous system with positron emission tomography. *Drug Discov Today* **19**:1936–1944.
- Hong G, Antaris AL, Dai H (2017) Near-infrared fluorophores for biomedical imaging. *Nat Biomed Eng* **1**:0010.
- Hosseinzadeh Anvar L and Ahmadi-pour A (2023) Fatty acid amide hydrolase C385A polymorphism affects susceptibility to various diseases. *BioFactors* **49**:62–78.
- Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantadol compounds. *Life Sci* **35**:1803–1810.
- Howlett AC and Abood ME (2017) CB₁ and CB₂ receptor pharmacology. *Adv Pharmacol* **80**:169–206.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* **54**:161–202.
- Howlett AC, Johnson MR, and Melvin LS (1990) Classical and nonclassical cannabinoids: mechanism of action—brain binding. *NIDA Res Monogr* **96**:100–111.
- Howlett AC, Johnson MR, Melvin LS, and Milne GM (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. *Mol Pharmacol* **33**:297–302.
- Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, and Deutsch DG (2011) Endocannabinoid tone versus constitutive activity of cannabinoid receptors. *Br Journal Pharmacol* **163**:1329–1343.

- Hryhorowicz S, Kaczmarek-Rys M, Andrzejewska A, Staszak K, Hryhorowicz M, Korcz A, and Słomski R (2019) Allosteric modulation of cannabinoid receptor 1—current challenges and future opportunities. *Int J Mol Sci* **20**:5874.
- Hsu HC, Tong S, Zhou Y, Elmes MW, Yan S, Kaczocha M, Deutsch DG, Rizzo RC, Ojima I, and Li H (2017) The antinociceptive agent SBBF-26 binds to anandamide transporters FABP5 and FABP7 at two different sites. *Biochemistry* **56**:3454–3462.
- Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, and Cravatt BF (2012) DAGL β inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nat Chem Biol* **8**:999–1007.
- Hua T, Li X, Wu L, Iliopoulos-Tsoutsouvas C, Wang Y, Wu M, Shen L, Brust CA, Nikas SP, Song F et al. (2020) Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures. *Cell* **180**:655–665.e18.
- Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB₁. *Nature* **547**:468–471.
- Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A et al. (2016) Crystal structure of the human cannabinoid receptor CB₁. *Cell* **167**:750–762.e14.
- Huang H, McIntosh AL, Martin GG, Dangott LJ, Kier AB, and Schroeder F (2018) Structural and Functional Interaction of Δ^9 -Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). *Biochemistry* **57**:6027–6042.
- Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, Sivakumar R, Coop A, Maeda DY, De Petrocellis L et al. (2001) Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. *J Biol Chem* **276**:42639–42644.
- Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc Natl Acad Sci USA* **99**:8400–8405.
- Huestis MA (2007) Human cannabinoid pharmacokinetics. *Chem Biodivers* **4**:1770–1804.
- Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, and Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB₂ receptor. *J Med Chem* **39**:3875–3877.
- Huggins JP, Smart TS, Langman S, Taylor L, and Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. *Pain* **153**:1837–1846.
- Iannotti FA, Di Marzo V, and Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. *Prog Lipid Res* **62**:107–128.
- Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, and Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. *Neurotherapeutics* **12**:699–730.
- Ibsen MS, Connor M, and Glass M (2017) Cannabinoid CB₁(1) and CB₂(2) receptor signaling and bias. *Cannabis Cannabinoid Res* **2**:48–60.
- Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M et al. (2015) A cannabinoid CB₁ receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. *Neuropsychopharmacology* **40**:2948–2959.
- Ikedo T, Nishida A, Yamano M, and Kimura I (2022) Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. *Pharmacol Ther* **239**:108273.
- Ilyasov AA, Milligan CE, Pharr EP, and Howlett AC (2018) The endocannabinoid system and oligodendrocytes in health and disease. *Front Neurosci* **12**:733.
- Im DS(2021) GPR119 and GPR55 as receptors for fatty acid ethanolamides, oleoylethanolamide and palmitoylethanolamide. *Int J Mol Sci* **22**:1034.
- Inoue M, Tsuboi K, Okamoto Y, Hidaka M, Uyama T, Tsutsumi T, Tanaka T, Ueda N, and Tokumura A (2017) Peripheral tissue levels and molecular species compositions of N-acyl-phosphatidylethanolamine and its metabolites in mice lacking N-acyl-phosphatidylethanolamine-specific phospholipase D. *J Biochem* **162**:449–458.
- Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M et al. (2010) Brain cannabinoid CB₂ receptor in schizophrenia. *Biol Psychiatry* **67**:974–982.
- Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, and Sudo M (2015) Identification of a highly potent and selective CB₂ agonist, RQ-00202730, for the treatment of irritable bowel syndrome. *Bioorg Med Chem Lett* **25**:236–240.
- Iyer MR, Cinar R, Wood CM, Zawatsky CN, Coffey NJ, Kim KA, Liu Z, Katz A, Abdalla J, Hassan SA et al. (2022) Synthesis, biological evaluation, and molecular modeling studies of 3, 4-diarylpiperazine series of compounds as potent, nonbrain penetrant antagonists of cannabinoid-1 (CB₁R) receptor with reduced lipophilicity. *J Med Chem* **65**:2374–2387.
- Jacobson MR, Watts JJ, Boileau I, Tong J, and Mizrahi R (2019) A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis. *Eur Neuropsychopharmacol* **29**:330–348.
- Jain AK, Ryan JR, McMahon FG, and Smith G (1981) Evaluation of intramuscular levonandradol and placebo in acute postoperative pain. *J Clin Pharmacol* **21**(Suppl 1):320S–326S.
- Janero DR, Korde A, and Makriyannis A (2017) Ligand-assisted protein structure (LAPS): an experimental paradigm for characterizing cannabinoid-receptor ligand-binding domains. *Methods Enzymol* **593**:217–235.
- Janssen FJ and van der Stelt M (2016) Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders. *Bioorg Med Chem Lett* **26**:3831–3837.
- Jarrharian A, Manna S, Edgemond WS, Campbell WB, and Hillard CJ (2000) Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. *J Neurochem* **74**:2597–2606.
- Jenniches I, Ternes S, Albayram O, Otte DM, Bach K, Bindila L, Michel K, Lutz B, Bilkei-Gorzo A, and Zimmer A (2016) Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. *Biol Psychiatry* **79**:858–868.
- Jha AK, Sarkar R, Udayan UK, Roy PK, Jha AK, and Chaudhary RKP (2018) Bimatoprost in dermatology. *Indian Dermatol Online J* **9**:224–228.
- Jin XH, Okamoto Y, Morishita J, Tsuboi K, Tonai T, and Ueda N (2007) Discovery and characterization of a Ca²⁺-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. *J Biol Chem* **282**:3614–3623.
- Jing H, Reed A, Ulanovskaya OA, Grigoleit JS, Herbst DM, Henry CL, Li H, Barbas S, Germain J, Masuda K et al. (2021) Phospholipase γ 2 regulates endocannabinoid and eicosanoid networks in innate immune cells. *Proc Natl Acad Sci USA* **118**:e2112971118.
- Johanek LM and Simone DA (2004) Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. *Pain* **109**:432–442.
- Johnson MR, Melvin LS, Althuis TH, Bindra JS, Harbert CA, Milne GM, and Weissman A (1981) Selective and potent analgetics derived from cannabinoids. *J Clin Pharmacol* **21**(Suppl 1):271S–282S.
- Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, and Fowler CJ (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. *Br J Pharmacol* **133**:1263–1275.
- Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C et al. (2014) Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. *Proc Natl Acad Sci USA* **111**:E5420–E5428.
- Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, and Piomelli D (2007) A key role for diacylglycerol lipase- α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. *Mol Pharmacol* **72**:612–621.
- Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K et al. (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun* **3**:1080.
- Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D et al. (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. *Biol Psychiatry* **64**:930–937.
- Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secchi ME, Mascia P, Banziera T, Armirotti A, Bertorelli R et al. (2015) Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. *Neuropsychopharmacology* **40**:2185–2197.
- Kaczocha M and Haj-Dahmane S (2022) Mechanisms of endocannabinoid transport in the brain. *Br J Pharmacol* **179**:4300–4310.
- Kaczocha M, Glaser ST, and Deutsch DG (2009) Identification of intracellular carriers for the endocannabinoid anandamide. *Proc Natl Acad Sci USA* **106**:6375–6380.
- Kaczocha M, Glaser ST, Chae J, Brown DA, and Deutsch DG (2010) Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. *J Biol Chem* **285**:2796–2806.
- Kaczocha M, Hermann A, Glaser ST, Bojesen IN, and Deutsch DG (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. *J Biol Chem* **281**:9066–9075.
- Kaczocha M, Rebecchi MJ, Ralph BP, Teng Y-HG, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC et al. (2014) Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. *PLoS One* **9**:e94200.
- Kaczocha M, Vivieca S, Sun J, Glaser ST, and Deutsch DG (2012) Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. *J Biol Chem* **287**:3415–3424.
- Kale VP, Gibbs S, Taylor JA, Zmarowski A, Novak J, Patton K, Sparrow B, Gorospe J, Anand S, Cinar R et al. (2019) Preclinical toxicity evaluation of JD5037, a peripherally restricted CB₁ receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis. *Regul Toxicol Pharmacol* **109**:104483.
- Kalliomäki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, and Segerdahl M (2013) Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. *Clin Exp Pharmacol Physiol* **40**:212–218.
- Kano M, Ohno-Shosaku T, Hashimoto-dani Y, Uchigashima M, and Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. *Physiol Rev* **89**:309–380.
- Kantae V, Ogino S, Noga M, Harms AC, van Dongen RM, Onderwater GL, van den Maagdenberg AM, Terwindt GM, van der Stelt M, Ferrari MD et al. (2017) Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. *J Lipid Res* **58**:615–624.
- Karst M, Salim K, Burstein S, Conrad I, Hoy L, and Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA* **290**:1757–1762.
- Katayama K, Ueda N, Katoh I, and Yamamoto S (1999) Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. *Biochim Biophys Acta* **1440**:205–214.
- Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, and Kato I (1997) Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. *Biochim Biophys Acta* **1347**:212–218.
- Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med* **9**:76–81.
- Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J, Webb M, Karbarz MJ, Brown S, Wilson S et al. (2008) Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. *Bioorg Med Chem Lett* **18**:4838–4843.
- Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. *Pharmacol Rev* **62**:265–304.
- Kendall DA and Yudowski GA (2016) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. *Front Cell Neurosci* **10**:294.

- Kerbrat A, Ferré J-C, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit J-Y, Le Tulzo Y et al. (2016) Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. *N Engl J Med* **375**:1717–1725.
- Khan H, Ghori FK, Ghani U, Javed A, and Zahid S (2022) Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis. *Mol Biol Rep* **49**:5117–5131.
- Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, Meng Z, Fan P, and Makriyannis A (1996) Head group analogs of arachidonyl ethanolamide, the endogenous cannabinoid ligand. *J Med Chem* **39**:4515–4519.
- Khasabova IA, Gable J, Johns M, Khasabov SG, Kalyuzhny AE, Golovko MY, Golovko SA, Kiven S, Gupta K, Seybold VS et al. (2023) Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease. *Haematologica* **108**:859–869.
- Khurana L, Mackie K, Piomelli D, and Kendall DA (2017) Modulation of CB1 cannabinoid receptor by allosteric ligands: pharmacology and therapeutic opportunities. *Neuropharmacology* **124**:3–12.
- Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, and Omura H (2008) Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. *J Pharmacol Sci* **106**:219–224.
- Kilaru A and Chapman KD (2020) The endocannabinoid system. *Essays Biochem* **64**:485–499.
- Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, and Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. *J Pharmacol Exp Ther* **330**:902–910.
- Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, and Sugiura T (2005) Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. *J Biochem* **137**:217–223.
- Klein TW and Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. *J Neuroimmune Pharmacol* **1**:50–64.
- Kleyer J, Nicolussi S, Taylor P, Simonelli D, Furger E, Anderle P, and Gertsch J (2012) Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. *Biochem Pharmacol* **83**:1393–1412.
- Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE, Yekhtin Z, Feldmann M, Gallily R, and Mechoulam R (2021) Novel CBG derivatives can reduce inflammation, pain and obesity. *Molecules* **26**:5601–5617.
- Kosiakova H, Berdyshev A, Dosenko V, Drevytska T, Herasymenko O, and Hula N (2022) The involvement of peroxisome proliferator-activated receptor gamma (PPARγ) in anti-inflammatory activity of *N*-stearoyl ethanolamine. *Heliyon* **8**:e11336.
- Krishna Kumar K, Shalev-Benami M, Robertson MJ, Hu H, Banister SD, Hollingsworth SA, Latorra NR, Kato HE, Hilger D, Maeda S et al. (2019) Structure of a signaling cannabinoid receptor 1-G protein complex. *Cell* **176**:448–458.e12.
- Lacroix S, Pechereau F, Leblanc N, Boubertakh B, Houde A, Martin C, Flamand N, Silvestri C, Raymond F, Di Marzo V et al. (2019) Rapid and concomitant gut microbiota and endocannabinoidome response to diet-induced obesity in mice. *mSystems* **4**:e00407–e00419.
- Lago-Fernandez A, Zarzo-Arias S, Jagerovic N, and Morales P (2021) Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. *Int J Mol Sci* **22**:1001.
- Lambert DM and Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. *J Med Chem* **48**:5059–5087.
- Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, and Makriyannis A (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. *J Med Chem* **42**:769–776.
- Laprairie RB, Bagher AM, Kelly ME, and Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol* **172**:4790–4805.
- Laprairie RB, Bagher AM, Kelly ME, and Denovan-Wright EM (2016) Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. *Mol Pharmacol* **89**:364–375.
- Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, and Lunn CA (2005) Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. *Bioorg Med Chem Lett* **15**:783–786.
- Lee HL, Jung KM, Fotio Y, Squire E, Palese F, Lin L, Torrens A, Ahmed F, Mabou Tagne A, Ramirez J et al. (2022) Frequent low-dose Δ9-tetrahydrocannabinol in adolescence disrupts microglia homeostasis and disables responses to microbial infection and social stress in young adulthood. *Biol Psychiatry* **92**:845–860.
- Lee SA, Yang KJZ, Brun P-J, Silvaroli JA, Yuen JJ, Shmarakov I, Jiang H, Feranil JB, Li X, Lackey AI et al. (2020) Retinol-binding protein 2 (RBP2) binds monoacylglycerols and modulates gut endocrine signaling and body weight. *Sci Adv* **6**:eaay8937.
- Lee Y, Jo J, Chung HY, Pothoulakis C, and Im E (2016) Endocannabinoids in the gastrointestinal tract. *Am J Physiol Gastrointest Liver Physiol* **311**:G655–G666.
- Lefort C, Roumain M, Van Hul M, Rastelli M, Manco R, Leclercq I, Delzenne NM, Marzo VD, Flamand N, Luquet S et al. (2020) Hepatic NAPE-PLD is a key regulator of liver lipid metabolism. *Cells* **9**:1247.
- Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, and Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. *Br J Pharmacol* **141**:253–262.
- Lei Q, Yu Z, Li H, Cheng J, and Wang Y (2022) Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway. *J Adv Res* **40**:197–206.
- Leishman E, Mackie K, Luquet S, and Bradshaw HB (2016) Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. *Biochim Biophys Acta* **1861**:491–500.
- Lemberger L and Rowe H (1975) Clinical pharmacology of nabilone, a cannabinoid derivative. *Clin Pharmacol Ther* **18**:720–726.
- Leo LM and Abood ME (2021) CB1 cannabinoid receptor signaling and biased signaling. *Molecules* **26**:5413.
- Leung D, Saghatelian A, Simon GM, and Cravatt BF (2006) Inactivation of *N*-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. *Biochemistry* **45**:4720–4726.
- Leung K, Elmes MW, Glaser ST, Deutsch DG, and Kaczocha M (2013) Role of FAAH-like anandamide transporter in anandamide inactivation. *PLoS One* **8**:e79355.
- Li D, Ihnysky Y, Ghasemi Gojani E, Kovalchuk O, and Kovalchuk I (2022) Analysis of anti-cancer and anti-inflammatory properties of 25 high-THC cannabis extracts. *Molecules* **27**:6057.
- Li X, Chang H, Bouma J, de Paus LV, Mukhopadhyay P, Paloczi J, Mustafa M, van der Horst C, Kumar SS, Wu L et al. (2023) Structural basis of selective cannabinoid CB2 receptor activation. *Nat Commun* **14**:1447.
- Li X, Hua T, Vemuri K, Ho JH, Wu Y, Wu L, Popov P, Benchama O, Zvonok N, Locke K et al. (2019) Crystal structure of the human cannabinoid receptor CB2. *Cell* **176**:459–467.
- Liang L, Takamiya R, Miki Y, Heike K, Taketomi Y, Sugimoto N, Yamaguchi M, Shitara H, Nishito Y, Kobayashi T et al. (2022) Group IVE cytosolic phospholipase A₂ limits psoriatic inflammation by mobilizing the anti-inflammatory lipid *N*-acylethanolamine. *FASEB J* **36**:e22301.
- Liedhegner ES, Vogt CD, Sem DS, Cunningham CW, and Hillard CJ (2014) Sterol carrier protein-2: binding protein for endocannabinoids. *Mol Neurobiol* **50**:149–158.
- Ligresti A, De Petrocellis L, and Di Marzo V (2016) From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. *Physiol Rev* **96**:1593–1659.
- Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G, and Di Marzo V (2004) Further evidence for the existence of a specific process for the membrane transport of anandamide. *Biochem J* **380**:265–272.
- Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, and Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. *Br J Pharmacol* **161**:336–349.
- Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, and Crippa JA (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. *Br J Psychiatry* **41**:9–14.
- Ling X, Zhang S, Shao P, Li W, Yang L, Ding Y, Xu C, Stella N, and Bai M (2015) A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R. *Biomaterials* **57**:169–178.
- Linhorst A and Lübke T (2022) The human Ntn-hydrolase superfamily: structure, functions and perspectives. *Cells* **11**:1592.
- Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, and Kunos G (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. *Biochem J* **346**:835–840.
- Liu Z, Yang N, Dong J, Tian W, Chang L, Ma J, Guo J, Tan J, Dong A, He K et al. (2022) Deficiency in endocannabinoid synthase DAGLB contributes to early onset parkinsonism and murine nigral dopaminergic neuron dysfunction. *Nat Commun* **13**:3490.
- Llorente-Berzal A, Terzian AL, di Marzo V, Micale V, Viveros MP, and Wotjak CT (2015) 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. *Psychopharmacology (Berl)* **232**:2811–2825.
- Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, and Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol Pharmacol* **67**:15–19.
- Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol* **5**:37–44.
- Long T, Wagner M, Demske D, Leipe C, and Tarasov PE (2017) Cannabis in Eurasia: origin of human use and Bronze Age trans-continental connections. *Veg Hist Archaeobot* **26**:245–258.
- López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Fowler CJ, Tiger G, de Lago E, Fernández-Ruiz J, and Ramos JA (2003a) Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. *Eur J Med Chem* **38**:403–412.
- López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Fowler CJ, Tiger G, de Lago E, Fernández-Ruiz J, and Ramos JA (2003b) Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. *J Med Chem* **46**:1512–1522.
- López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Lastres-Becker I, González S, Fernández-Ruiz J, and Ramos JA (2001) Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. *J Med Chem* **44**:4505–4508.
- Lötsch J, Weyer-Menkhoff I, and Tegeder I (2018) Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. *Eur J Pain* **22**:471–484.
- Lu Y and Anderson HD (2017) Cannabinoid signaling in health and disease. *Can J Physiol Pharmacol* **95**:311–327.
- Lutz B (2020) Neurobiology of cannabinoid receptor signaling. *Dialogues Clin Neurosci* **22**:207–222.
- Lynch A, Tammireddy SR, Doherty MK, Whitfield PD, and Clarke DJ (2019) The glycine lipids of *Bacteroides thetaiotaomicron* are important for fitness during growth in vivo and in vitro. *Appl Environ Microbiol* **85**:e02157–e18.
- Lynn AB and Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. *J Pharmacol Exp Ther* **268**:1612–1623.
- Maccarrone M (2017) Metabolism of the endocannabinoid anandamide: open questions after 25 years. *Front Mol Neurosci* **10**:166.
- Maccarrone M (2020) Missing pieces to the endocannabinoid puzzle. *Trends Mol Med* **26**:263–272.
- Maccarrone M (2023) Deciphering complex interactions in bioactive lipid signaling. *Molecules* **28**:2622.

- Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P et al. (2015) Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci* **36**:277–296.
- Maccarrone M, Bari M, Battista N, and Finazzi-Agrò A (2002) Estrogen stimulates arachidonylethanolamide release from human endothelial cells and platelet activation. *Blood* **100**:4040–4048.
- Maccarrone M, Dainese E, and Oddi S (2010) Intracellular trafficking of anandamide: new concepts for signaling. *Trends Biochem Sci* **35**:601–608.
- Maccarrone M, De Chiara V, Gasperi V, Viscomi MT, Rossi S, Oddi S, Molinari M, Musella A, Finazzi-Agrò A, and Centonze D (2009) Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. *J Neurochem* **109**:371–381.
- Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agrò A, and Ascoli F (2000) Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. *FEBS Lett* **468**:176–180.
- Maccarrone M, Guzmán M, Mackie K, Doherty P, and Harkany T (2014) Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. *Nat Rev Neurosci* **15**:786–801.
- Maccarrone M, Maldonado R, Casas M, Henze T, and Centonze D (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? *Expert Rev Clin Pharmacol* **10**:443–455.
- Maccarrone M, Rapino C, Francavilla F, and Barbonetti A (2021) Cannabinoid signalling and effects of cannabis on the male reproductive system. *Nat Rev Urol* **18**:19–32.
- Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agrò A et al. (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. *Nat Neurosci* **11**:152–159.
- Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegthart JFG, and Agrò AF (1998) Anandamide hydrolysis by human cells in culture and brain. *J Biol Chem* **273**:32332–32339.
- Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. *Handb Exp Pharmacol* **168**:299–325.
- Mackie K (2008) Signaling via CNS cannabinoid receptors. *Mol Cell Endocrinol* **286**(1–2, Suppl 1):S60–S65.
- Mäder P, Bartholomäus R, Nicolussi S, Baumann A, Weis M, Chicca A, Rau M, Simão AC, Gertsch J, and Altmann KH (2021) Synthesis and biological evaluation of endocannabinoid uptake inhibitors derived from WOBE437. *ChemMedChem* **16**:145–154.
- Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, and Garau G (2015) Structure of human *N*-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. *Structure* **23**:598–604.
- Maione S, Costa B, and Di Marzo V (2013) Endocannabinoids: a unique opportunity to develop multitarget analgesics. *Pain* **154**(Suppl 1):S87–S93.
- Malamas MS, Farah SI, Lamani M, Peleoudas DN, Perry NT, Rajarshi G, Miyabe CY, Chandrashekar H, West J, Pavlopoulos S et al. (2020) Design and synthesis of cyanamides as potent and selective *N*-acylethanolamine acid amidase inhibitors. *Bioorg Med Chem* **28**:115195.
- Mallat A and Lotersztajn S (2008) Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. *Am J Physiol Gastrointest Liver Physiol* **294**:G9–G12.
- Mallipeddi S, Kreimer S, Zvonok N, Vemuri K, Karger BL, Ivanov AR, and Makriyannis A (2017) Binding site characterization of AM1336, a novel covalent inverse agonist at human cannabinoid 2 receptor, using mass spectrometric analysis. *J Proteome Res* **16**:2419–2428.
- Manca C, Shen M, Boubertakh B, Martin C, Flamand N, Silvestri C, and Di Marzo V (2020a) Alterations of brain endocannabinoidome signaling in germ-free mice. *Biochim Biophys Acta Mol Cell Biol Lipids* **1865**:158786.
- Manca C, Boubertakh B, Leblanc N, Deschênes T, Lacroix S, Martin C, Houde A, Veilleux A, Flamand N, Muccioli GG et al. (2020b) Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. *J Lipid Res* **61**:70–85.
- Manning JJ, Green HM, Glass M, and Finlay DB (2021) Pharmacological selection of cannabinoid receptor effectors: signalling, allosteric modulation and bias. *Neuropharmacology* **193**:108611.
- Marchalant Y, Brownjohn PW, Bonnet A, Kleffmann T, and Ashton JC (2014) Validating antibodies to the cannabinoid CB2 receptor: antibody sensitivity is not evidence of antibody specificity. *J Histochem Cytochem* **62**:395–404.
- Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G et al. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. *Nat Neurosci* **13**:951–957.
- Marsicano G and Lutz B (2006) Neuromodulatory functions of the endocannabinoid system. *J Endocrinol Invest* **29**(3, Suppl):27–46.
- Martella A, Sijben H, Rufer AC, Grether U, Fingerle J, Ullmer C, Hartung T, Jzerman AP, van der Stelt M, and Heitman LH (2017) A novel selective inverse agonist of the CB₂ receptor as a radiolabeled tool compound for kinetic binding studies. *Mol Pharmacol* **92**:389–400.
- Martellotta MC, Cossu G, Fattore L, Gessa GL, and Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naïve mice. *Neuroscience* **85**:327–330.
- Martin GG, Landrock D, Chung S, Dangott LJ, Seeger DR, Murphy EJ, Golovko MY, Kier AB, and Schroeder F (2017) Fcbp1 gene ablation inhibits high-fat diet-induced increase in brain endocannabinoids. *J Neurochem* **140**:294–306.
- Martin GG, Seeger DR, McIntosh AL, Milligan S, Chung S, Landrock D, Dangott LJ, Golovko MY, Murphy EJ, Kier AB et al. (2019) Sterol carrier protein-2/sterol carrier protein-x/fatty acid binding protein-1 ablation impacts response of brain endocannabinoid to high-fat diet. *Lipids* **54**:583–601.
- Martin-Couce L, Martín-Fontecha M, Palomares O, Mestre L, Cordomi A, Hernangomez M, Palma S, Pardo L, Guaza C, López-Rodríguez ML et al. (2012) Chemical probes for the recognition of cannabinoid receptors in native systems. *Angew Chem Int Ed Engl* **51**:6896–6899.
- Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Verá C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X et al. (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB₂ receptors. *Front Pharmacol* **8**:744.
- Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, and Parolaro D (2008) 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* **104**:1091–1100.
- Masson J, Sagné C, Hamon N, and El Mestikawy S (1999) Neurotransmitter transporters in the central nervous system. *Pharmacol Rev* **51**:439–464.
- Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, Marcello S, Murineddu G, and Lazzari P (2013) NESS06SM reduces body weight with an improved profile relative to SR141716A. *Pharmacol Res* **74**:94–108.
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* **346**:561–564.
- Mauler F, Hinz V, Augstein KH, Fassbender M, and Horváth E (2003) Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. *Brain Res* **989**:99–111.
- Mauler F, Mittendorf J, Horváth E, and De Vry J (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxo)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. *J Pharmacol Exp Ther* **302**:359–368.
- McGilveray IJ (2005) Pharmacokinetics of cannabinoids. *Pain Res Manag* **10**(Suppl A):15A–22A.
- McKinney MK and Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. *Annu Rev Biochem* **74**:411–432.
- McPartland JM, Duncan M, Di Marzo V, and Pertwee RG (2015) Are cannabidiol and Δ(9)-tetrahydrocannabinol negative modulators of the endocannabinoid system? A systematic review. *Br J Pharmacol* **172**:737–753.
- McReynolds JR, Doncheck EM, Li Y, Vranjkovic O, Graf EN, Ogasawara D, Cravatt BF, Baker DA, Liu QS, Hillard CJ et al. (2018) Stress promotes drug seeking through glucocorticoid-dependent endocannabinoid mobilization in the prefrontal cortex. *Biol Psychiatry* **84**:85–94.
- Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. *Br J Pharmacol* **146**:913–915.
- Mechoulam R (2023) A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. *Annu Rev Pharmacol Toxicol* **63**:1–13. 10.1146/annurev-pharmtox-051921-083709.
- Mechoulam R and Gaoni Y (1967) The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. *Tetrahedron Lett* **12**:1109–1111.
- Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* **50**:83–90.
- Mechoulam R, Hanus L, and Frider E (1998) Towards cannabinoid drugs—revisited. *Prog Med Chem* **35**:199–243.
- Mehrpoura-Bahrami P, Chitralla KN, Ganewatta MS, Tang C, Murphy EA, Enos RT, Velazquez KT, McCellan J, Nagarkatti M, and Nagarkatti P (2017) Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. *Sci Rep* **7**:15645.
- Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, and Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. *J Neurosci* **24**:53–62.
- Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, and Howlett AC (1993) Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. *Mol Pharmacol* **44**:1008–1015.
- Melvin LS, Milne GM, Johnson MR, Wilken GH, and Howlett AC (1995) Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. *Drug Des Discov* **13**:155–166.
- Migliore M, Pontis S, Fuentes de Arriba AL, Realini N, Torrente E, Armirotti A, Romeo E, Di Martino S, Russo D, Pizzirani D et al. (2016) Second-generation non-covalent NAAA inhibitors are protective in a model of multiple sclerosis. *Angew Chem Int Ed Engl* **55**:11193–11197.
- Milani M, Kamtekar S, Wood DC, Benson TE, Cravatt BF, and Stevens RC (2010) Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. *J Mol Biol* **400**:743–754.
- Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo FM, Offertaler L, Pacher P, Kunos G et al. (2006) *N*-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. *Proc Natl Acad Sci USA* **103**:2428–2433.
- Miralpeix C, Reguera AC, Fosch A, Zagmutt S, Casals N, Cota D, and Rodríguez-Rodríguez R (2021) Hypothalamic endocannabinoids in obesity: an old story with new challenges. *Cell Mol Life Sci* **78**:7469–7490.
- Mirlohi S, Bladen C, Santiago MJ, Arnold JC, McGregor I, and Connor M (2022) Inhibition of human recombinant T-type calcium channels by phytocannabinoids in vitro. *Br J Pharmacol* **179**:4031–4043.
- Misto A, Provensi G, Vozella V, Passani MB, and Piomelli D (2019) Mast cell-derived histamine regulates liver ketogenesis via oleoylethanolamide signaling. *Cell Metab* **29**:91–102.e5.
- Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J et al. (2020) Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. *Nat Chem Biol* **16**:667–675.

- Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D et al. (2005) Identification of a high-affinity binding site involved in the transport of endocannabinoids. *Proc Natl Acad Sci USA* **102**:17852–17857.
- Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, and Piomelli D (2004) Cyclohexylcarbamate acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. *J Med Chem* **47**:4998–5008.
- Morales P and Reggio PH (2017) An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. *Cannabis Cannabinoid Res* **2**:265–273.
- Morales P, Hernandez-Folgado L, Goya P, and Jagerovic N (2016) Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. *Expert Opin Ther Pat* **26**:843–856.
- Morales P, Hurst DP, and Reggio PH (2017) Molecular targets of the phytocannabinoids: a complex picture. *Prog Chem Org Nat Prod* **103**:103–131.
- Morales P, Lago-Fernandez A, Hurst DP, Sotudne N, Brailoiu E, Reggio PH, Abood ME, and Jagerovic N (2020) Therapeutic exploitation of GPR18: beyond the cannabinoids? *J Med Chem* **63**:14216–14227.
- Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, and Cani PD (2010) The endocannabinoid system links gut microbiota to adipogenesis. *Mol Syst Biol* **6**:392.
- Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T et al. (2016) The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. *Br J Pharmacol* **173**:446–458.
- Mukhopadhyay P, Pan H, Rajesh M, Bátkai S, Patel V, Harvey-White J, Mukhopadhyay B, Haskó G, Gao B, Mackie K et al. (2010b) CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. *Br J Pharmacol* **160**:657–668.
- Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Bátkai S, Gao B, Haskó G, and Pacher P (2010a) Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. *Free Radic Biol Med* **48**:457–467.
- Mukhopadhyay S, Shim JY, Assi AA, Norford D, and Howlett AC (2002) CB1 cannabinoid receptor-G protein association: a possible mechanism for differential signaling. *Chem Phys Lipids* **121**:91–109.
- Muller C, Morales P, and Reggio PH (2019) Cannabinoid ligands targeting TRP channels. *Front Mol Neurosci* **11**:487.
- Müller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, and Schindler C (2021) Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. *Mov Disord* **36**:2413–2418.
- Müller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, and Schindler C (2022) Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: a phase 1 randomized, placebo-controlled study. *Pharmacopsychiatry* **55**:148–156.
- Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**:61–65.
- Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, and Di Marzo V (2013) The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats. *Physiol Behav* **109**:88–95.
- Nackley AG, Makriyannis A, and Hohmann AG (2003) Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. *Neuroscience* **119**:747–757.
- Nagappan A, Shin J, and Jung MH (2019) Role of cannabinoid receptor type 1 in insulin resistance and its biological implications. *Int J Mol Sci* **20**:2019.
- Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, and Brown DL (2008) MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. *Br J Pharmacol* **155**:1104–1116.
- Nakamura Y, Dryanovskii DI, Kimura Y, Jackson SN, Woods AS, Yasui Y, Tsai S-Y, Patel S, Covey DP, Su T-P et al. (2019) Cocaine-induced endocannabinoid signaling mediated by sigma-1 receptors and extracellular vesicle secretion. *eLife* **8**:e47209.
- National Academies of Sciences, Engineering, and Medicine (2017) *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: National Academies Press. <https://doi.org/10.17226/24625>
- Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G et al. (2018) Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. *J Neuroinflammation* **15**:64.
- Navarro G, Varani K, Lillo A, Vincenzi F, Rivas-Santesteban R, Raich I, Reyes-Resina I, Ferreira-Verca C, Borea PA, Sánchez de Medina V et al. (2020) Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB₁, CB₂ and CB₁/CB₂ heteromer receptors. *Pharmacol Res* **159**:104940.
- Nettekoven M, Adam JM, Bendels S, Bissantz C, Fingerle J, Grether U, Grüner S, Guba W, Kimbara A, Ottaviani G et al. (2016) Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases. *ChemMedChem* **11**:179–189.
- Nettekoven M, Fingerle J, Grether U, Grüner S, Kimbara A, Püllmann B, Rogers-Evans M, Röver S, Schuler F, Schulz-Gasch T et al. (2013) Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-throughput screening. *Bioorg Med Chem Lett* **23**:1177–1181.
- Nicolussi S (2014) Identification and characterization of potent and selective inhibitors of endocannabinoid uptake. *GCB Grad Sch Univ Bern, Switz* **14**:1–173.
- Nicolussi S and Gertsch J (2015) Endocannabinoid transport revisited. *Vitam Horm* **98**:441–485.
- Nicolussi S, Chicca A, Rau M, Rihs S, Soeberdt M, Abels C, and Gertsch J (2014a) Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent. *Biochem Pharmacol* **92**:669–689.
- Nicolussi S, Viveros-Paredes JM, Gachet MS, Rau M, Flores-Soto ME, Blunder M, and Gertsch J (2014b) Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. *Pharmacol Res* **80**:52–65.
- Niphakis MJ, Cognetta 3rd AB, Chang JW, Buczynski MW, Parsons LH, Byrne F, Burston JJ, Chapman V, and Cravatt BF (2013) Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. *ACS Chem Neurosci* **4**:1322–1332.
- Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, and Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* **140**:49–61.
- Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B et al. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *Science* **334**:809–813.
- O'Brien LD, Limebeer CL, Rock EM, Bottegoni G, Piomelli D, and Parker LA (2013) Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (*Suncus murinus*). *Br J Pharmacol* **170**:1130–1136.
- O'Sullivan SE (2016) An update on PPAR activation by cannabinoids. *Br J Pharmacol* **173**:1899–1910.
- Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M et al. (2012) Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. *Bioorg Med Chem Lett* **22**:2803–2806.
- Oddi S, Fezza F, Catanzaro G, De Simone C, Pucci M, Piomelli D, Finazzi-Agrò A, and Maccarrone M (2010) Pitfalls and solutions in assaying anandamide transport in cells. *J Lipid Res* **51**:2435–2444.
- Oddi S, Fezza F, Pasquariello N, D'Agostino A, Catanzaro G, De Simone C, Rapino C, Finazzi-Agrò A, and Maccarrone M (2009) Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. *Chem Biol* **16**:624–632.
- Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E, Finazzi-Agrò A, and Maccarrone M (2008) Evidence for the intracellular accumulation of anandamide in adiposomes. *Cell Mol Life Sci* **65**:840–850.
- Oddi S, Scipioni L, and Maccarrone M (2020) Endocannabinoid system and adult neurogenesis: a focused review. *Curr Opin Pharmacol* **50**:25–32.
- Oddi S, Stepniwski TM, Totaro A, Selent J, Scipioni L, Dufresne B, Fezza F, Dainese E, and Maccarrone M (2017) Palmitoylation of cysteine 415 of CB₁ receptor affects ligand-stimulated internalization and selective interaction with membrane cholesterol and caveolin 1. *Biochim Biophys Acta Mol Cell Biol Lipids* **1862**:523–532.
- Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E et al. (2006) Peripheral cannabinoid receptor, CB₂, regulates bone mass. *Proc Natl Acad Sci USA* **103**:696–701.
- Ogasawara D, Deng H, Viader A, Baggelaar MP, Breman A, den Dulk H, van den Nieuwendijk AM, Soethoudt M, van der Wel T, Zhou J et al. (2016) Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition. *Proc Natl Acad Sci USA* **113**:26–33.
- Ogura Y, Parsons WH, Kamat SS, and Cravatt BF (2016) A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. *Nat Chem Biol* **12**:669–671.
- Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, Toda Y, and Saito S (2007) N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability. *Bioorg Med Chem Lett* **17**:6299–6304.
- Okamoto Y, Morishita J, Tsuboi K, Tonai T, and Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. *J Biol Chem* **279**:5298–5305.
- Ortar G, Cascio MG, Moriello AS, Camalli M, Morera E, Nalli M, and Di Marzo V (2008) Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical reevaluation. *Eur J Med Chem* **43**:62–72.
- Ortar G, Ligresti A, De Petrocellis L, Morera E, and Di Marzo V (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. *Biochem Pharmacol* **65**:1473–1481.
- Ortega-Gutiérrez S, Hawkins EG, Viso A, López-Rodríguez ML, and Cravatt BF (2004) Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. *Biochemistry* **43**:8184–8190.
- Oyagawa CRM, de la Harpe SM, Saroz Y, Glass M, Vernall AJ, and Grimsey NL (2018) Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. *Front Pharmacol* **9**:1202.
- Pacher P and Kunos G (2013) Modulating the endocannabinoid system in human health and disease—successes and failures. *FEBS J* **280**:1918–1943.
- Pacher P and Gao B (2008) Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. *Am J Physiol Gastrointest Liver Physiol* **294**:G850–G854.
- Pacher P and Haskó G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. *Br J Pharmacol* **153**:252–262.
- Pacher P and Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? *Prog Lipid Res* **50**:193–211.
- Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* **58**:389–462.
- Pacher P, Kogan NM, and Mechoulam R (2020) Beyond THC and Endocannabinoids. *Annu Rev Pharmacol Toxicol* **60**:637–659.

- Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, and Kunos G (2008) Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. *Hypertension* **52**:601–607.
- Pacioni G, Rapino C, Zarivi O, Falconi A, Leonardi M, Battista N, Colafarina S, Sergi M, Bonfigli A, Miranda M et al. (2015) Truffles contain endocannabinoid metabolic enzymes and anandamide. *Phytochemistry* **110**:104–110.
- Pagano Zottola AC, Severi I, Cannich A, Ciofi P, Cota D, Marsicano G, Giordano A, and Bellocchio L (2022) Expression of functional cannabinoid type-1 (CB1) receptor in mitochondria of white adipocytes. *Cells* **11**:2582.
- Pagé D, Balaux E, Boisvert L, Liu Z, Milburn C, Tremblay M, Wei Z, Woo S, Luo X, Cheng YX et al. (2008) Novel benzimidazole derivatives as selective CB2 agonists. *Bioorg Med Chem Lett* **18**:3695–3700.
- Pagé D, Wei Z, Liu Z, Tremblay M, Desfosses H, Milburn C, Srivastava S, Yang H, Brown W, Walpole C et al. (2010) 5-Sulfonamide benzimidazoles: a class of cannabinoid receptors agonists with potent in vivo antinociception activity. *Letts Drug Des Discov* **7**:208–213.
- Palese F, Pontis S, Realini N, Torrens A, Ahmed F, Assogna F, Pellicano C, Bossù P, Spalletta G, Green K et al. (2022) Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. *Pharmacol Res* **182**:106338.
- Pandey P, Roy KK, and Doerksen RJ (2020) Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. *J Biomol Struct Dyn* **38**:32–47.
- Parker LA, Rock EM, and Limebeer CL (2011) Regulation of nausea and vomiting by cannabinoids. *Br J Pharmacol* **163**:1411–1422.
- Patel S, Hill MN, Cheer JF, Wotjak CT, and Holmes A (2017) The endocannabinoid system as a target for novel anxiolytic drugs. *Neurosci Biobehav Rev* **76** (Pt A): 56–66.
- Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, and Chaplan SR (2021) The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. *Neuropsychopharmacology* **46**:1011–1019.
- Peng X, Studholme K, Kanjiya MP, Luk J, Bogdan D, Elmes MW, Carbonetti G, Tong S, Gary Teng YH, Rizzo RC et al. (2017) Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms. *Mol Pain* **13**:1744806917697007.
- Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. *Curr Med Chem* **6**:635–664.
- Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. *Gut* **48**:859–867.
- Pertwee RG (2002) Cannabinoids and multiple sclerosis. *Pharmacol Ther* **95**:165–174.
- Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. *Life Sci* **76**:1307–1324.
- Pertwee RG (2008a) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol* **153**:199–215.
- Pertwee RG (2008b) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. *Addict Biol* **13**:147–159.
- Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. *Philos Trans R Soc Lond B Biol Sci* **367**:3353–3363.
- Pertwee RG (2014) *Handbook of Cannabis*. Oxford University press, Oxford, U.K.
- Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. *Pharmacol Rev* **62**:588–631.
- Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, Smoum R, Parker LA, and Mechoulam R (2018) Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT_{1A} receptor-mediated suppression of nausea and anxiety in rats. *Br J Pharmacol* **175**:100–112.
- Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, and Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. *Br J Pharmacol* **105**:980–984.
- Petitot F, Jeantaud B, Reibaud M, Imperato A, and Dubroeuq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. *Life Sci* **63**:PL1–PL6.
- Petitot F, Marin L, and Doble A (1996) Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. *Neuroreport* **7**:789–792.
- Petrosino S and Di Marzo V (2017) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. *Br J Pharmacol* **174**:1349–1365.
- Petrosino S, Schiano Moriello A, Verde R, Allarà M, Imperatore R, Ligresti A, Mahmoud AM, Peritore AF, Iannotti FA, and Di Marzo V (2019) Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. *J Neuroinflammation* **16**:274.
- Petrov RR, Ferrini ME, Jaffar Z, Thompson CM, Roberts K, and Diaz P (2011) Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells. *Bioorg Med Chem Lett* **21**:5859–5862.
- Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, and Gertsch J (2017) Peppan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. *Sci Rep* **7**:9560.
- Pharma Intelligence (2022) Olorinab. Arena cannabinoid pain compound misses in phase IIb IBS trial. Scrip, informa.com (accessed October 2022).
- Piazza PV, Cota D, and Marsicano G (2017) The CB1 receptor as the cornerstone of exostasis. *Neuron* **93**:1252–1274.
- Piomelli D (2003) The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* **4**:873–884.
- Piomelli D and Mabou Tagne A (2022) Endocannabinoid-based therapies. *Annu Rev Pharmacol Toxicol* **62**:483–507.
- Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie X-Q, and Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. *Proc Natl Acad Sci USA* **96**:5802–5807.
- Piomelli D, Scalvini L, Fotio Y, Lodola A, Spadoni G, Tarzia G, and Mor M (2020) N-acylethanolamine acid amidase (NAAA): structure, function, and inhibition. *J Med Chem* **63**:7475–7490.
- Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS, Grinari M, Banni S et al. (2011) Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. *Nutr Metab (Lond)* **8**:51.
- Piscitelli F, Guida F, Luongo L, Iannotti FA, Boccella S, Verde R, Lauritano A, Imperatore R, Smoum R, Cristino L et al. (2020) Protective effects of N-oleoylglycine in a mouse model of mild traumatic brain injury. *ACS Chem Neurosci* **11**:1117–1128.
- Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, and Wadleigh RG (1991) Recent clinical experience with dronabinol. *Pharmacol Biochem Behav* **40**:695–700.
- Plau J, Golczak M, Paik J, Calderon RM, and Blaner WS (2022) Retinol-binding protein 2 (RBP2): More than just dietary retinoid uptake. *Biochim Biophys Acta Mol Cell Biol Lipids* **1867**:159179.
- Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L et al. (2017) A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* **23**:107–113.
- Ponzano S, Bertozzi F, Mengatto L, Dionisi M, Armirotti A, Romeo E, Berteotti A, Fiorelli C, Tarozzo G, Reggiani A et al. (2013) Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamate esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. *J Med Chem* **56**:6917–6934.
- Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J Pharmacol Exp Ther* **301**:1020–1024.
- Porter RF, Szczesniak AM, Toguri JT, Gebremeskel S, Johnston B, Lehmann C, Fingerle J, Rothenhäusler B, Perret C, Rogers-Evans M et al. (2019) Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. *Molecules* **24**:3338.
- Portier M, Rinaldi-Carmona M, Pececu F, Combes T, Pointot-Chazel C, Calandra B, Barth F, le Fur G, and Casellas P (1999) SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. *J Pharmacol Exp Ther* **288**:582–589.
- Powell DR, Gay JP, Wilganowski N, Doree D, Savelieva KV, Lanthorn TH, Read R, Vogel P, Hansen GM, Brommage R et al. (2015) Diacylglycerol lipase α knockout mice demonstrate metabolic and behavioral phenotypes similar to those of cannabinoid receptor 1 knockout mice. *Front Endocrinol (Lausanne)* **6**:86.
- Prevet H and Collins I (2019) Labelled chemical probes for demonstrating direct target engagement in living systems. *Future Med Chem* **11**:1195–1224.
- Priestley R, Glass M, and Kendall D (2017) Functional selectivity at cannabinoid receptors. *Adv Pharmacol* **80**:207–221.
- Procaccia S, Lewitus GM, Lipson Feder C, Shapira A, Berman P, and Meiri D (2022) Cannabis for medical use: versatile plant rather than a single drug. *Front Pharmacol* **13**:894960.
- Pryce G and Baker D (2015) Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. *Handb Exp Pharmacol* **231**:213–231.
- Punt JM, van der Vliet D, and van der Stelt M (2023) Chemical probes to control and visualize lipid metabolism in the brain. *Acc Chem Res* **55**:3205–3217.
- Raduner S, Bisson W, Abagyan R, Altmann K-H, and Gertsch J (2007) Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. *J Nat Prod* **70**:1010–1015.
- Rahman IAS, Tsuboi K, Hussain Z, Yamashita R, Okamoto Y, Uyama T, Yamazaki N, Tanaka T, Tokumura A, and Ueda N (2016) Calcium-dependent generation of N-acylethanolamines and lysophosphatidic acids by glycerophosphodiesterase GDE7. *Biochim Biophys Acta* **1861** (12 Pt A):1881–1892.
- Rahman SMK, Hussain Z, Morito K, Takahashi N, Sikder MM, Tanaka T, Ohta KI, Ueno M, Takahashi H, Yamamoto T et al. (2022) Formation of N-acyl-phosphatidylethanolamines by cytosolic phospholipase A_{2c} in an ex vivo murine model of brain ischemia. *Biochim Biophys Acta Mol Cell Biol Lipids* **1867**:159222.
- Rajesh M, Pan H, Mukhopadhyay P, Bátkai S, Osei-Hyiaman D, Haskó G, Liaudet L, Gao B, and Pacher P (2007) Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. *J Leukoc Biol* **82**:1382–1389.
- Rakhshan F, Day TA, Blakely RD, and Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. *J Pharmacol Exp Ther* **292**:960–967.
- Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, Santerre JL, Makriyannis A, and Salamone JD (2010) The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. *Pharmacol Biochem Behav* **97**:179–184.
- Rau M, Nicolussi S, Chicca A, and Gertsch J (2016) Assay of endocannabinoid uptake. *Methods Mol Biol* **1412**:191–203.
- Razdan RK (1986) Structure-activity relationships in cannabinoids. *Pharmacol Rev* **38**:75–149.
- Reggio PH, Seltzman HH, Compton DR, Prescott Jr WR, and Martin BR (1990) Investigation of the role of the phenolic hydroxyl in cannabinoid activity. *Mol Pharmacol* **38**:854–862.
- Reynoso-Moreno I and Gertsch J (2021) Small-molecule inhibitors of endocannabinoid transport and trafficking. *Drug Discov Series* **76**:414–450.
- Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, and Gertsch J (2018) The endocannabinoid reuptake inhibitor WOBE437 is orally bioavailable

- and exerts indirect polypharmacological effects via different endocannabinoid receptors. *Front Mol Neurosci* **11**:180.
- Reynoso-Moreno I, Najar-Guerrero I, Escareño N, Flores-Soto MEME, Gertsch J, Viveros-Paredes JMJM, Escareño N, Flores-Soto MEME, Gertsch J, and Viveros-Paredes JMJM (2017) An endocannabinoid uptake inhibitor from black pepper exerts pronounced anti-inflammatory effects in mice. *J Agric Food Chem* **65**:9435–9442.
- Reynoso-Moreno I, Rau M, Chicca A, Nicolussi S, and Gertsch J (2023) Assay of endocannabinoid uptake. *Methods Mol Biol* **2576**:329–348.
- Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, and Chicca A (2021) Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. *ACS Pharmacol Transl Sci* **4**:765–779.
- Ribeiro A, Pontis S, Mengatto L, Armirotti A, Chiurchiù V, Capurro V, Fiasella A, Nuzzi A, Romeo E, Moreno-Sanz G et al. (2015) A potent systemically active N-acyl ethanolamine acid amidase inhibitor that suppresses inflammation and human macrophage activation. *ACS Chem Biol* **10**:1838–1846.
- Riether D (2012) Selective cannabinoid receptor 2 modulators: a patent review 2009–present. *Expert Opin Ther Pat* **22**:495–510.
- Riether D, Zindell R, Wu L, Betageri R, Jenkins JE, Khor S, Berry AK, Hickey ER, Ermann M, Albrecht C et al. (2015) Selective CB2 receptor agonists. Part 2: structure-activity relationship studies and optimization of proline-based compounds. *Bioorg Med Chem Lett* **25**:581–586.
- Rinaldi M, Barth F, Casellas P, Congy C, Oustric D, Bell MR, D'Ambra TE, and Philion RE (1996) Utilisation de composés agonistes du récepteur cb2 humain pour la préparation de médicaments immunomodulateurs, nouveaux composés agonistes du récepteur cb2 et les compositions pharmaceutiques les contenant. *FR Pat*, FR2735774A1.
- Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC, and Le Fur G (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. *Life Sci* **56**:1941–1947.
- Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. *J Pharmacol Exp Ther* **284**:644–650.
- Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, and Ringel Y (2014) Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. *Aliment Pharmacol Ther* **40**:200–207.
- Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. *Br J Psychiatry* **178**:107–115.
- Rock EM, Limebeer CL, Pertwee RG, Mechoulam R, and Parker LA (2021) Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. *Cannabis Cannabinoid Res* **6**:266–274.
- Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S et al. (2001) An anorexic lipid mediator regulated by feeding. *Nature* **414**:209–212.
- Ronesi J, Gerdeman GL, and Lovinger DM (2004) Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. *J Neurosci* **24**:1673–1679.
- Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. *Br J Pharmacol* **140**:790–801.
- Rossi F, Bellini G, Nobili B, Maione S, Perrone L, and del Giudice EM (2011) Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: an alternative way to highlight the CB2 hepatoprotective properties. *Hepatology* **54**:1102, author reply 1102–1103.
- Rossi G, Gioacchini G, Pengo G, Suchodolski JS, Jergens AE, Allenspach K, Gavazza A, Scarpona S, Berardi S, Galosi L et al. (2020) Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes. *Neurogastroenterol Motil* **32**:e13717.
- Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamillard M et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med* **13**:35–37.
- Rouzer CA and Marnett LJ (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. *Chem Rev* **111**:5899–5921.
- Rubin A, Lemberger L, Warrick P, Crabtree RE, Sullivan H, Rowe H, and Obermeyer BD (1977) Physiologic disposition of nabilone, a cannabinol derivative, in man. *Clin Pharmacol Ther* **22**:85–91.
- Russo EB (2018) Cannabis therapeutics and the future of neurology. *Front Integr Neurosci* **12**:51.
- Russo EB, Jiang HE, Li X, Sutton A, Carboni A, del Bianco F, Mandolino G, Potter DJ, Zhao YX, Bera S et al. (2008) Phytochemical and genetic analyses of ancient cannabis from Central Asia. *J Exp Bot* **59**:4171–4182.
- Saghatelian A, McKinney MK, Bandell M, Patapoutian A, and Cravatt BF (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. *Biochemistry* **45**:9007–9015.
- Saleh N, Hucke O, Kramer G, Schmidt E, Montel F, Lipinski R, Ferger B, Clark T, Hildebrand PW, and Tautermann CS (2018) Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the cannabinoid CB1 receptor. *Angew Chem Int Ed Engl* **57**:2580–2585.
- Sanson B, Wang T, Sun J, Wang L, Kaczocha M, Ojima I, Deutsch D, and Li H (2014) Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. *Acta Crystallogr D Biol Crystallogr* **70**:290–298.
- Sarott RC, Westphal MV, Pfaff P, Korn C, Sykes DA, Gazzi T, Brennecke B, Atz K, Weise M, Mostinski Y et al. (2020) Development of high-specificity fluorescent probes to enable cannabinoid type 2 receptor studies in living cells. *J Am Chem Soc* **142**:16953–16964.
- Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M et al. (2013) Antinociceptive effects of the N-acyl ethanolamine acid amidase inhibitor ARN077 in rodent pain models. *Pain* **154**:350–360.
- Sasso O, Pontis S, Armirotti A, Cardinali G, Kovacs D, Migliore M, Summa M, Moreno-Sanz G, Picardo M, and Piomelli D (2016) Endogenous N-acyl taurines regulate skin wound healing. *Proc Natl Acad Sci USA* **113**:E4397–E4406.
- Sasso O, Summa M, Armirotti A, Pontis S, De Mei C, and Piomelli D (2018) The N-acyl ethanolamine acid amidase inhibitor ARN077 suppresses inflammation and pruritus in a mouse model of allergic dermatitis. *J Invest Dermatol* **138**:562–569.
- Saumell-Esnaola M, Barrondo S, García Del Caño G, Goicolea MA, Sallés J, Lutz B, and Monry K (2021) Subsynaptic distribution, lipid raft targeting and G protein-dependent signalling of the type 1 cannabinoid receptor in synaptosomes from the mouse hippocampus and frontal cortex. *Molecules* **26**:6897.
- Schafroth MA and Carreira EM (2017) Synthesis of phytocannabinoids. *Prog Chem Org Nat Prod* **103**:37–59.
- Schiano Moriello A, López Chinarro S, Novo Fernández O, Eras J, Amodeo P, Canela-Garayoa R, Vitale RM, Di Marzo V, and De Petrocellis L (2018) Elongation of the hydrophobic chain as a molecular switch: discovery of capsaicin derivatives and endogenous lipids as potent transient receptor potential vanilloid channel 2 antagonists. *J Med Chem* **61**:8255–8281.
- Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J, Goldberg SR, and Justinova Z (2016a) Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. *Neuropsychopharmacology* **41**:2283–2293.
- Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, Goldberg SR, and Justinova Z (2016b) Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. *Psychopharmacology (Berl)* **233**:1867–1877.
- Schlossburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. *Nat Neurosci* **13**:1113–1119.
- Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, Van Der Ark P, Palmer JA, Saad ZS, Pemberton DJ et al. (2021) The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. *Neuropsychopharmacology* **46**:1004–1010.
- Schurman LD, Carper MC, Moncayo LV, Ogasawara D, Richardson K, Yu L, Liu X, Poklis JL, Liu QS, Cravatt BF et al. (2019) Diacylglycerol lipase- α regulates hippocampal-dependent learning and memory processes in mice. *J Neurosci* **39**:5949–5965.
- Schurman LD, Lu D, Kendall DA, Howlett AC, and Lichtman AH (2020) Molecular mechanism and cannabinoid pharmacology. *Handb Exp Pharmacol* **258**:323–353.
- Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, Cuomo V, and Piomelli D (2008) The lipid messenger OEA links dietary fat intake to satiety. *Cell Metab* **8**:281–288.
- Seillier A and Giuffrida A (2018) The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: further evidence for transporter-mediated endocannabinoid release. *Neuropharmacology* **130**:1–9.
- Sellitto I, Le Bourdonnec B, Worm K, Goodman A, Savolainen MA, Chu GH, Ajello CW, Saeui CT, Leister LK, Cassel JA et al. (2010) Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability. *Bioorg Med Chem Lett* **20**:387–391.
- Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, and Rosenbaum DM (2016) High-resolution crystal structure of the human CB1 cannabinoid receptor. *Nature* **540**:602–606.
- Sharkey KA and Wiley JW (2016) The role of the endocannabinoid system in the brain-gut axis. *Gastroenterology* **151**:252–266.
- Shen W, Shen M, Zhao X, Zhu H, Yang Y, Lu S, Tan Y, Li G, Li M, Wang J et al. (2017) Anti-obesity effect of capsaicin in mice fed with high-fat diet is associated with an increase in population of the gut bacterium *Akkermansia muciniphila*. *Front Microbiol* **8**:272.
- Shin M, Snyder HW, Donvito G, Schurman LD, Fox TE, Lichtman AH, Kester M, and Hsu KL (2018) Liposomal delivery of diacylglycerol lipase- β inhibitors to macrophages dramatically enhances selectivity and efficacy in vivo. *Mol Pharm* **15**:721–728.
- Shin M, Ware TB, and Hsu KL (2020) DAGL- β functions as a PUFA-specific triacylglycerol lipase in macrophages. *Cell Chem Biol* **27**:314–321.e5.
- Shonesy BC, Bluett RJ, Ramikie TS, Báladi R, Hermanson DJ, Kingsley PJ, Marnett LJ, Winder DG, Colbran RJ, and Patel S (2014) Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. *Cell Rep* **9**:1644–1653.
- Shonesy BC, Stephenson JR, Marks CR, and Colbran RJ (2020) Cyclic AMP-dependent protein kinase and D1 dopamine receptors regulate diacylglycerol lipase- α and synaptic 2-arachidonoyl glycerol signaling. *J Neurochem* **153**:334–345.
- Shonesy BC, Wang X, Rose KL, Ramikie TS, Cavener VS, Rentz T, Baucum 2nd AJ, Jalan-Sakrikar N, Mackie K, Winder DG et al. (2013) CaMKII regulates diacylglycerol lipase- α and striatal endocannabinoid signaling. *Nat Neurosci* **16**:456–463.
- Shore DM and Reggio PH (2015) The therapeutic potential of orphan GPCRs, GPR35 and GPR55. *Front Pharmacol* **6**:69.
- Showalter VM, Compton DR, Martin BR, and Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther* **278**:989–999.
- Sigel E, Baur R, Rácz I, Marazzi J, Smart TG, Zimmer A, and Gertsch J (2011) The major central endocannabinoid directly acts at GABA(A) receptors. *Proc Natl Acad Sci USA* **108**:18150–18155.

- Sihag J and Di Marzo V (2022) (Wh)olistic (e)ndocannabinoidome-microbiome-axis modulation through (n)utrition (WHEN) to curb obesity and related disorders. *Lipids Health Dis* **21**:9.
- Simard M, Archambault A-S, Lavoie JC, Dumais É, Di Marzo V, and Flamand N (2022) Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and *N*-acyl-ethanolamine families. *Biochem Pharmacol* **205**:115261.
- Simon GM and Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-*N*-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. *J Biol Chem* **281**:26465–26472.
- Simon GM and Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-*N*-acyl ethanolamine precursors in mouse brain. *J Biol Chem* **283**:9341–9349.
- Singh S, Oyagawa CRM, Macdonald C, Grimsey NL, Glass M, and Vernall AJ (2019) Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor. *ACS Med Chem Lett* **10**:209–214.
- Sink KS, McLaughlin PJ, Wood JAT, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis A et al. (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. *Neuropsychopharmacology* **33**:946–955.
- Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, and Salamone JD (2010) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. *Eur Neuropsychopharmacol* **20**:112–122.
- Sionov RV and Steinberg D (2022) Anti-microbial activity of phytocannabinoids and endocannabinoids in the light of their physiological and pathophysiological roles. *Biomedicines* **10**:631.
- Sipe JC, Chiang K, Gerber AL, Beutler E, and Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. *Proc Natl Acad Sci USA* **99**:8394–8399.
- Slavik R, Grether U, Müller Herde A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, and Ametamey SM (2015) Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor. *J Med Chem* **58**:4266–4277.
- Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, and Hohmann AG (2020) Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine-induced dependence or reward. *Front Mol Neurosci* **13**:54.
- Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, and Hohmann AG (2018) Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. *Biol Psychiatry* **84**:722–733.
- Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, and Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J Pharmacol Exp Ther* **270**:219–227.
- Snider NT, Nast JA, Tesmer LA, and Hollenberg PF (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. *Mol Pharmacol* **75**:965–972.
- Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N et al. (2017) Cannabinoid CB₂ receptor ligand profiling reveals biased signalling and off-target activity. *Nat Commun* **8**:13958.
- Soethoudt M, Stolze SC, Westphal MV, van Stralen L, Martella A, van Rooden EJ, Guba W, Varga ZV, Deng H, van Kasteren SI et al. (2018a) Selective photoaffinity probe that enables assessment of cannabinoid CB₂ receptor expression and ligand engagement in human cells. *J Am Chem Soc* **140**:6067–6075.
- Soethoudt M, Hoorens MWH, Doelman W, Martella A, van der Stelt M, and Heitman LH (2018b) Structure-kinetic relationship studies of cannabinoid CB₂ receptor agonists reveal substituent-specific lipophilic effects on residence time. *Biochem Pharmacol* **152**:129–142.
- Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F et al. (2009) Selective *N*-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. *Proc Natl Acad Sci USA* **106**:20966–20971.
- Solymsi K and Kófalvi A (2017) Cannabis: a treasure trove or Pandora's box? *Mini Rev Med Chem* **17**:1223–1291.
- Somvanshi RK, Zou S, Kadhimi S, Padania S, Hsu E, and Kumar U (2022) Cannabinol modulates neuroprotection and intraocular pressure: a potential multi-target therapeutic intervention for glaucoma. *Biochim Biophys Acta Mol Basis Dis* **1868**:166325.
- Stasiulewicz A, Lesniak A, Setny P, Bujalska-Zadrożny M, and Sulkowska JI (2022) Identification of CB1 ligands among drugs, phytochemicals and natural-like compounds: virtual screening and in vitro verification. *ACS Chem Neurosci* **13**:2991–3007.
- Stella N (2023) THC and CBD: similarities and differences between siblings. *Neuron* **111**:302–327.
- Sticht MA, Rock EM, Limebeer CL, and Parker LA (2015) Endocannabinoid mechanisms influencing nausea. *Int Rev Neurobiol* **125**:127–162.
- Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, Lutz B, Mackie K, Makriyannis A, Macnaughton WK et al. (2010) Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. *Neurogastroenterol Motil* **22**:787–796, e223.
- Straiker A, Wilson S, Corey W, Dvorakova M, Bosquez T, Tracey J, Wilkowski C, Ho K, Wager-Miller J, and Mackie K (2021) An evaluation of understudied phytocannabinoids and their effects in two neuronal models. *Molecules* **26**:5352.
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* **215**:89–97.
- Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunk P, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R et al. (2007) Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). *Bioorg Med Chem Lett* **17**:3511–3515.
- Sun Y, Alexander SP, Kendall DA, and Bennett AJ (2008) Involvement of fatty acid binding proteins in the transport of endocannabinoids to peroxisome proliferator activated receptors, in 18th ICRS Annual Symposium (International Cannabinoid Research Society ed) p 17, Burlington.
- Suzuki N, Suzuki M, Murakami K, Hamajo K, Tsukamoto T, and Shimajo M (2012) Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. *Brain Res* **1430**:93–100.
- Szymanski D, Papanastasiou M, Pandarinathan L, Zvonok N, Janero DR, Pavlopoulos S, Vouros P, and Makriyannis A (2018) Aliphatic azides as selective cysteine labeling reagents for integral membrane proteins. *J Med Chem* **61**:11199–11208.
- Szymanski DW, Papanastasiou M, Melchior K, Zvonok N, Mercier RW, Janero DR, Thakur GA, Cha S, Wu B, Karger B et al. (2011) Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. *J Proteome Res* **10**:4789–4798.
- Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS et al. (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. *Cell Metab* **16**:167–179.
- Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J et al. (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. *J Clin Invest* **120**:2953–2966.
- Tanimura A, Yamazaki M, Hashimoto-dani Y, Uchigashima M, Kawata S, Abe M, Kita Y, Hashimoto K, Shimizu T, Watanabe M et al. (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. *Neuron* **65**:320–327.
- Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Piazzi PV, Park C, Kathuria S, and Piomelli D (2003) Design, synthesis, and structure-activity relationships of alkylcarbamate aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J Med Chem* **46**:2352–2360.
- Tepper MA, Zurier RB, and Burstein SH (2014) Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. *Bioorg Med Chem* **22**:3245–3251.
- Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS et al. (2005) Virtual computational chemistry laboratory—design and description. *J Comput Aided Mol Des* **19**:453–463.
- Thakur GA, Tichkule R, Bajaj S, and Makriyannis A (2009) Latest advances in cannabinoid receptor agonists. *Expert Opin Ther Pat* **19**:1647–1673.
- Tham M, Yilmaz O, Alaverdshvili M, Kelly MEM, Denovan-Wright EM, and Laprairie RB (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. *Br J Pharmacol* **176**:1455–1469.
- Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, and Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol* **150**:613–623.
- Tsang CC and Giudice MG (2016) Nabilone for the management of pain. *Pharmacotherapy* **36**:273–286.
- Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, Wang J, Deutsch DG, Burns MP, Ulloa NM et al. (2011) Enzymatic formation of *N*-acylethanolamines from *N*-acylethanolamine plasmalogen through *N*-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. *Biochim Biophys Acta* **1811**:565–577.
- Tsuboi K, Okamoto Y, Rahman IA, Uyama T, Inoue T, Tokumura A, and Ueda N (2015) Glycerophosphodiesterase GDE4 as a novel lysophospholipase D: a possible involvement in bioactive *N*-acylethanolamine biosynthesis. *Biochim Biophys Acta* **1851**:537–548.
- Tsuboi K, Tai T, Yamashita R, Ali H, Watanabe T, Uyama T, Okamoto Y, Kitakaze K, Takenouchi Y, Go S et al. (2021) Involvement of acid ceramidase in the degradation of bioactive *N*-acylethanolamines. *Biochim Biophys Acta Mol Cell Biol Lipids* **1866**:158972.
- Tsuboi K, Takezaki N, and Ueda N (2007a) The *N*-acylethanolamine-hydrolyzing acid amidase (NAAA). *Chem Biodivers* **4**:1914–1925.
- Tsuboi K, Uyama T, Okamoto Y, and Ueda N (2018) Endocannabinoids and related *N*-acylethanolamines: biological activities and metabolism. *Inflamm Regen* **38**:28.
- Tsuboi K, Zhao LY, Okamoto Y, Araki N, Ueno M, Sakamoto H, and Ueda N (2007b) Predominant expression of lysosomal *N*-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. *Biochim Biophys Acta* **1771**:623–632.
- Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, and Chavatte P (2017) Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and *N*-acylethanolamine acid amidase inhibitors. *J Med Chem* **60**:4–46.
- Turner SE, Williams CM, Iversen L, and Whalley BJ (2017) Molecular pharmacology of phytocannabinoids. *Prog Chem Org Nat Prod* **103**:61–101.
- Tutunchi H, Saghafi-Asl M, and Ostadrahimi A (2020) A systematic review of the effects of oleylethanolamide, a high-affinity endogenous ligand of PPAR- α , on the management and prevention of obesity. *Clin Exp Pharmacol Physiol* **47**:543–552.
- Ueda N, Tsuboi K, and Uyama T (2010) *N*-acylethanolamine metabolism with special reference to *N*-acylethanolamine-hydrolyzing acid amidase (NAAA). *Prog Lipid Res* **49**:299–315.
- Uyama T, Ikematsu N, Inoue M, Shinohara N, Jin XH, Tsuboi K, Tonai T, Tokumura A, and Ueda N (2012) Generation of *N*-acylphosphatidylethanolamine by members of the phospholipase A/acyltransferase (PLA/AT) family. *J Biol Chem* **287**:31905–31919.

- Uyama T, Tsuboi K, and Ueda N (2017) An involvement of phospholipase A/acyltransferase family proteins in peroxisome regulation and plasmalogen metabolism. *FEBS Lett* **591**:2745–2760.
- van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agrò A, Vliegthart JFG, and Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J Med Chem* **45**:3709–3720.
- van Egmond N, Straub VM, and van der Stelt M (2021) Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. *Annu Rev Pharmacol Toxicol* **61**:441–463.
- Vandevoorde S and Fowler CJ (2005) Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. *Br J Pharmacol* **145**:885–893.
- Varga K, Lake K, Martin BR, and Kunos G (1995) Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. *Eur J Pharmacol* **278**:279–283.
- Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, Veldink GA, Vliegthart JFG, Bär PR, Nicolay K et al. (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoygenases. *J Neurosci* **23**:4127–4133.
- Verhoeckx KC, Voortman T, Balvers MG, Hendriks HFM, M Wortelboer H, and Witkamp RF (2011) Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. *Biochim Biophys Acta* **1811**:578–586.
- Viader A, Ogasawara D, Joslyn CM, Sanchez-Alavez M, Mori S, Nguyen W, Conti B, and Cravatt BF (2016) A chemical proteomic atlas of brain serine hydrolases identifies cell type-specific pathways regulating neuroinflammation. *eLife* **5**:e12345.
- Vogel Z, Barg J, Levy R, Saya D, Heldman E, and Mechoulam R (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J Neurochem* **61**:352–355.
- Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cernus DP, Melis JHJM, Majek A, Vjaters E, Urban M, Ramonas H et al. (2017) Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. *Urology* **103**:191–197.
- Wang B, Zhou Z, and Li L (2022) Gut microbiota regulation of AHR signaling in liver disease. *Biomolecules* **12**:1244.
- Wang J, Okamoto Y, Morishita J, Tsuboi K, Miyatake A, and Ueda N (2006) Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. *J Biol Chem* **281**:12325–12335.
- Wang L, Liu J, Harvey-White J, Zimmer A, and Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. *Proc Natl Acad Sci USA* **100**:1393–1398.
- Wangsten T, Akselsen H, Holmen J, Undlien D, and Retterstøl L (2011) A common haplotype in NAPEPLD is associated with severe obesity in a Norwegian population-based cohort (the HUNT study). *Obesity (Silver Spring)* **19**:612–617.
- Ward A and Holmes B (1985) Nabilone, a preliminary review of its pharmacological properties and therapeutic use. *Drugs* **30**:127–144.
- Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, and Nilius B (2003) Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. *Nature* **424**:434–438.
- Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, and Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. *Biol Pharm Bull* **19**:1109–1111.
- Watanabe K, Yamaori S, Funahashi T, Kimura T, and Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabivins by human hepatic microsomes. *Life Sci* **80**:1415–1419.
- Watson JE, Kim JS, and Das A (2019) Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. *Prostaglandins Other Lipid Mediat* **143**:106337.
- Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, and Cravatt BF (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. *J Biol Chem* **281**:36569–36578.
- Weichert D and Gmeiner P (2015) Covalent molecular probes for class A G protein-coupled receptors: advances and applications. *ACS Chem Biol* **10**:1376–1386.
- Westphal MV, Sarott RC, Zirwes EA, Osterwald A, Guba W, Ullmer C, Grether U, and Carreira EM (2020) Highly selective, amine-derived cannabinoid receptor 2 probes. *Chemistry* **26**:1380–1387.
- Wilkerson JL, Bilbrey JA, Felix JS, Makriyannis A, and McMahon LR (2021) Untapped endocannabinoid pharmacological targets: pipe dream or pipeline? *Pharmacol Biochem Behav* **206**:173192.
- Wilkerson JL, Donvito G, Grim TW, Abdullah RA, Ogasawara D, Cravatt BF, and Lichtman AH (2017) Investigation of diacylglycerol lipase alpha inhibition in the mouse lipopolysaccharide inflammatory pain model. *J Pharmacol Exp Ther* **363**:394–401.
- Wilkerson JL, Ghosh S, Bagdas D, Mason BL, Crowe MS, Hsu KL, Wise LE, Kinsey SG, Damaj MI, Cravatt BF et al. (2016) Diacylglycerol lipase beta inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. *Br J Pharmacol* **173**:1678–1692.
- Wold EA, Chen J, Cunningham KA, and Zhou J (2019) Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts. *J Med Chem* **62**:88–127.
- Woodhams SG, Chapman V, Finn DP, Hohmann AG, and Neugebauer V (2017) The cannabinoid system and pain. *Neuropharmacology* **124**:105–120.
- Woodward DF, Wang JW, and Poloso NJ (2013) Recent progress in prostaglandin F2 α ethanolamide (prostamide F2 α) research and therapeutics. *Pharmacol Rev* **65**:1135–1147.
- Wortley MA, Adcock JJ, Dubuis ED, Maher SA, Bonvini SJ, Delescluse I, Kinloch R, McMurray G, Perros-Huguet C, Papakosta M et al. (2017) Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy. *Eur Respir J* **50**:1700782.
- Wu S, Liao D, Li X, Liu Z, Zhang L, Mo FM, Hu S, Xia J, and Yang X (2021) Endogenous oleylethanolamide crystals-loaded lipid nanoparticles with enhanced hydrophobic drug loading capacity for efficient stroke therapy. *Int J Nanomedicine* **16**:8103–8115.
- Xie X, Li Y, Xu S, Zhou P, Yang L, Xu Y, Qiu Y, Yang Y, and Li Y (2022) Genetic blockade of NAAA cell-specifically regulates fatty acid ethanolamides (FAEs) metabolism and inflammatory responses. *Front Pharmacol* **12**:817603.
- Xing C, Zhuang Y, Xu TH, Feng Z, Zhou XE, Chen M, Wang L, Meng X, Xue Y, Wang J et al. (2020) Cryo-EM structure of the human cannabinoid receptor CB2-G α signaling complex. *Cell* **180**:645–654.e13.
- Xiu Y, Wang K, Chen J, Zhuo Z, and Xiu Y (2020) Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis. *RSC Advances* **10**:34197–34202.
- Yanaka N (2007) Mammalian glycerophosphodiester phosphodiesterases. *Biosci Biotechnol Biochem* **71**:1811–1818.
- Yang L, Li L, Chen L, Li Y, Chen H, Li Y, Ji G, Lin D, Liu Z, and Qiu Y (2015) Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR- α . *Sci Rep* **5**:13565.
- Yang X, van Veldhoven JPD, Offringa J, Kuiper BJ, Lenselink EB, Heitman LH, van der Es D, and IJzerman AP (2019) Development of covalent ligands for G protein-coupled receptors: a case for the human adenosine A $_3$ receptor. *J Med Chem* **62**:3539–3552.
- Yang X, Wang X, Xu Z, Wu C, Zhou Y, Wang Y, Lin G, Li K, Wu M, Xia A et al. (2022) Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1. *Nat Chem Biol* **18**:831–840.
- Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ et al. (2009) Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. *J Pharmacol Exp Ther* **328**:141–151.
- Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, Grayson GK, Zhu CZ, Pai M, Chandran P et al. (2008) In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. *Br J Pharmacol* **153**:390–401.
- Yates ML and Barker EL (2009) Organized trafficking of anandamide and related lipids. *Vitam Horm* **81**:25–53.
- Yeliseev A, Iyer MR, Joseph TT, Coffey NJ, Cinar R, Zoubak L, Kunos G, and Gawrisch K (2021) Cholesterol as a modulator of cannabinoid receptor CB $_2$ signaling. *Sci Rep* **11**:3706.
- Yoon S, Myczek K, and Penzes P (2021) cAMP signaling-mediated phosphorylation of diacylglycerol lipase α regulates interaction with ankyrin-G and dendritic spine morphology. *Biol Psychiatry* **90**:263–274.
- Yu S, Levi L, Casadesus G, Kunos G, and Noy N (2014) Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPAR β/δ) in the brain. *J Biol Chem* **289**:12748–12758.
- Yuan CY, Zhou Y, Sauber G, Stollenwerk T, Komorowski R, López A, Tolón RM, Romero J, Hillard CJ, and Drobyski WR (2021) Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. *Blood* **137**:1241–1255.
- Yuan J, Jiang C, Wang J, Chen CJ, Hao Y, Zhao G, Feng Z, and Xie XQ (2022) In silico prediction and validation of CB2 allosteric binding sites to aid the design of allosteric modulators. *Molecules* **27**:453.
- Zhang HY, Shen H, Jordan CJ, Liu QR, Gardner EL, Bonci A, and Xi ZX (2019) CB $_2$ receptor antibody signal specificity: correlations with the use of partial CB $_2$ -knockout mice and anti-rat CB $_2$ receptor antibodies. *Acta Pharmacol Sin* **40**:398–409.
- Zhang S, Shao P, Ling X, Yang L, Hou W, Thorne SH, Beaino W, Anderson CJ, Ding Y, and Bai M (2015b) In vivo inflammation imaging using a CB2R-targeted near infrared fluorescent probe. *Am J Nucl Med Mol Imaging* **5**:246–258.
- Zhang YM, Greco MN, Macielag MJ, Teleha CA, DesJarlais RL, Tang Y, Ho G, Hou C, Chen C, Zhao S et al. (2018) 6-Benzhydryl-4-amino-quinolin-2-ones as potent cannabinoid type 1 (CB1) receptor inverse agonists and chemical modifications for peripheral selectivity. *J Med Chem* **61**:10276–10298.
- Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L, Gao HQ, Cravatt BF, and Liu QS (2015a) Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. *Hippocampus* **25**:16–26.
- Zhao LY, Tsuboi K, Okamoto Y, Nagahata S, and Ueda N (2007) Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. *Biochim Biophys Acta* **1771**:1397–1405.
- Zhao P and Abood ME (2013) GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. *Life Sci* **92**:453–457.
- Zhou Y, Elmes MW, Sweeney JM, Joseph OM, Che J, Hsu HC, Li H, Deutsch DG, Ojima I, Kaczocha M et al. (2019a) Identification of fatty acid binding protein 5 inhibitors through similarity-based screening. *Biochemistry* **58**:4304–4316.
- Zhou P, Xiang L, Yang Y, Wu Y, Hu T, Liu X, Lin F, Xiu Y, Wu K, Lu C et al. (2019b) N-acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis. *Pharmacol Res* **145**:104264.
- Zhou Y, Howell FV, Glebov OO, Albrecht D, Williams G, and Doherty P (2016) Regulated endosomal trafficking of Diacylglycerol lipase alpha (DAGL α) generates distinct cellular pools; implications for endocannabinoid signaling. *Mol Cell Neurosci* **76**:76–86.
- Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A, Zhu KL, Parzei N, Sidhu J, Haj C, Mechoulam R et al. (2020) An evaluation of the anti-

- hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain. *Br J Pharmacol* **177**:2712–2725.
- Zindell R, Walker ER, Scott J, Amouzegh P, Wu L, Ermann M, Thomson D, Fisher MB, Fullenwider CL, Grbic H et al. (2011) Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters. *Bioorg Med Chem Lett* **21**:4276–4280.
- Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, and Braun J (2006) Formation of B and T cell subsets require the cannabinoid receptor CB2. *Immunogenetics* **58**:714–725.
- Zoja C, Locatelli M, Corna D, Villa S, Rottoli D, Nava V, Verde R, Piscitelli F, Di Marzo V, Fingerle J et al. (2016) Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. *Nephron* **132**:59–69.
- Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, and Burstein SH (1998) Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. *Arthritis Rheum* **41**:163–170.
- Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sjørgård M, Di Marzo V, Julius D, and Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature* **400**:452–457.